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Abstract 
Dyskeratosis congenita (DC) is a multi system disorder that exhibits considerable 
clinical and genetic heterogeneity. It is characterised by mucocutaneous features, bone 
marrow failure and a predisposition to cancer. Research has identified mutations 
affecting several telomerase components and patients often have short telomeres, 
implicating defective telomere maintenance in this disease. Affected components 
include dyskerin, NOP10 and NHP2, which together with GAR1 form a protein core 
common to telomerase and all other H/ACA ribonucleoprotein complexes (H/ACA 
RNPs). Initially characterised as H/ACA RNP components important for 
pseudouridylation and rRNA processing, their role in the functionally distinct 
telomerase complex and telomere maintenance is less defined.  
In order to better understand their implications in DC, this study investigated the 
importance of these core proteins for the integrity and function of telomerase in 
human cells. RNAi knockdown studies demonstrated that dyskerin, NOP10 and 
NHP2 are necessary for the accumulation of TERC (telomerase RNA component); 
dyskerin and NOP10 for telomerase activity. Moreover, dyskerin was found to be 
important for maintaining telomere length over time. The impact of NOP10 and 
NHP2 missense mutations was also analysed in vitro, which indicated that they impair 
TERC accumulation. The potential effect on pseudouridylation was also considered in 
this study; the analysis of other H/ACA RNA levels in these knockdown experiments 
and in a cohort of patients with DKC1 mutations revealed an irregular and 
inconsistent impact compared to that observed on TERC.  
Finally, defective telomere maintenance is heavily implicated as the primary cause of 
DC and very short telomeres have been proposed as a diagnostic marker. This study 
investigated telomere length in a patient cohort of unprecedented size. It demonstrated 
the prevalence of the telomere length defect, but telomere length was not found to 
correlate with either genetic subtype or disease severity, implicating the rate of 
telomere shortening as the correlating factor instead.    
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Chapter 1. Introduction 
1.1. Dyskeratosis Congenita 
First described over 100 years ago dyskeratosis congenita (DC), also known as 
Zinsser-Engman-Cole syndrome, is a rare inherited multi system disorder classically 
characterised by a triad of mucocutaneous features: nail dystrophy, leucoplakia and 
abnormal skin pigmentation (Drachtman and Alter 1995). Considered to be a rare 
bone marrow failure (BMF) syndrome due to the prevalence of bone marrow (BM) 
abnormalities, the incidence of age related features including premature hair 
loss/greying, predispositions to malignancy, pulmonary and skeletal abnormalities 
also allow DC to be considered a premature ageing syndrome (Dokal 2001). Genetic 
and molecular studies have subsequently indicated the primary underlying pathology 
of this disease to be a defect in telomere maintenance (reviewed Walne et al. 2005). 
 
1.2. Clinical features of DC 
DC classically presents with a mucocutaneous triad of abnormalities: abnormal skin 
pigmentation, nail dystrophy, and leucoplakia (figure 1.1), which form the basis for its 
diagnosis. However, a range of abnormalities in the dental, gastrointestinal, 
genitourinary, neurological, ophthalmic, pulmonary and skeletal systems are also 
reported in this multi system disorder (table 1). Progressing with age the onset of 
disease typically occurs during childhood, the nail and skin abnormalities often visible 
by 10yrs of age followed by leucoplakia in the early teens. During adolescence and 
early adulthood the more severe abnormalities begin to develop which vary 
considerably between patients, though 80-89% suffer BMF by 30yrs of age. Early 
mortality is also characteristic of DC, usually the result of BMF but also the 
pulmonary complications and malignancy associated with this disease; typically head, 
neck and gynaecological squamous cell carcinomas (particularly oral) as well as acute 
leukaemias and MDS (Drachtman and Alter 1995; Knight et al. 1998; Dokal 2000; 
Alter et al. 2009). Disease severity varies and is generally gauged by the age of BMF 
onset and the number of somatic abnormalities that manifest: BMF before the age of 
10yrs and several other features of DC classed as severe; BMF after the age of 20yrs 
classed as mild (Dokal 2000). What’s more, the diversity in clinical presentation and 
severity can create difficulty in diagnosing DC, an issue compounded by substantial 
clinical overlap with other syndromes (table 1) (reviewed Marrone and Dokal 2006).  
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Table 1. Clinical features of DC and their overlap with other syndromes. 
Clinical features BMF syndromes Premature ageing 
syndromes 
 DC AA AML MDS PNH DBA FA SDS BS CS HGPS RTS WS 
Characteristic               
Abnormal skin 
pigmentation 
89% 
     
 
 
     
Nail dystrophy 88%             
Leucoplakia  78%             
BMF 86%             
Common               
Epiphora  31%             
Mental retardation 25%             
Pulmonary disease 20%             
Short stature 20%             
Dental carries/loss 17%             
Oesophageal 
stricture 
17%             
Premature hair loss/  
greying 
16% 
        
 
 
  
Hyperhidrosis  15%             
Less frequent               
Malignancy 10%             
Liver disease 7%             
Ataxia/cerebellar   
hypoplasia  
7% 
            
Hypogonadism  6%             
Microcephaly  6%             
Urethral stricture/ 
phimosis  
5% 
            
Osteoporosis 5%             
Deafness 1%             
AA: Aplastic anaemia; AML: Acute myeloid leukaemia; PNH: Paroxysmal nocturnal haemoglobinuria; DBA: 
Diamond-Blackfan anaemia; FA: Fanconi anaemia; SDS: Shwachman-Diamond syndrome; BS: Bloom 
syndrome; CS: Cockayne syndrome; HGPS: Hutchinson-Gilford progeria syndrome; RTS: Rothmund-
Thomson syndrome; WS: Werner syndrome. (from Marrone and Dokal 2006) 
a 
c 
b 
Figure 1.1. The mucocutaneous triad of DC, (a) abnormal skin 
pigmentation, (b) nail dystrophy and (c) leucoplakia. 
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1.3. Genetic features of DC 
DC exhibits three modes of inheritance X-linked recessive, autosomal dominant (AD) 
and autosomal recessive (AR). With the majority of cases reported in males, X-linked 
is the most common and is associated with the more classical severe form of the 
disease. AD and AR forms are more variable with AD being the rarest and mildest 
form of DC while AR can be severe in some cases. Clearly then DC has multiple 
genetic basis’, each of which can be associated with a different degree of pathological 
impact and disease severity (Dokal 2000; Marrone and Mason 2003).  
 
The Dyskeratosis Congenita Registry (DCR) was established at the Hammersmith 
Hospital in 1995 (relocated to Barts and The London in 2006) to facilitate research 
into the underlying genetics and mechanism of DC disease. At the point of 
commencing this study five different genes had been implicated in DC, two of which 
were unpublished at the time. These are the X-linked recessive gene DKC1 (Heiss et 
al. 1998), the AD genes TERC and TERT (Vulliamy et al. 2001b; Armanios et al. 
2005; Vulliamy et al. 2005) and the unpublished AR genes NOP10 and NHP2.  
However, collectively these genes are not sufficient to explain all cases of the disease. 
X-linked DC represents ~32% of DCR patients and AD-DC only ~5% with the 
remaining 63% a mixture of AR inheritance and sporadic cases (Marrone and Dokal 
2006), of which the NOP10 and NHP2 mutations account for only one and two 
families respectively. Therefore, the genetic basis for a large proportion of the DCR 
remains elusive.  
 
DKC1, NOP10 and NHP2 encode the highly conserved nucleolar proteins dyskerin, 
NOP10 and NHP2. These are all components of H/ACA ribonucleoprotein complexes 
(H/ACA RNPs) which are important for ribosomal RNA (rRNA) processing and pre 
messenger RNA (mRNA) splicing (Meier 2005). Similarly, these proteins are also 
core components of the telomerase complex, a specialised H/ACA RNP serving a 
uniquely different role in telomere maintenance. Through telomerase this functional 
link can be extended to include TERC and TERT which encode the complexes 
distinguishing components, the telomerase RNA component (TERC) and telomerase 
reverse transcriptase (TERT) (Collins and Mitchell 2002). Together, these five genes 
implicate two structurally related yet functionally distinct complexes in the molecular 
pathology of DC, but particularly telomerase and telomere maintenance. 
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1.4. H/ACA ribonucleoprotein complexes 
H/ACA ribonucleoprotein complexes (H/ACA RNPs) are a class of small RNP 
complexes involved in the post translation modification of RNAs, specifically the 
isomerisation of specific uridine residues to pseudouridines in a process known as 
pseudouridylation. The exact purpose of this modification is unclear but is thought to 
increase stability of the target RNA and a break down in this process has been shown 
to severely impair rRNA processing and ribosomal assembly. H/ACA RNPs are 
characterised by their H/ACA RNA component which guides this process through site 
directed base pairing with the target RNA. In this way the many different species of 
H/ACA RNA creates diversity among the H/ACA RNPs and allow them to 
collectively target a multitude of different uridine residues. The H/ACA RNAs 
themselves are defined by specific H (ANANNA) and ACA box sequence motifs and 
form secondary structures that feature a double hairpin containing pseudouridylation 
pockets in which the target specific sequence elements are located (figure 1.2).  
 
 
 
Most H/ACA RNPs localise to the nucleoli where they target rRNAs and are referred 
to as small nucleolar RNPs (H/ACA snoRNPs), their RNAs as H/ACA snoRNAs. 
However, some H/ACA RNAs contain a CAB box sequence motif which targets the 
RNP for localisation to Cajal bodies where they target spliceosomal small nuclear 
RNAs (snRNAs) and are referred to as small Cajal body RNPs (H/ACA scaRNPs), 
their RNAs as H/ACA scaRNAs. Despite differences in their localisation and RNA 
component all H/ACA RNPs comprise the same four proteins at their core: dyskerin, 
NOP10, NHP2, and GAR1, which are evolutionarily conserved with orthologues in 
Figure 1.2. A model of H/ACA RNA secondary structure. 
Pseudouridylation 
pocket 
H Box ACA 
5’ 3’ 
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many species including mice, yeast and archaea. (reviewed Filipowicz and Pogacic 
2002; Henras et al. 2004a; Meier 2005).   
 
Initially characterised as H/ACA RNP components in yeast, through the orthologues: 
Cbf5p (dyskerin), Nop10p (NOP10), Nhp2p (NHP2), and Gar1p (GAR1), these 
proteins were all found to be essential for pseudouridylation and rRNA processing. 
Sharing significant homology with the bacterial pseudouridine synthase TruB, Cbf5p 
was identified as the enzymatic component of the complex but was also shown to be 
important for RNP stability and H/ACA RNA accumulation along with Nop10p and 
Nhp2p (Girard et al. 1992; Bousquet-Antonelli et al. 1997; Henras et al. 1998; 
Lafontaine et al. 1998; Watkins et al. 1998; Dez et al. 2001; Henras et al. 2004b). 
Since then research in mice has revealed much about the interaction of these H/ACA 
RNP components. Assembly of the H/ACA RNP is indicated to takes place at the site 
of H/ACA RNA transcription in the nucleus. The protein NAF1 is implicated in 
chaperoning NAP57 (dyskerin) to this location where it associates with NOP10 and 
NHP2 (via NOP10) to form a core protein trimer that recruits the newly transcribed 
H/ACA RNA. GAR1 does not seem to play a part at this stage, associating with the 
complex post RNA recruitment to create a mature, functional H/ACA RNP (figure 
1.3). At this point NAF1 is no longer associated with the complex and the discovery 
that GAR1 and NAF1 competitively bind to NAP57 suggests that these two proteins 
interchange during this maturation process (Wang and Meier 2004; Darzacq et al. 
2006). Indeed, this may serve to explain why GAR1 was not found to be important for 
H/ACA RNA stability and accumulation. 
 
 
H/ACA RNA 
NOP10 
NHP2 
Dyskerin 
GAR1 
Figure 1.3. A schematic representation of an H/ACA RNP. 
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Taken together the data suggests a system in which the protein components associate 
first before recruiting a newly synthesised H/ACA RNA and that RNP integration is 
necessary for the H/ACA RNAs stability and accumulation. Conversely, studies have 
shown that NAP57, NOP10, NHP2 and GAR1 are capable of forming a protein only 
complex that does not require an associated H/ACA RNA for its stability (Wang and 
Meier 2004). Further, H/ACA RNAs have been shown to bind irreversibly to the 
RNP, specifically NAP57, indicating that once formed H/ACA RNP’s do not 
exchange their RNA components (Wang and Meier 2004; Kittur et al. 2006).   
 
1.5. Telomeres and the telomerase complex 
Telomeres are DNA-protein complexes that cap the ends of eukaryotic chromosomes 
and their function is essentially to protect the stability of the genome by preserving 
the integrity of the chromosome. The DNA component is a long stretch of 6bp 
TTAGGG repeats that is processed by unidentified nuclease activity to terminate in a 
single stranded 3’ overhang. This telomeric DNA is folded back on itself, the ssDNA 
overhang invading the dsDNA to form a closed loop structure at the end of the 
chromosome called the T-loop. The exact mechanism behind this loop formation is 
not fully understood but is thought to be mediated by shelterin, a protein complex that 
associates along the length of the telomere (figure 1.4) (reviewed Blackburn 2001; de 
Lange 2005; Shay and Wright 2005). This effectively provides a ‘neat and tidy’ end to 
the chromosome that protects it from random degradation and fusion events, 
disguising it from DNA repair mechanisms that might otherwise mistake it for a 
chromosomal break point.  
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Telomeres also protect against the degradation that occurs with DNA replication. 
Semi-conservative DNA replication, or more specifically its 5’-3’ nature, gives rise to 
the ‘end replication problem’ where the 3’ lagging strand is unable to fully replicate 
causing 50-100bp to be lost from the end of the DNA with each division (figure 1.5). 
Telomeric DNA provides a ‘buffer zone’ protecting the genome from this slow 
attrition (reviewed Blackburn 2001; Shay and Wright 2005). The consequence of this 
is progressive telomere shortening as cells divide which can be observed with ageing 
both in vivo and in vitro (Harley et al. 1990; Vaziri et al. 1994; Allsopp et al. 1995). 
When telomeres are reduced to a critical length further cell divisions are prevented 
Figure 1.4. T-Loop formation and the proposed role of shelterin. (A) The 
telomere is extended during DNA replication and processed to create a long 3’ 
overhang. (B) Shelterin proteins associate to form complexes along the length 
of the telomere. (C) Thought to be mediated by shelterin, the telomere is folded 
back on itself forming the T-loop. (D) The T-loop is closed by the 3’ overhang 
invading the dsDNA of the telomere, creating a smaller D-loop in the process. 
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and the cell enters replicative senescence or apoptosis (reviewed Blackburn 2001; 
Shay and Wright 2005) This correlates with earlier observations that normal somatic 
cells undergo a finite number of divisions the maximum possible called the Hayflick 
limit (Hayflick 1965). Telomere shortening is a particular threat to stem cell pools and 
proliferating tissues where cells replicate frequently, haematopoietic stem cells in the 
bone marrow being a relevant example. The answer to this problem for many of these 
cell types is telomerase.  
 
 
 
Telomerase is an RNP complex with a specialised reverse transcriptase (RT) function 
that acts to extend the telomere repeat region during DNA replication, allowing 
telomere length to be maintained through successive cell divisions and protecting the 
cell from telomere related senescence or apoptosis. It is composed of several subunits 
3’ 5’ 
3’ 5’ 
B 
5’ 3’ 
3’ 5’ C 
A 
Replication bubble 
3’ 5’ 
Leading strand 
5’ 3’ 
Lagging strand 
Figure 1.5. The end replication problem. (A) A replication bubble forms and 
DNA is replicated outward in both directions. (B) Synthesis of the lagging 
strand is fragmented - Okasaki fragments. (C) Primers (red) are removed and 
the gaps filled. This is not possible at the 5’ end of the daughter strand leading 
to incomplete replication of the parental 3’ strand and progressive DNA loss.  
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but two in particular are responsible for its functional activity: a catalytic component 
TERT provides the enzymatic RT activity; and an RNA component TERC which 
provides the template for telomere elongation. Telomerase was also found to comprise 
an H/ACA RNP at its core (the telomerase RNP) via discovery of the H/ACA motif 
towards the 3’ end of TERC, subsequent studies confirming its interaction with 
dyskerin, NOP10, NHP2 and GAR1 like any other H/ACA RNA. The telomerase 
RNP then recruits TERT to create a mature, functional telomerase complex (figure 
1.6) (Reviewed Collins and Mitchell 2002; Cong et al. 2002). However, the role of 
telomerase is uniquely different to that of other H/ACA RNPs and no 
pseudouridylation targets have been identified to imply that TERC has a dual role. 
Therefore, in the context of telomerase, the catalytic function of dyskerin appears to 
be redundant suggesting that in this instance the role of the H/ACA RNP is simply to 
provide a structural framework for the larger complex. Certainly, like other H/ACA 
RNAs, in both yeast and mice the stable accumulation of TERC has been shown to 
depend on dyskerin, NOP10 and NHP2 (Dez et al. 2001; Wang and Meier 2004). 
 
 
 
1.6. DC: a defect of telomere maintenance? 
The first DC mutations characterised were in the X-linked dyskerin gene DKC1. A 
highly conserved protein, dyskerin was identified as the human orthologue to Cbf5p 
in yeast and the key catalytic component of human H/ACA RNPs (Heiss et al. 1998; 
Dragon et al. 2000; Pogacic et al. 2000). Structurally it has two key functional 
TERT 
NOP10 
NHP2 
Dyskerin GAR1 
TERC 
Figure 1.6. A schematic representation 
of the telomerase complex.  
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domains: a TruB domain responsible for its catalytic activity; and a PUA domain that 
is important for RNA binding (Heiss et al. 1998; Aravind and Koonin 1999). Most of 
the dyskerin mutations identified in DC cluster in or around the PUA domain 
suggesting that they impact on dyskerin-H/ACA RNA interactions (Rashid et al. 
2006; Vulliamy et al. 2006). Initially the association with telomerase was unknown 
and DC was thought to stem from a defect in pseudouridylation and rRNA processing 
(Luzzatto and Karadimitris 1998). However, the discovery that dyskerin is also part of 
the telomerase complex offered an alternative possibility and gave rise to renewed 
thought on the cause of DC. Indeed, subsequent research on cells from patients with 
DKC1 mutations revealed no discernible differences in H/ACA RNA accumulation, 
pseudouridine content or rRNA processing between affected and unaffected family 
members. Instead patients exhibit a marked decrease in TERC accumulation, 
telomerase activity and telomere length (Mitchell et al. 1999b; Vulliamy et al. 2001a; 
Montanaro et al. 2002; Wong et al. 2004; Wong and Collins 2006). 
 
Following this, heterozygous mutations in the AD form of DC were discovered in a 
second gene TERC, encoding the telomerase RNA: TERC (Vulliamy et al. 2001b). A 
functional RNA molecule, TERC undergoes rapid 3’ end processing from the nascent 
RNA transcript to the mature functional molecule with a complex secondary structure. 
Within this structure are four key elements of functional significance (figure 1.7). 
Two are important for the catalytic activity of telomerase, the pseudoknot and the 
CR4-CR5 domains. The other two appear to be important for correct processing and 
accumulation of the mature TERC, these are the H/ACA and CR7 domains (reviewed 
Chen and Greider 2004). Mutations have been found in all of these elements and also 
deletions in both the 5’ and 3’ regions, though most locate to the pseudoknot domain 
(Marrone and Dokal 2006). As there are no pseudouridylation targets associated with 
TERC, pseudouridylation defects are not implicated by these mutations. Instead these 
patients also exhibit shorter than average telomeres and there is functional data to 
demonstrate that TERC mutations reduce telomerase activity through diminished 
TERC stability and accumulation or direct disruption to the catalytic process 
(Vulliamy et al. 2001b; Marrone et al. 2004; Vulliamy et al. 2004). In the 
heterozygous state these mutations do not have a dominant negative effect but instead 
cause haploinsufficiency, the unaffected allele proving inadequate for maintaining 
optimal telomerase activity. The result is gradual shortening of the telomeres that 
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gives rise to a delayed clinical presentation and disease anticipation in affected 
families, where the manifestation and severity of the disease increases with successive 
generations (Marrone et al. 2004; Vulliamy et al. 2004). 
 
 
 
Heterozygous mutations have also been found in the TERT gene of some AD DC 
patients (Armanios et al. 2005; Vulliamy et al. 2005). TERT is a large protein with 
several functionally conserved regions. The characteristic, highly conserved RT motif 
and an adjacent telomerase specific T-motif are located in the C-terminal half of the 
protein (Reviewed Cong et al. 2002). Heterozygous mutations in TERT have been 
associated with reduced telomerase activity by haploinsufficiency, but generally the 
disease significance of TERT mutations is variable and considered more a risk factor 
than a cause (Armanios et al. 2005; Vulliamy et al. 2005; Yamaguchi et al. 2005).    
 
Finally, homozygous mutations in the AR DC genes NOP10 and NHP2 are very rare 
with instances in only one and two families respectively. The NOP10 protein 
measures only 64 amino acids in length and has no known functional motifs (Henras 
et al. 1998). NHP2 is an RNA binding protein, its specificity for H/ACA RNAs 
determined indirectly through its association with the H/ACA RNP (Wang and Meier 
2004). Though other H/ACA RNAs and pseudouridylation have not been investigated 
3’ 
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Figure 1.7. A model of TERC’s secondary structure highlighting key domains  
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here, the patients affected with these mutations were found to have short telomeres 
and low levels of TERC. In vitro studies have shown that TERC is a limiting factor 
for telomerase activity (Wong and Collins 2006) and so these patients would be 
predicted to have reduced telomerase activity.    
 
It is clear from the mutations discovered and characterised to date that the telomerase 
complex and telomere length is heavily implicated in DC pathology with shorter than 
average telomeres a common feature. Mutations have been found in five telomerase 
components, DKC1 and TERC mutations featuring most prominently, and can be 
associated with a negative impact on TERC accumulation and telomerase activity. As 
telomerase functions to maintain telomere length it is understandable how reduced 
telomerase activity could lead to short telomeres. This fits well with the DC 
phenotype which presents most significantly in proliferating cells and tissues that are 
particularly susceptible to accelerated telomere shortening. Consequently, current 
opinion centres on DC being primarily a disorder of telomerase activity and telomere 
maintenance. However, it is important not to ignore the important roles dyskerin, 
NOP10 and NHP2 play in pseudouridylation and ribosomal processing and the 
potential implication for multiple defects in DC. Certainly it is noteworthy that these 
three H/ACA RNP components are associated with the more severe X-linked and AR 
forms of DC while the telomerase specific TERC and TERT are linked with the 
milder AD form of the disease. Perhaps the more severe phenotype is the result of a 
ribosomal defect also contributing to the disease? Evidence to support this can be 
found in mouse models of DC where Dkc1 (DKC1) was mutated in an attempt to 
replicate this disease. Mice bearing a hypomorphic mutation that reduced Dkc1 
expression (fourfold in males, twofold in females) displayed DC like features 
including dyskeratosis of the skin, features of BMF and an increased propensity to 
developing tumours. These mice exhibited defects in pseudouridylation and rRNA 
processing as well as a reduction in mTR (TERC) levels and telomerase activity. 
However, telomere length defects were not observed until the fourth generation while 
the features of disease were clearly manifest from the first generation onwards 
(Ruggero et al. 2003). This model of DC would therefore suggest that the 
development of DC disease is independent of the telomerase defect. An in vitro 
mouse study specifically investigating two dyskerin mutations found in DC patients 
also observed defects in pseudouridylation and rRNA processing, though impacts on 
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telomerase activity and telomere length were only evident for one of the mutations 
(Mochizuki et al. 2004). Meanwhile, a study in human breast carcinomas found both 
TERC levels and pseudouridylation activity to be diminished in response to reduced 
dyskerin expression (Montanaro et al. 2006). Taken together these findings provide a 
convincing argument that defects in pseudouridylation and ribosomal processing 
could play a significant role in DC. The lack of corroborating evidence from patient 
studies, however, favours the disruption in telomerase activity and telomere 
maintenance as the principle defect in this disease (Mitchell et al. 1999b; Montanaro 
et al. 2002; Wong and Collins 2006). 
 
1.7. Genetically related disorders 
As already mentioned, DC has a heterogeneous clinical presentation that shares 
significant overlap with several other diseases. As the molecular basis of DC 
continues to be unravelled genetic overlap is also evident in some cases, particularly 
Hoyeraal Hreidarsson syndrome (HH), aplastic anaemia (AA) and myelodysplasia 
(MDS). HH is a severe multisystem disorder with prenatal onset that is typically 
characterised by intrauterine growth restriction, developmental delay, microcephaly, 
cerebellar hypoplasia, BMF and immunodeficiency. Investigated based on the clinical 
similarity to DC and x-linked inheritance in this disease, DKC1 mutations have been 
identified in multiple cases of HH (Knight et al. 1999; Yaghmai et al. 2000). A 
homozygous TERT mutation has also been reported in a rare case of female HH 
(Marrone et al. 2007). These patients are found to have short telomeres and are 
considered severe variants of DC, death from BMF often occurring before the more 
characteristic features of DC can manifest. AA is a BMF syndrome characterised by 
pancytopenia and hypocellular bone marrow where the cause is idiopathic in the 
majority of cases. An initial presentation of AA has been associated with DC and 
analysis has identified TERC and TERT mutations in a subset of idiopathic AA 
patients that also have short telomeres (Vulliamy et al. 2002; Yamaguchi et al. 2003; 
Yamaguchi et al. 2005). Linking their disease to DC, these patients do not usually 
develop classical features of the disease and so they are considered to be ‘cryptic 
forms of DC’. Similarly, TERC mutations and short telomeres have also been 
identified in a subset of patients with MDS, a global BMF syndrome characterised by 
ineffective haematopoiesis and reduced BM progenitor cells (Yamaguchi et al. 2003).  
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1.8. Project aims and objectives 
The mutations identified in DC patients heavily implicate the telomerase complex and 
telomere maintenance in the underlying molecular pathology of this disease. Initially 
characterised as H/ACA RNP components important for pseudouridylation and rRNA 
processing, the roles of dyskerin, NOP10 and NHP2 in this functionally distinct 
complex are less defined.  
 
In order to better understand their implications in DC this study aims to investigate 
the importance of these core proteins for the integrity and function of telomerase as 
well as telomere maintenance. Moreover, to provide in vitro analysis of the potential 
impact dyskerin, NOP10 and NHP2 mutations may have on their function.  
 
Finally, with growing implications for defective telomere maintenance in DC this 
study also aims to further investigate the prevalence of short telomeres in this disease 
and any potential correlations with mutation status. 
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Chapter 2. Materials and Methods 
2.1. Materials 
2.1.1. Chemicals and Reagents 
All laboratory chemicals were of analytical or molecular biology grade and were 
obtained from BDH (supplied by VWR), Sigma-Aldrich, Fisher, or Merck. Tissue 
culture reagents were obtained from Lonza and Harlan. Various specialised reagents and 
materials used in these experiments were purchased from Invitrogen, Qiagen, Bio-Rad, 
Perkin Elmer or GE Healthcare, and are specifically identified in the methods section. 
 
2.1.2. Enzymes and Kits 
Various specialised kits, PCR master mixes and enzymes used in this study were 
supplied by Qiagen, Dako, Bio-Rad, Chemicon, Applied Biosystems, Roche, 
Invitrogen, Bioline, New England Biolabs (NEB), Thermo Scientific, Fermentas and 
Sigma-Aldrich. These are detailed individually in the methods section.   
 
2.1.3. Primers and siRNAs 
Listed in appendix B, all PCR primers and other oligonucleotides were synthesised by 
Sigma-Genosys and dissolved in sterile de-ionised water to give a stock concentration 
of 100µM, stored at -20°C. Specific TaqMan® Gene Expression Assays were purchased 
from Applied Biosystems as detailed in appendix B. The siRNAs used in this study are 
listed in appendix A and were obtained from Ambion unless otherwise stated.  
 
2.1.4. Plasmid Expression Vectors 
The pSilencer 2.1-U6 neo shRNA expression vector was purchased from Ambion and 
the MISSION shRNA lentiviral expression vectors from Sigma-Aldrich. The pCAG-
kGP1.1R, pCAG4-RTR2, pCAGG5-VSVG and pCL10.1 MSCV Ir-GFP plasmids 
used for lentiviral packaging were kind gifts from Amit Nathwani (UCL). The 
pIRES2-EGFP plasmid was laboratory stock but originates from Clontech.  
 
2.1.5. Bacterial Strains and Cell Lines 
The DH5α ™ competent cells used for plasmid cloning were obtained from 
Invitrogen. The HeLa and HEK293T cell lines were laboratory stock.  
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2.1.6. Patient Samples 
The DC patients and healthy controls included in aspects of this study were all 
recruited to the DCR in London, from whom samples of whole blood were obtained 
with written consent in accordance with the Declaration of Helsinki and with approval 
from the East London and City Research Ethics Committee. The DCR currently holds 
clinical and genetic information for 387 families worldwide and comprises 569 
affected individuals (415 male, 154 female). Current criteria for entry into the DCR 
requires that the index case present either: (i) the diagnostic triad of mucocutaneous 
features (nail dystrophy, leukoplakia, and abnormal skin pigmentation), (ii) 1 or more 
of the mucocutaneous features (nail dystrophy, leukoplakia, and abnormal skin 
pigmentation), combined with a hypoplastic bone marrow and at least 2 of the other 
somatic features associated with DC, or (iii) at least 4 the 6 common features of HH 
(intrauterine growth restriction, developmental delay, microcephaly, cerebellar 
hypoplasia, BMF or immunodeficiency). Families of patients initially presenting AA 
that were found to have mutations in the TERC or TINF2 genes have also be included 
in the DCR (Vulliamy et al. 2011b).  
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2.2. Methods 
2.2.1. Tissue Culture 
Experiments were performed using HeLa cells an immortalised human cervical cancer 
cell line and HEK293T cells an immortalised embryonic kidney cell line, both of 
which are adherent. Cells were cultured in Dulbecco’s Modified eagle Medium 
(DMEM) containing 4.5g/l Glucose, L-Glutamine, Sodium Pyruvate (Lonza) 
supplemented with Foetal Calf serum to 10% (Harlen), Penicillin (100units/ml), 
Streptomycin (100ug/ml) and Fungizone (250ng/ml) (Lonza). Cells were cultured 
under humidified conditions at 5% CO2 and 37°C. To passage the cultures all DMEM 
was removed and the cells washed with 1x phosphate buffered saline (PBS) (Lonza) 
solution. Trypsin/versin solution, enough to cover the cells, was added and incubated 
at 37°C for 2-3min to allow the cells to detach from the surface of the culturing flask. 
An equal or greater volume of DMEM was added to neutralise the trypsin/versin, the 
cells pelleted (1500rpm, 5min) and the supernatant removed. The cells were washed 
by resuspending in a suitable volume of 1x PBS and pelleted again. Depending on 
requirements, the cells were resuspended in a small volume of medium and counted 
for seeding at a specific densities or seeded less specifically i.e. 1 in 4.  
 
2.2.2. Transfections 
2.2.2.1. Transient 
Cells were seeded into 6 well plates at a density of 3-5x10
5
 cells per well and in 1.5ml 
of antibiotic free DMEM 24hr prior to transfection. Transfections were carried out 
using Lipofectamine 2000 or Lipofectamine RNAiMAX (Invitrogen) according to the 
manufactures protocol. Appropriate amounts of siRNA or plasmid were complexed 
with 5µl (siRNA)  or 10µl (plasmid) of lipofectamine reagent in 500µl of serum and 
antibiotic free DMEM at room temperature for 20min before adding to the cells, 
giving a final culture volume of 2ml. At relevant time points, cells were harvested for 
analysis by detaching with trypsin/versin solution and washing as described in 2.2.1. 
 
2.2.2.2. Stable 
Cells were initially seeded into 6 well plates, cultured and transfected as described for 
a transient transfection. Plasmid was complexed with 10µl of lipofectamine reagent in 
500µl of serum and antibiotic free DMEM at room temperature for 20min before 
adding to the cells giving a final culture volume of 2ml. After 24hr the cells were 
Functional characterisation of the genes mutated in dyskeratosis congenita 
  34  
transferred to a T75 flask containing 10ml of DMEM, supplemented after 48hr with 
neomycin (G418) at 800µg/ml and maintained for 2-3 weeks to select for stably 
transfected cells conferring the antibiotic resistance. After this time neomycin was 
used at 400µg/ml to maintain the selective pressure. 
 
2.2.3. Lentiviral Packaging 
The human embryonic kidney cell line HEK293T was used to package lentiviral 
particles for downstream transduction of target cells. Cells were seeded into T175 
flasks and cultured in antibiotic free DMEM to between 50-75% confluence. Plasmid 
constructs expressing the necessary components for lentiviral packaging were then 
transfected into the cells using Lipofectamine LTX (Invitrogen) according to the 
manufactures protocol. 12g gag/pol enzymatic component plasmid: pCAG-
kGP1.1R, 4g Rev/Tat response element packaging plasmid: pCAG4-RTR2, g 
vesicular stomatitis virus G protein envelope plasmid: pCAGG5-VSVG and 20g 
lentiviral genome vector: pCL10.1 MSCV Ir-GFP (All gifts from Amit Nathwani, 
UCL (Kyriakou et al)) were mixed and then complexed with 94µl of Lipofectamine 
LTX reagent in 7.5ml of antibiotic and serum free DMEM at room temperature for 
30min. The transfection complexes were then applied to the cells, replacing the 
medium in the flask with 22.5ml of fresh antibiotic free DMEM to give a final culture 
volume of 30ml. After culturing overnight the cells were rinsed in the flask with 1x 
PBS twice before adding 16ml of fresh DMEM. Cells were then cultured for a further 
24-36hr while they produced packaged lentiviral particles. The lentivirus containing 
culture medium was then collected and passed through a 0.45m filter to remove any 
cells.  
 
2.2.4. Lentiviral Concentration 
Lentiviral particles were concentrated by complexing with chondroitin sulphate C 
(CSC) and polybrene (PB). Filtered lentivirus containing medium was divided into 
1.5ml aliquots then PB (Sigma) and CSC (Sigma) added, 4µl (20mg/ml) each. 
Samples were incubated at 37°C for 20min to allow lentiviral complexes to form 
before pelleting them (13000rpm, 5min). Each lentivirus containing pellet was 
resuspended in 100µl of 1x PBS before pooling together and separating into 50µl 
aliquots for use in downstream applications or storage at -70°C.  
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2.2.5. Lentiviral Transduction  
Cells were seeded into a 6 well plate at a density of 3-5x10
5
 cells per well and in 2ml 
of DMEM 24hr prior to transduction. Viral particles were applied to the cells in 50µl 
aliquots and cultured for 6hr before transferring the cells to a T75 flask containing 
10ml of DMEM. Culture medium was supplemented with puromycin to 1µg/ml after 
48hr and maintained for a further 2-3 weeks to select for transduced cells conferring 
the puromycin resistance. 
 
2.2.6. RNA Extraction and DNase Treatment 
Total RNA was extracted from cells using the RNeasy mini kit (Qiagen) according to 
manufacturer protocols. Cell pellets were resuspended in 350µl of the RLT cell lysis 
buffer (Qiagen), homogenized and stored at -70°C to be completed in larger batches at 
a later date. To complete the extraction cell lysates were precipitated with an equal 
volume of 70% ethanol and applied to RNA binding spin columns (13,000rpm, 
30sec). Columns were subsequently washed through once with 700µl of buffer RW1 
(Qiagen) and then twice with 500µl of buffer RPE (70% ethanol) (Qiagen) before 
‘dry’ spinning the column to ensure all residual buffer was removed (all spins 
13,000rpm, 1min). RNA was eluted from the column into ~35µl of RNase/DNase free 
water. DNA contamination was removed by adding 1 unit of DNase1 enzyme 
(Invitrogen), 4µl of 10x DNase buffer and incubating at 37°C for 15min. The enzyme 
was then deactivated by heating to 65°C for 10min. All RNA samples were stored at -
70°C. 
 
2.2.7. First Strand cDNA Synthesis 
First strand cDNA synthesis was performed using M-MLV RT enzyme (Invitrogen) 
according to manufacturer protocols. Total RNA was used to prepare cDNA in 40µl 
reactions consisting of 20µl RNA (DNase treated), 1x reaction buffer (50mM Tris-
HCl pH 8.3, 75mM KCl, 3mM MgCl2), 10mM DTT, 60units RNasin (Bioline), 200ng 
random hexamers (Qiagen), 0.5mM dNTP mix (Invitrogen), 300units M-MLV RT 
enzyme.  The reaction mixture was incubated at 37°C for a minimum of 1hr before 
the reaction was stopped by heat inactivating the RT enzyme at 70°C for 15min. All 
cDNA samples were stored at -20°C. 
 
Functional characterisation of the genes mutated in dyskeratosis congenita 
  36  
2.2.8. Standard PCR 
PCR was performed using Taq DNA polymerase (Thermo Scientific) in a 
programmable thermocycler (Eppendorf Mastercycler). 25µl reactions consisted of 
1µl cDNA or DNA template, 1x PCR buffer (Thermo Scientific; 75mM Tris-HCl pH 
8.8, 20mM (NH4)2SO4, 0.01% Tween® 20), 1.5mM MgCl2, 0.2mM dNTP mix 
(Invitrogen), 0.2mM of each primer (forward and reverse) and 1 unit of enzyme. 
Reactions were run using a standard PCR cycle program: 95°C for 2min; then 35 
cycles of 95°C for 30sec, 58°C for 45sec, 72°C for 1min; followed by 72°C for 5min.  
 
2.2.9. Quantitative Real Time PCR 
Quantitative real time PCR (qPCR) uses sequence detection methods to quantify 
amplification products after each cycle of the PCR. One approach uses dual-labelled 
oligonucleotide probes specific to a short sequence within that to be amplified. During 
amplification the exonuclease activity of the Taq polymerase releases a fluorophore 
from the probes 5’ end which allows it to fluoresce by liberating it from the effects of 
a quencher at the 3’ end. Alternatively, DNA binding dyes can be used that only 
fluoresce when intercalated with double stranded DNA i.e. amplified PCR products. 
In both cases the fluorescence generated is directly proportional to the amount of 
amplified products and is measured after each cycle allowing product accumulation to 
be quantified. Quantification is achieved by reference to either a calibrator sample 
(relative quantification) or to a standard curve generated using data from samples in 
which the copy number is already known (absolute quantification). To control for 
variations in sample loading values are normalised to that of an endogenous control 
that is also quantified. In this study both methods of detection and quantification have 
been employed using the endogenous ABL gene to normalise. 
 
2.2.9.1. Standard Curve Preparation 
Standard curve samples were generated from PCR products for the target gene to be 
quantified, initially amplified in a standard PCR reaction. A post amplification copy 
number was determined using product concentration, length, the molecular weight of 
DNA (660g/bp) and Avogadro’s constant (6.022E+23) in the following calculation. 
 
 
 
Concentration (ng/ul) x 6.022E+23 
       Length (bp) x 1x10
9
 x 660 
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The PCR products were then serially diluted to generate an 8 point standard curve 
comprising 10
9
, 10
7
, 10
6
, 10
5
, 10
4
, 10
3
, 10
2
 and 0 copies/2µl. 
 
2.2.9.2. Probe Based Detection – TaqMan

 Probes   
Reactions were carried out using the TaqMan

 probe PCR system (Applied 
Biosystems) according to manufacturer protocols. 20µl reactions consisted of 2µl 
cDNA, 1x TaqMan
®
 Universal Master Mix (Applied Biosystems) and primers and 
probes that varied depending on the gene assayed (details in appendix B). Reactions 
were set up in triplicate and run on an ABI 7500 real time PCR machine (Applied 
Biosystems) using the following cycle program: 50°C for 2min, 95°C for 10min; then 
50 cycles of 95°C for 15sec, 60°C for 1min* (* denotes fluorescence signal detection 
step).  
 
2.2.9.3. DNA Dye Based Detection – SYBR

 Green 
Reactions were carried out using SYBR

 Green PCR Master Mix, (Applied 
Biosystems) according the manufacturers protocol. 20µl reactions consisted of 1µl 
cDNA, 1x SYBR Green PCR Master Mix (Applied Biosystems), and 0.2mM of each 
primer (details in appendix B). Reactions were set up in duplicate and run on an ABI 
7500 real time PCR machine (Applied Biosystems) using the following cycle 
program: 50°C for 2min, 95°C for 10min; then 50 cycles of 95°C for 15sec, 60°C for 
1min* (* denotes fluorescence signal detection step).  
 
2.2.9.4. qPCR Analysis 
Initial analysis of the raw fluorescence data generated was performed in an automated 
process using the 7500 System Sequence Detection Software v1.2.3 (Applied 
Biosystems). Firstly, fluorescence signals were normalised to that of the passive 
reference dye ROX™, included within the PCR master mix, to give a reporter 
normalised (Rn) value for each cycle of the reaction. Next, a baseline signal was 
determined to account for background fluorescence and the Rn values baseline 
corrected to give ΔRn values. Finally, amplification curves were plotted using log 
(ΔRn) against cycle number and a threshold ΔRn value set to intersect the exponential 
(or geometric) phase of the curves. The point of intersection determines the threshold 
cycle (CT) number which is used as the basic measure of relative target concentration 
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within the PCR. The CT values for experimental and control samples were then used 
in subsequent calculations to achieve either absolute or relative target quantification. 
  
2.2.9.4.1. Absolute Quantification 
Absolute quantities were determined by comparison to a standard curve, generated by 
plotting log copy number against CT for the standard curve samples. The equation of 
the line was then used to extrapolate copy number information from the CT values of 
unknown samples. Copy numbers were calculated for each PCR replicate before 
averaging to obtain a final copy number for the sample. Target copy numbers were 
then normalised to those of the ABL endogenous control also measured in each sample 
as a reference. This was achieved by dividing the target and ABL copy numbers to 
give a target/ABL ratio which is used as the final measure of target quantity for 
comparison. 
 
2.2.9.4.2. Relative Quantification 
Relative quantities were determined using the comparative CT method described by 
Applied Biosystems. The amount of target was normalised to the ABL reference and 
calculated relative to a designated calibrator sample using only CT values in the 
mathematical formula 2
-ΔΔC
T as follows.   
 
1. ABL (R) CT subtracted from target (X) CT to give ΔCT.   
ΔCT  =  CT,X  -  CT,R  
 
2. Calibrator (C) ΔCT subtracted from sample (S) ΔCT to give ΔΔCT.   
ΔΔCT  =  ΔCT,S  -  ΔCT,C 
 
3. Relative quantity = 2-ΔΔCT 
 
2.2.10. Agarose Gel Electrophoresis  
PCR products and other nucleic acids samples were separated by electrophoresis on 
agarose gels made at 1.5% in 100ml of 0.5x Tris-Borate-EDTA buffer (TBE: 90mM 
Tris, 90mM Boric acid, 2mM EDTA), with 10µg of ethidium bromide. 6x loading 
buffer (3x TBE, 30% glycerol, 0.3% bromophenol blue) was added to the samples to 
give 1x final concentration and 10µl loaded for electrophoresis. Gels were run in 0.5x 
TBE buffer and visualised under UV illumination. 
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2.2.11. Gel Extraction and Purification 
Gel extraction and purifications were carried out using the QIAquick Gel Extraction 
kit (Qiagen). DNA bands were cut from agarose gel under UV illumination. A volume 
of Buffer GE (Qiagen) was added corresponding to the 3x the weight of the excised 
gel fragment (100µg = 300µl) and incubated at 50°C for 10min to dissolve the gel. A 
volume of 100% isopropanol corresponding to 1x the weight was added before 
applying to a DNA binding spin column (all spins 13,000rpm, 1min). Columns were 
subsequently washed through with Buffer PE (Qiagen) and the DNA eluted into 30-
50µl of buffer EB (Qiagen). Purified DNA bands stored at -20°C. 
 
2.2.12. Oligonucleotide Annealing 
Long, complementary oligonucleotides encoding shRNA sequences were annealed to 
create double stranded DNA molecules for cloning into the pSilencer™ 2.1-U6 neo 
expression plasmid (Ambion). Oligonucleotides were diluted to 1µg/µl in TE buffer 
(10mM Tris, 1mM EDTA) prior to annealing. In 50µl reactions, 2µg of each 
oligonucleotide were mixed in 1x DNA annealing solution (Ambion) and heated to 
95°C for 3-4min before leaving to cool slowly for 1hr. The annealed oligonucleotides 
are then ready for downstream applications or storage at -20°C. 
 
2.2.13. Ligation  
Ligations were carried out using T4 DNA ligase (Fermentas) in 10µl reactions 
consisting of 1µl annealed oligonucleotides, 1µl linear pSilencer™ 2.1-U6 neo 
(Ambion), 1µl ligase mixed in 1x ligation buffer (Fermentas). Reactions were 
incubated at 4°C overnight and stopped by heating to 65°C for 10min. 
 
2.2.14. Transformation of Competent E.Coli. 
Transformations were performed using DH5α ™ competent cells (Invitrogen), 25µl of 
the cells were mixed with 3µl of ligation reaction and incubated on ice for 30min. 
Reactions were then heat shocked at 42°C for 20sec and returned to the ice for a 
further 2min before adding 500µl of Luria-Bertani broth (LB) (Merck) and incubating 
at 37°C for 1hr.  70µl were then plated on LB agar (Merck) plates containing 
ampicillin (Sigma) at 50µg/ml and incubated at 37°C overnight. 
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2.2.15. Small Scale Plasmid DNA Preparation 
Bacteria from a single colony were cultured overnight in 2ml LB, supplemented with 
ampicillin at 50µg/ml, at 37°C with shaking. Cells were then pelleted (13,000rpm, 
5min) and plasmid extracted using the QIAprep Spin Miniprep kit (Qiagen) according 
to manufacturer’s protocols. Cells were resuspended in 250µl of Buffer P1 (Qiagen) 
before lysing with 250µl of Buffer P2 (Qiagen), after 5min the lysis reaction was 
stopped with 350µl of Buffer N3 (Qiagen). Protein precipitate was pelleted 
(13,000rpm, 10min) and the supernatant applied to the DNA binding spin columns 
(all spins 13,000rpm, 1min). Columns were subsequently washed through with 750µl 
of Buffer PE (Qiagen), spun empty to remove any residual buffer and the plasmid 
DNA eluted from the column with 50µl of buffer EB (Qiagen). Plasmids were stored 
at -20°C. 
 
2.2.16. Large Scale Plasmid DNA Preparation 
Bacteria from a single colony were cultured for 6-8hr in 1ml LB supplemented with 
ampicillin to 50µg/ml, at 37°C with shaking. The starter culture was then added to 
500ml LB supplemented with ampicilin to 50µg/ml and cultured overnight at 37°C 
with shaking. Bacteria were then pelleted (6000x g, 15min, 4°C) and plasmid DNA 
extracted using the QIAGEN Plasmid Maxi kit (Qiagen) according to manufacturer 
protocols. Bacterial cells were resuspended in 10ml of Buffer P1 (Qiagen) before 
lysing with 10ml of Buffer P2 (Qiagen) at room temp for 5min. The lysis reaction was 
stopped with 10ml of chilled Buffer P3 (Qiagen), incubating on ice for 15min to 
precipitate the protein. The precipitate was then pelleted (20,000x g, 30min, 4°C) and 
the plasmid DNA containing supernatant centrifuged a second time (20,000x g, 
15min, 4°C) to ensure all protein precipitate was removed. The supernatant was then 
applied to DNA binding filter columns (QIAGEN-tip 500), pre-equilibrated with 10ml 
of Buffer QBT (Qiagen), and allowed to pass through by gravity flow. Columns were 
subsequently washed through twice with 30ml Buffer QC (Qiagen) and the plasmid 
DNA eluted from the column with 15ml of buffer QF (Qiagen). Plasmid DNA was 
then precipitated by mixing with 10.5ml of isopropanol, pelleted  (15,000x g, 30min, 
4°C) and washed with 5ml of 70% ethanol before pelleting again (15,000x g, 10min). 
The plasmid DNA pellet was left to air dry for 5-10min before dissolving in a suitable 
volume (typically 1ml) of TE buffer (Qiagen). Plasmids were stored at -20°C. 
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2.2.17. Genomic DNA Extraction  
Genomic DNA was extracted from cells using the Gentra

 Puregene

 DNA extraction 
kit (Qiagen) according to manufacturer protocols. Cell pellets were resuspended in a 
suitable volume of Cell Lysis Solution (Qiagen) to completely lyse the cells. Protein 
was then removed from the lysate by adding a volume of Precipitation Solution 
(Qiagen) (equivalent to 1/3 of the volume used to lyse the cells) and incubated on ice 
for 5min. Precipitate was pelleted (13000rpm, 1min) and the DNA containing 
supernatant carefully removed to a clean tube. DNA was then precipitated by adding a 
volume of 100% isopropanol (equivalent to that used to lyse the cells) and pelleted 
(13000rpm, 1min). The DNA pellet was washed in 300µl of 70% ethanol and pelleted 
again (13000rpm, 1min). The ethanol wash was carefully removed and the DNA 
pellet left to air dry for 5-10min before resuspending in a suitable volume of DNA 
Hydration Solution (Qiagen). Pellets were either left to slowly dissolve overnight or 
more rapidly by heating to 60°C for 1hr. 
 
2.2.18. DNA/RNA Quantification 
DNA and RNA samples were quantified using the NanoDrop 1000 spectrophotometer 
(Thermo Scientific). 1µl of neat sample was applied directly to the machine which 
directly measured and calculated concentration as ng/µl. 
 
2.2.19. Telomere Length Measurement by Southern Blot 
Employing a subtelomeric probe specific to chromosome 7 (pTelBam8) (Brown et al. 
1990), southern blotting was used to specifically identify and measure telomere 
lengths within a DNA sample. Genomic DNA was digested completely with a 
restriction endonuclease to create smaller restriction fragments. These were 
subsequently size separated using agarose gel electrophoresis before transfer and 
immobilisation onto a nylon membrane. The DNA was fixed on the membrane before 
hybridising with a radio-labelled DNA probe to identify the telomeric DNA.  
 
5-10µg of genomic DNA was digested with the BamHI restriction enzyme in 70µl 
reactions consisting of 4µl BamHI (NEB), 7µl 10x RE buffer (NEB) and incubated at 
37°C overnight (16hr +/-). Loading buffer (see 2.2.10) was added to a 1x final 
concentration and the digested products separated by electrophoresis on 0.8% agarose 
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gels made with 450ml 1x Tris-Acetate-EDTA buffer (TAE: 40mM Tris, 20mM 
Acetic acid, 1mM EDTA) containing 150µg of ethidium bromide. Gels were run at 
~60v in 1x TAE buffer for 20-24hr to allow sufficient separation of the restriction 
fragments. Under UV illumination to enable visualising the DNA, excess areas were 
trimmed and discarded prior to soaking the gel in an alkaline denaturing solution 
(1.5M NaCl, 0.5M NaOH) for 40min to denature the DNA. The gel was then 
assembled into a ‘blotting’ stack to facilitate transfer of the DNA from the gel to the 
nylon membrane. This was done by placing the gel, face down, onto a larger sized 
piece of 20mm whatman paper, the ‘wick’, before carefully layering on top a 
corresponding sized piece of nylon Hybond N+  membrane (GE healthcare) and 2 size 
matched pieces of 20mm whatman paper. Extra care was taken not to create or to 
remove any air bubbles that formed between the different layers. Paper towelling was 
then stacked on top to a height of 20-30cm. The stack was assembled above a tray 
containing 20x saline sodium citrate solution (SSC: 3M NaCl, 0.3M trisodium citrate, 
pH 7) into which the ends of the wick extended. This was left overnight (16hr +/-) to 
allow SSC to be absorbed through the stack and to transfer of ssDNA from the gel to 
the membrane. The membrane was then rinsed in 2 changes of 3x SSC before 
incubating at 80°C for 2-3hr in order to cross link the DNA with the membrane. After 
briefly rehydrating in 3x SSC the membrane was incubated in 40ml pre-hybridisation 
solution (6x SSC; 2.5x Denhardt’s solution: 0.05% Ficoll 400, 0.05% PVP-40, 0.05% 
BSA; 10mg carrier DNA and 0.75% SDS) for 4hr at 67°C in preparation for 
hybridisation with the probe.  
 
32P labelled DNA probes were prepared using the Megaprime kit (GE healthcare). 
Primer and probe DNA were pre-annealed in 35µl reactions consisting 5µl primer 
solution and 20-30ng probe DNA heated to 95°C for 5min before slow cooling on the 
bench. This was then supplemented to also consist of 1x labelling buffer (GE 
healthcare), 2-5µl [32P] dCTP (6000Ci/mmol, 20mCi/ml) (Perkin Elmer) and 2µl 
klenow fragment DNA polymerase, making a final volume of 50µl, before incubating 
at 37°C for 30min. The labelled probe was then purified by adding 50µl TE + 0.1% 
SDS and applying to a sephadex G50 spin column (1700x g, 4min) before mixing 
with 400µl of carrier DNA (10µg/µl). Labelled probe was heat denatured at 95°C for 
5min before incubating with the membrane in 10ml hybridisation solution (6x SSC, 
Functional characterisation of the genes mutated in dyskeratosis congenita 
  43  
2.5x Denhardt’s solution, 10mg carrier DNA and 0.75% SDS) at 67°C overnight 
(16hr +/-). The membrane was then subjected to a series of washes to remove any 
unbound probe, all at 67°C as follows: 10ml 2x SSC for 10min; 50ml 2x SSC for 
30min; twice in 10ml 0.2x SSC for 10min. The membrane was wrapped in plastic and 
secured in a developing cassette for exposure overnight (16-24hr +/-) or longer. 
 
Note - All radioactive aspects of this protocol were carried out by Dr T Vulliamy. 
 
2.2.20. Telomere Length Measurements by Flow FISH 
Adapting the protocol according to Baerlocher et al the Telomere PNA kit/FITC 
(Dako) was used to measure relative telomere length (RTL) within nucleated white 
blood cells (Baerlocher et al. 2006). The assay involves fluorescence in situ 
hybridisation (FISH) performed on a cell suspension consisting of white blood cells 
mixed with calf thymocytes (as a control cell) both in the presence and absence of a 
telomere specific PNA/FITC probe which can be detected by flow cytometry. 
Measured a single cell at a time, the fluorescence generated is proportional to the total 
amount of telomeric DNA within the cell. Using samples treated without the probe to 
control for background cell fluorescence, an average RTL for the white cell 
population can be determined using a calibrator sample of pre-determined telomere 
length. 
 
2.2.20.1. White Blood Cell Preparation  
White blood cells were separated from samples of whole blood using red cell lysis 
buffer (RCLB; 155mM NH4Cl, 10mM KHCO3, 0.1mM EDTA, pH 7.4). A volume of 
whole blood was mixed with a minimum of 3 volumes of ice cold RCLB and 
incubated at room temperature for a minimum of 10min to lyse the red blood cells. 
White blood cells were then pelleted (2000rpm, 5min) and the supernatant carefully 
discarded. The cell pellet was resuspended in 1ml of ice cold RCLB and transferred to 
a microfuge tube before centrifuging briefly (12000rpm, 15sec) to pellet the cells 
again. The supernatant was carefully removed and the white cell pellet resuspended in 
a suitable volume of PBS, typically 300µl, and mixed with an equal volume of cell 
freezing medium (FCS, 20% DMSO) before storage at -70°C. 
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2.2.20.2. Probe Hybridisation 
Approximately 2x10
6
 calf thymocytes were mixed with the white blood cell sample 
and then pelleted (12000rpm, 15sec). The supernatant was carefully discarded and the 
cells resuspended in 1ml of PBS before dividing into duplicate 500µl aliquots and 
pelleting again (12000rpm, 15sec). Carefully discarding the supernatant, one of the 
duplicates was resuspended in 150µl of Hybridization Solution (Dako) and the other 
in 150µl of Telomere PNA Probe/FITC in Hybridization Solution (Dako) before 
incubating at 82°C for 10min to denature the DNA. Samples were mixed briefly on a 
vortex and left in a dark place at room temperature to cool overnight and allow the 
probe to hybridise. Samples were washed by mixing with 500µl of Wash Solution 
(Dako) and incubating at 40°C for 10min before pelleting the cells (1500x g, 5min, 
16°C). The supernatant was carefully removed, the cells resuspended in 500µl of 
Wash Solution and incubated at 40°C for 10min for a second time before pelleting 
again (900x g, 5min, 16°C). The supernatant was carefully removed and the cells 
resuspended in 300µl of DNA counterstaining solution (PBS, 0.1% BSA, 1000 U/ml 
Rnase T1, 12.4ng/ml LDS751) before incubating at 4°C for a minimum of 30min. 
Samples were then ready for analysis by flow cytometry and could be stored at 4°C 
for up to 7 days. 
 
2.2.20.3. Flow Cytometry – Data Acquisition and Analysis 
Samples were analysed on a BD FACSCanto II (BD Biosceinces) flow cytometer 
using BD FACSDiva™ software v6.1.3 (BD Biosceinces). LDS751 DNA stain was 
detected using the PerCP-Cy5-5 (red) channel and the PNA probe using the FITC 
(green) channel, both set to linear. Adapted from Baerlocher et al, cell populations 
were selectively gated and data acquired for a combined total of 30-50,000 events as 
outlined in figure 2.1 A-C. All data was collected from the SSC, FSC, PerCP-Cy5-5 
and FITC channels for later analysis. FlowJo software v.8.7.1 (Tree Star) was used to 
perform post acquisition analysis in which the cell populations were gated again and 
median FITC values obtained for each of the cell types as outlined in figure 2.1 A-E.  
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D E 
A B C 
Figure 2.1. RTL by flow FISH. (A) Single cells were gated using PerCP-
Cy5-5-A against PerCP-Cy5-5-W. (B) Sample quality was verified using SSC 
against FSC, checking for the mixed thymocyte/lymphocyte and granulocyte 
populations. (C) Separation of the thymocytes and lymphocytes populations 
was achieved using PerCP-Cy5-5-A against FSC, allowing the 3 cell types to 
be gated individually. (D) For each, FITC singles were visualised as a 
histogram and any ‘low level noise’ removed by gating the predominant 
population. (E) Median FITC values were obtained for the final gated 
populations. 
 
Functional characterisation of the genes mutated in dyskeratosis congenita 
  46  
2.2.20.4. Calculating Relative Telomere Length (RTL)  
For each sample delta FITC median values were calculated by subtracting the median 
obtained from treatment without probe (background) from those obtained with probe, 
for each of the cell populations: thymocytes, lymphocytes and granulocytes. The delta 
FITC median values were then used in the subsequent calculation to determine the 
telomere length relative to the calibration sample.  
 
 
 
2.2.21. Telomere Length Measurement by Monochrome Multiplex qPCR 
Monochrome multiplex qPCR (MMqPCR) was used to measure relative telomere 
lengths within a DNA sample. Devised by Cawthon, this technique is a manipulation 
of qPCR to determine telomere length from a DNA sample (Cawthon 2009). From 
genomic DNA a telomere specific amplicon (T) is amplified by qPCR using the 
SYBR Green DNA dye for detection and quantification. The amplicon is of a fixed 
length (79bp) but is able to prime at sites along the full length of the telomere. As a 
result longer telomeres are able to produce more amplicons meaning that the amount 
of T generated is proportional to telomere length. Therefore, quantification of T can 
be used as a measure of the average telomere length within the DNA sample. To 
control for variations in DNA loading, T is normalised to a single copy gene amplicon 
(S) also quantified, in this case the human beta globin gene. Here, T and S values are 
divided to give a T/S ratio that is used as the final measure of average telomere length 
for the DNA sample. Quantification is achieved by reference to relative standard 
curves for T and S generated by titration of total DNA input of a chosen ‘standard 
DNA’. Consequently, T/S ratios for the unknown samples are relative to that of the 
standard DNA, which is always 1. Therefore, samples with a T/S > 1.0 have an 
average telomere length that is relatively longer than the standard DNA while samples 
with a T/S < 1.0 have an average telomere length that is relatively shorter.  
x  x ?kb 
Bc 
Ac 
AX 
BX 
A = Cell type in question (Lymph or Gran) 
B = Thymocytes  
C = Calibration sample  
X = Sample in question  
? = Telomere length of calibration sample 
(Taken from Baerlocher et al 2006) 
Functional characterisation of the genes mutated in dyskeratosis congenita 
  47  
2.2.21.1. MMqPCR Reactions 
DNA samples were carefully diluted to 2ng/µl and the standard DNA to 15ng/µl, 
serially diluted to give a five point standard curve of 15, 5, 1.666, 0.555, 0.185ng/µl. 
15μl reactions consisted of 1x Roche SYBR Green Master I reaction mix (Roche 
Applied Science), T primers at 1µM each (telc and telg, appendix B), S primers at 
200nM each (hbgu and hbgd, appendix B), and 5µl of DNA. This gave a total DNA 
input of 10ng for experimental samples and 75, 25, 8.333, 2.775, 0.925ng for the five 
point standard curve. Reactions were performed in triplicate and run on a Roche 
LightCycler 480 real time thermal cycler (Roche Applied Science) using cycle 
parameters of: 95°C for 15min; 2 cycles of 94°C for 15sec, 49°C for 15sec; and then 
32 cycles of 94°C for 15sec, 62°C for 10sec, 74°C for 15sec*, 84°C for 10sec, 88°C 
for 15sec* (* denotes fluorescence signal detection steps). 
 
2.2.21.2. MMqPCR Analysis 
The multiplex nature of MMqPCR requires fluorescence data to be acquired twice 
during each cycle. This generates two sets of fluorescence data, one for T and one for 
S, that have to be separated prior to analysis in order to generate independent 
amplification curves for the two. Raw data was exported from the LC480 lightcyler as 
a ‘txt’ file and imported into excel where the two data sets, identifiable by cycle 
details, could be separated manually. Individual data files for T and S were then 
passed through the file conversion software Conversion v1.5 (Dr J.M.Ruijter) from 
which they could be imported into the software LinRegPCR v12.2 (Dr J.M.Ruijter) 
for analysis. In an automated process, the raw fluorescence data was normalised, 
baseline corrected and plotted to obtain CT values as described in 2.2.9.4.   
 
Standard curves for T and S were plotted as log DNA input against CT and the 
equation of the line used to extrapolate DNA input information (as a measure of 
relative abundance) from the CT values of unknown samples. DNA input was 
calculated for each PCR replicate before averaging to obtain a final DNA input value. 
T and S values from the same sample were then divided to give a T/S ratio used as the 
final measure of relative telomere length.  
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2.2.22. Protein Extraction 
Whole cell protein extracts were prepared using Radio-ImmunoPrecipitation Assay 
(RIPA) cell lysis buffer (50mM Tris-HCl pH 8, 150mM NaCl, 1% NP40, 0.1% SDS, 
0.5% sodium deoxycholate) containing 1mM PMSF (phenylmethylsulphonyl 
fluoride) and cocktail protease inhibitors (Sigma). Cell pellets were lysed by mixing 
with a suitable volume of freshly prepared ice cold RIPA lysis buffer and incubating 
on ice for 30mins. Cellular debris was pelleted (12,000rpm, 25min, 4°C) and the 
protein containing supernatant transferred to a fresh tube. Protein lysate were stored at 
-70°C. 
 
2.2.23. Protein Assay 
Protein concentrations were measured using the DC™ protein assay (Bio-Rad), a 
detergent compatible colorimetric assay for soluble protein. Based on the Lowry 
assay, the protein sample is treated with alkaline copper tartrate and Folin reagent 
sequentially. The alkaline copper treated proteins remove oxygen atoms from the 
Folin reagent in a reduction reaction that results in a quantifiable blue colour change 
proportional to the protein concentration. Comparison to a standard curve enables the 
amount of protein to be calculated. Reactions were performed according to the 
manufacturer’s microplate assay protocol. Protein standard II (bovine serum albumin) 
(Boi-Rad) was used to create a standard curve by serially diluting from 1.6 – 
0.1mg/ml. 5µl of protein lysate or standard were first mixed with 25µl of reagent A 
(Bio-Rad), then 200µl of reagent B (Bio-Rad) and incubated at room temperature for 
15mins. Colour change was then measured by absorbance at 750nm and protein 
concentration calculated against the standard curve.  
 
2.2.24. Telomerase Repeat Amplification Protocol (TRAP) Assay 
Telomerase activity was measured using the TRAPeze
®
 RT Telomerase Detection Kit 
(Chemicon). This is a fluorometric PCR based assay for in vitro analysis of 
telomerase activity in the cells of interest. The assay initially involves preparing a cell 
extract which is subsequently used in two separate enzymatic reactions performed in 
one tube. In the first, telomerase activity extends a synthetic telomere (TS) mimicking 
telomere extension within the cell. In the second, the extended TS is amplified by 
qPCR using the fluorescently labeled Amplifluor® reverse primer complementary to 
GGTTAG of the telomere repeat sequence. Fluorescence emission occurs only when 
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the Amplifluor
®
 reverse primer is incorporated into a PCR product, the measure of 
which is directly proportional to the amount of TRAP products generated i.e. to the 
level of telomerase activity in the first reaction. Quantification is achieved by 
reference to a standard curve which is generated using the TSR8 control template (TS 
primer extended with 8 telomeric repeats AG(GGTTAG)7).  
 
2.2.24.1. TRAP Assay Reactions 
Reactions were setup and performed according to the manufacturer protocol. Cell 
extracts were prepared by lysing with ice cold CHAPS lysis buffer (Chemicon), 
typically 150-200µl, and incubating on ice for 30mins. Cellular debris was pelleted 
(12,000rpm, 25min, 4°C) and the protein containing supernatant transferred to a fresh 
tube. Protein concentration was determined and a 500ng/µl dilution made for use in 
the actual TRAP assay. Assay controls included heat inactivated extracts, where an 
aliquot of cell extract was heated to 85°C for 10min to inactivate telomerase, and 
CHAPS buffer alone. A four point standard curve was prepared by diluting the TSR8 
control template to 20, 2, 0.2, and 0.02amoles/µl. 25µl reactions consisted 2µl of 
either cell extract (1µg), TSR8 dilutions or control sample, 1x TRAPeze
®
 RT reaction 
mix (Chemicon) and 2 units of titanium Taq (Clontech). Reactions were run on an 
ABI 7500 real time PCR machine (Applied Biosystems), first incubating at 30°C for 
30min before entering into the following PCR program: 95°C for 2min then 45 cycles 
of 94°C for 15sec, 59°C for 1min, 45°C 30sec* (* denotes fluorescence signal 
detection step). 
 
2.2.24.2. TRAP Assay Analysis 
As a qPCR based assay data analysis was performed as described for absolute 
quantification by qPCR in sections 2.2.9.4 and 2.2.9.4.1 with one exception. The 
TRAP assay does not include quantification of a reference against which to normalise 
for sample loading variation. Therefore copy number is the final measure of quantity 
for subsequent comparisons.  
 
2.2.25. Western Blotting 
Specific proteins were identified in cell lysates by western blotting under reducing 
and denaturing conditions. Proteins were size separated by polyacrylamide gel 
electrophoresis (PAGE) before transfer and immobilisation onto a nitrocellulose 
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membrane. The membrane was then blocked with a milk solution and probed with a 
primary antibody specific to the protein under investigation. Detection was achieved 
using horseradish peroxidise (HRP)-conjugated secondary antibodies specific to the 
primary antibody and enhanced chemoluminescence (ECL) reagents, a mixture of 
luminol and hydrogen peroxide. In the presence of hydrogen peroxide HRP catalyses 
the oxidation of the luminol exciting it to emit light which can be detected using X-
ray film.  
 
PAGE gels were prepared at the desired concentration (typically 10%) composed of a 
lower running gel (0.375M Tris-HCl pH8.8, 0.2% SDS, 10% polyacrylamide, 0.033% 
ammonium persulfate, 0.066% TEMED; typically 6-7ml final volume) and an upper 
stacking gel (0.25M Tris-HCl pH6.6, 0.4% SDS, 2.6% polyacrylamide, 0.033% 
ammonium persulfate, 0.066% TEMED; typically 3-4ml final volume) in which the 
sample wells were set. Protein samples (typically 10µg) were prepared by adding 
loading buffer to a 1x concentration (62.5mM Tris-HCl pH6.8, 10% glycerol, 2% 
SDS, 5% DTT, 0.002% bromophenol blue) and heat denaturing at 100°C for 5-10min. 
Samples were loaded alongside a size standard and gels run for 90min at 100v in 1x 
running buffer (25mM Tris, 0.2M glycine, 0.1% SDS). Post electrophoresis the upper 
stacking gel was trimmed from the lower running gel and discarded. To transfer 
proteins from the gel, a corresponding sized piece of nitrocellulose membrane (Bio-
Rad) was carefully laid upon the gel which was then sandwiched between pieces of 
20mm whatman paper of the same size, 3 pieces on either side. Extra care was taken 
not to create or to remove any air bubbles that formed between the different layers. 
Proteins were transferred from the gel to the membrane for 1hr at 100v in 1x transfer 
buffer (25mM Tris, 0.2M glycine) after which the membrane was incubated in 10ml 
blocking solution (1x Tris buffered saline (TBS): 50mM Tris-HCl pH7.4, 150mM 
NaCl; 5% powdered milk) for at least 1hr to reduce non specific antibody binding. An 
appropriate dilution of the primary antibody was prepared in blocking solution and 
added to the membrane for 2-3hr at room temperature or overnight at 4°C. The 
membrane was washed 3 times in 10ml 1x TBS for 5min before incubating with an 
appropriate dilution of secondary antibody, also in blocking solution, for 2hr at room 
temperature. The membrane was washed 3 times in 10ml 1x TBS, 0.5% Tween for 
5min before developing in 5ml of ECL solution (Thermo Fisher) for 5min. The 
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membrane was wrapped in plastic and secured in a developing cassette for X-ray film 
exposure. 
 
2.2.26. Sequencing 
Aliquots of samples and primers were sent for external sequencing at the QMUL core 
genomics centre. Sequencing reactions were performed by dideoxy nucleotide 
termination utilising Big Dye™ chemistry (Applied Biosystems) with products 
separated by capillary electrophoresis. The sequence data returned was viewed and 
aligned using VectorNTI v10 software (Invitrogen). 
 
2.2.27. Statistical Analysis 
The Mann-Whitney U test was used to determine the statistical significance of 
differences between healthy controls and DC patient groups in some aspects of this 
study. Performed using GraphPad Prism 5 software (GraphPad Software Inc), this 
tests the null hypothesis that observations from two populations are similar against the 
alternative hypothesis that those from one are larger than the other by comparing the 
sum of their ranks. Because of this the Mann-Whitney U test does not require the 
populations to be normally distributed and provides a non-parametric alternative to 
the unpaired t-test that is more robust in the presence of outliers. The calculation for 
this test is outlined below.  
 
 
 
 
 
 
 
 
 
 
 
N is the sample size, R is the sum of ranks 
U = N1N2 +  
N1(N1 + 1) 
        2 
 - R1  
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Chapter 3. Transient Knockdown of Dyskerin, NOP10, NHP2 and 
GAR1 
3.1. Introduction 
As discussed in chapter 1, impaired telomere maintenance features prominently in DC 
with different patients found to harbour mutations affecting several telomerase 
components including the proteins dyskerin, NOP10 and NHP2. Together with GAR1 
these form a protein core that is common to telomerase and all other H/ACA RNPs 
(Mitchell et al. 1999a; Dragon et al. 2000; Pogacic et al. 2000). Much of what is 
known about these proteins comes from their initial characterisation as H/ACA RNP 
components in yeast via the homologues Cbf5p, Nop10p, Nhp2p and Gar1p. Here it 
was shown that only Cbf5p, Nop10p and Nhp2p are important for RNP stability and 
H/ACA RNA accumulation, including exogenously expressed human TERC, but all 
four proteins are vital for pseudouridylation activity with Cbf5p acting as the catalytic 
component (Girard et al. 1992; Bousquet-Antonelli et al. 1997; Henras et al. 1998; 
Lafontaine et al. 1998; Watkins et al. 1998; Dez et al. 2001; Henras et al. 2004b). 
Subsequent studies have corroborated these findings in mice (Wang et al. 2002; Wang 
and Meier 2004) and the conserved homology of these proteins across yeast, mouse 
and humans provided confidence that this would also hold true in the human context, 
although it had not been confirmed when this study began. Yeast telomerase differs 
from that of mammals however and is not an H/ACA RNP incorporating these 
proteins. Consequently characterisation did not extend to their implications in 
telomerase function and with the exception of dyskerin little is known about their 
importance in this specialised complex. In order to better understand the role of these 
core proteins in the molecular pathology of DC, the aim in this part of the project was 
to investigate their significance for the integrity and function of telomerase. 
 
With catalytic activity guided by the associated H/ACA RNA logic would suggest 
that activity is dependent on their stable recruitment and accumulation. In human cells 
the reduction of dyskerin has been associated with a reduction in TERC levels and 
telomerase activity as well as pseudouridylation (Montanaro et al. 2006). In patients, 
however, DKC1 mutations have been associated with reduced TERC levels and 
telomerase activity (shown in vitro to be a direct consequence of the TERC reduction) 
but not other H/ACA RNAs or pseudouridylation (Mitchell et al. 1999b; Vulliamy et 
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al. 2001a; Wong and Collins 2006). In contrast, studies in mice have shown that 
DKC1 mutations reduce the levels of multiple H/ACA RNAs and impair both 
pseudouridylation and telomerase activity (Ruggero et al. 2003; Mochizuki et al. 
2004).  
 
Knockdown experiments were conducted to systematically target dyskerin, NOP10, 
NHP2 and GAR1 so that their individual significance in the accumulation of TERC 
and telomerase activity could be determined. Also, with a view to ratifying the 
findings of yeast and mouse studies for the first time in human cells, the levels of 
other H/ACA RNA’s were also assessed. Unfortunately pseudouridylation could not 
be measured directly as the assay (described in Mochizuki et al. 2004) relies on the 
enzyme RNase T2 to completely digest ribosomal RNA, which has become 
commercially unavailable. 
 
The discovery of RNA interference (RNAi) profoundly altered the understanding of 
post transcriptional gene regulation and revolutionised the approach to gene silencing 
through manipulation of the RNAi pathway (figure 3.1) (reviewed Bantounas et al. 
2004; Leung and Whittaker 2005). Now a highly developed tool, RNAi provides 
simple and effective ways to suppress gene expression levels that are used routinely in 
the modern lab. As an ideal technology to employ in this study, commercially 
available short interfering RNAs (siRNAs) pre-designed to target DKC1 (dyskerin), 
NOP10 (NOP10), NHP2 (NHP2) and GAR1 (GAR1) transcripts were tested to assess 
their silencing potential. Successfully efficient candidates were subsequently used in 
transient knockdown experiments from which functional impacts could be assessed. 
 
A particular concern in siRNA experiments is the question of specificity with several 
reports of widespread off target effects despite sequence specific targeting (Jackson et 
al. 2003; Sledz et al. 2003; Lin et al. 2005; Birmingham et al. 2006; Jackson et al. 
2006). Falling into two categories, off target effects can be sequence related and 
specific to each siRNA or sequence independent and caused by siRNAs in general. 
The introduction of siRNAs (i.e. double stranded RNA - dsRNA) into the cell can 
mimic a viral threat and trigger an interferon response with widespread consequences 
on cellular processes such as protein synthesis, cell cycle and apoptosis. Independent 
of the siRNAs sequence or its target, this is simply a response to the presence of  
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Figure 3.1. The RNAi pathway. Long dsRNA, either endogenous or 
introduced into the cell, is processed by the Dicer protein into smaller pieces 
called siRNA. The siRNA is then integrated into the RNA induced silencing 
complex (RISC). Specific base pairing between the siRNA and mRNA 
directs targeted mRNA cleavage by the RISC complex and subsequent gene 
silencing.  
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siRNA in general and correlates with the amount of the siRNA used. This response is 
not always activated, however and avoiding high concentrations of siRNA is an 
effective control against it (Sledz et al. 2003, reviewed Jackson and Linsley 2004). 
More commonly off target affects are sequence dependant and specific to each 
siRNA; as with PCR primers, non-specific binding is possible. Complementarity to a 
7nt seed region at the 5’ end of the siRNA (between base positions 2-8) is not only 
crucial but also sufficient to elicit an RNAi response (Lin et al. 2005; Birmingham et 
al. 2006; Jackson et al. 2006). Further, these imperfect matches do not always cause 
transcript cleavage but may inhibit translation as a method of suppression instead, 
behaving much like miRNAs (Zeng et al. 2003). Sequence homology to a 7nt siRNA 
seed region elsewhere in the genome is pretty much unavoidable making sequence 
specific off target effects almost inevitable and difficult to predict. However, these off 
target effects are generally less efficient and much weaker by comparison to the 
targeted effect on the intended transcript (Jackson and Linsley 2004).  
 
Despite the varying implications of off targeting it does not render the technology 
useless as long as they are considered and controlled for. In the knockdown 
experiments presented here, possible non-specific effects as a result of the procedure 
or the addition of siRNA in general are controlled for using mock and negative siRNA 
transfections. Similarly, sequence specific off targeting is controlled for by using two 
different siRNAs against each target. Obtaining the same experimental results with 
independent siRNAs provides support for a target specific effect. 
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3.2. siRNA Efficiency Testing 
3.2.1. Experimental Procedure 
Transient transfection experiments were used to determine siRNA silencing 
efficiencies. Pre-designed siRNAs were obtained in sets of three targeting the same 
mRNA and a negative control siRNA having no sequence similarity to human gene 
products (Ambion; detailed in appendix A).   
 
Figure 3.2 provides an overview of the experimental workflow. HeLa cells were 
transfected with siRNA at an optimal concentration, 30nM for control siRNAs as 
recommended by the manufacturer, and cultured for 24hr. RNA was extracted, first 
strand cDNA synthesized and tested for quality and DNA contamination by PCR of 
the ABL gene (primers ABL1 and ABL2 - appendix B; data not shown). Quantitative 
real time PCR (qPCR) employing TaqMan
®
 probes (details in appendix B) was then 
used to assess target silencing, final gene expression calculated relative to the 
untransfected control for comparison (described in chapter 2.2.9).  
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Figure 3.2. siRNA screening – experimental workflow. 
 
 
 
 
 
 
 
RNA extraction completed and DNase treated.  
First strand cDNA synthesis reaction. 
At a later date 
6 well plates seeded with HeLa cells at 2-4x10
5
 
cells per well.  
Day -1 
Day 0 
Cells harvested for RNA extraction.  Day 1 
cDNA quality tested with ABL PCR. 
Quantitative real-time PCR  
 ABL (Endogenous control) 
 siRNA target (first readout) 
Transfection 
1. Untransfected 
2. Mock transfection 
3. Negative siRNA 
4. Target siRNA 1 
5. Target siRNA 2  
6. Target siRNA 3 
 
1 2 3 
4 5 6 
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3.2.2. Silencing Efficiency Results 
Following the manufacturer recommendations for siRNA transfection (as outlined in 
2.2.2.1) very little optimization was required. Cell density and confluence at the time 
of transfection is important for transfection efficiency and cell viability during the 
experiment. Seeding 2-5x10
5
 cells per well was found to result in a suitable 
confluence for transfection after 24hr with good cell viability. The next step was to 
optimize siRNA concentrations for a maximal silencing effect. Ambion recommend 
concentrations between 10-50nM for most cell types, extending to 100nM if 
necessary and suggesting 30nM as a starting point. Using the NOP10 siRNAs 30, 50 
and 100nM concentrations were tested. Results showed highly efficient silencing 
(95%+) at all concentrations (figure 3.3). Optimal siRNA concentrations will vary for 
different targets, however, depending on expression levels and cell type. For reasons 
of practicality, with regards to sample number and cost, it was decided to screen 
siRNAs at a single concentration and optimize further only if necessary. Therefore all 
siRNAs were screened at the upper limit of the recommended range: 50nM. 
 
NOP10 - siRNA 1 was the least efficient and decreased expression by only 70.8% at 
100nM. At only 50nM, siRNAs 2 and 3 were more effective and suppressed 
expression by 96.7 % and 93.5% respectively (figure 3.3).  
 
NHP2 – The most effective siRNAs where 1 and 3, reducing expression by 93.7% and 
94.2% respectively. In contrast, siRNA 2 elicited only a 35.9% reduction (figure 
3.4a). 
 
GAR1 – Less efficient by comparison, siRNAs 2 and 3 suppressed expression by 79% 
and 74.8% respectively, siRNA 1 by only 30% (figure 3.4b). 
 
DKC1 - Two sets of siRNAs had to be screened in order to obtain two that were 
effective. In screen 1 only siRNA 2 was of any value, suppressing expression by 
91.4% while siRNAs 1 and 3 only eliciting decreases of 40% and 22.3% respectively 
(figure 3.4c). In screen 2, siRNAs, 4, 5 and 6 were all highly effective and suppressed 
expression by 91.9%, 93.8% and 96.6%, respectively (figure 3.4d). 
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3.2.3. Discussion 
The aim here was to test and identify at least two efficient siRNAs to each of the 
targets: DKC1, NOP10, NHP2 and GAR1. At a final concentration of 50nM in culture, 
two out of the three siRNAs tested for NOP10, NHP2 and GAR1 suppressed gene 
expression with substantial efficiency. For each siRNA, NOP10 and NHP2 expression 
levels were reduced to less than 10% of that seen in experimental controls and for 
GAR1 each siRNA reduced expression to less than 25%. The DKC1 siRNAs proved 
to be more problematic and required a total of six (two sets of three) to be screened 
before the desired target of at least two effective siRNAs was achieved. In fact, four 
of the six siRNAs tested reduced dyskerin expression to less than 10% compared to 
experimental controls. 
 
In conclusion, initial siRNA tests were successful in identifying at least two highly 
effective gene silencers for DKC1, NOP10, NHP2 and GAR1 with the impressive 
decreases observed suggesting an extremely efficient transfection process. Most 
importantly, results from two independent siRNAs for each target corroborate to 
indicate a specific targeted affect which is further supported by the potency with 
which they suppress gene transcript levels.   
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3.3. Functional Analysis of Target Gene Knockdown 
3.3.1. Experimental Procedure 
To determine any functional impacts, the siRNAs identified in chapter 3.2 were used 
to independently to suppress gene expression and knockdown the levels of dyskerin 
(DKC1), NOP10 (NOP10), NHP2 (NHP2) and GAR1 (GAR1) in HeLa cells. 
Extending the time course of the experiment to allow downstream effects to be seen, 
the same transient transfection system described in chapter 3.2.1 was implemented 
with samples collected at 48 and 72hr post transfection for analysis. For each target 
both siRNAs were used independently at final concentrations of 50nM, figure 3.5 
provides a detailed overview of the experimental workflow. Knockdown experiments 
were conducted in duplicate and functional data averaged to provide the final result. 
 
Note: - Technical difficulties in some stages required the NOP10 and NHP2 
experiments to be performed a third time in order to obtain all the functional data. 
Target gene silencing and TERC levels represents the average of all three 
experiments, TRAP activity and H/ACA RNA levels the average of only two. 
 
3.3.1.1. Target Gene Silencing 
Target gene silencing was assessed at 48 and 72hr. As before, RNA was extracted and 
first strand cDNA synthesised. DNA contamination and cDNA quality were assessed 
by ABL PCR (primers ABL1 and ABL2 - appendix B; data not shown). Target gene 
expression was then determined by qPCR using TaqMan
®
 probes (details in appendix 
B), calculated relative to the 48hr untransfected control for comparison (described in 
chapter 2.2.9).  
 
In siRNA experiments it is beneficial to validate target knockdown at the protein 
level. However, suitable antibodies were not readily available for all of the targets, 
only dyskerin courtesy of an antibody generously gifted by Yves Henry. Western 
blotting (described in chapter 2.2.25) was used to verify dyskerin levels against those 
of a β-actin loading control at 48hr post transfection. For each sample, 30µg of protein 
were loaded onto a 12% gel and separated under denaturing and reducing conditions. 
Immunoblotting was then performed using rabbit anti dyskerin (Yves Henry) and 
mouse anti β-actin (Abcam) primary antibodies in combination with goat anti rabbit-
HRP (BD) and goat anti mouse-HRP (BD) secondary antibodies.  
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At a later date 
 
Functional analysis 
 RNA extractions & cDNA synthesis 
 qPCR  
 ABL (Endogenous control) 
 siRNA target (first readout) 
 TERC levels 
 H/ACA levels 
 
 Protein lysates 
 Western (Dyskerin only) 
 TRAP assay 
 
 
6 well plates seeded with HeLa cells at 2-4x10
5
 
cells per well. (No antibiotics) 
Day -1 
Media changed. (No antibiotics) Day 1 
48hr time point harvested. Day 2 
72hr time point harvested. Day 3 
 
Transfection 
1. Untransfected 
2. Mock transfection 
3. Negative siRNA 
4. Target siRNA 1 
5. Target siRNA 2  
 
1 2 3 
4 5  
Day 0 
 
Figure 3.5. Transient siRNA knockdown – experimental workflow. 
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3.3.1.2. TERC Accumulation 
Impacts on TERC accumulation were assessed at 48 and 72hr. TERC levels were 
determined by PCR using a TaqMan
®
 probe (details in appendix B), calculated  
relative to the 48hr untransfected control for comparison (described in chapter 2.2.9). 
 
3.3.1.3. TRAP Activity 
Functional impacts on telomerase activity were assessed at 48hr post transfection. 
Extracts were prepared from cells collected at this time point and telomerase activity 
measured using the TRAP assay (described in chapter 2.2.24), activity levels 
calculated relative to the untransfected control for comparison. 
 
3.3.1.4. H/ACA RNA Accumulation 
To investigate any affects on H/ACA RNAs more generally a set of 5 different RNAs 
from this class: E3, U64, U68, U70, U108, were quantified alongside TERC and the 
control C/D box RNA U3. Preparing a standard curve for each, absolute copy 
numbers were determined in the cDNA samples by quantitative real time PCR using 
SYBR green (described in chapter 2.2.9, primers in appendix B). Measured 48 and 
72hr post transfection, values are calculated as a target/ABL ratio and expressed 
relative to the untransfected controls for comparison.  
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3.3.2. Results 
3.3.2.1. Target Silencing Efficiency 
Corroborating with results from the siRNA efficiency tests, when used at 50nM the 
siRNAs against DKC1, NOP10, NHP2 and GAR1 all successfully reduced target gene 
expression compared to the experimental controls (figure 3.6). In each case the 
decreases were sustained over the 72hr with comparable results for both siRNAs and 
experimental duplicates. In summary, both siRNAs against NOP10 and NHP2 
reduced expression to less than 8% and 6% respectively (figures 3.6a & b), GAR1 
siRNAs reducing expression to below 30% (figure 3.6c). The DKC1 siRNAs 
performed less efficiently than in the initial tests with DKC1 expression remaining as 
high as 36.9–40.8% for siRNA 4 and 17.7–32.6% for the siRNA 5 (figure 3.6d).  
However, this was still a substantial decrease.   
 
Western blotting performed on samples taken from the dyskerin experiment at 48hr 
successfully identified bands corresponding to dyskerin (expected size ~57kDa) and 
β-actin (expected size ~42kDa) (figure 3.7). Measured across both the experimental 
duplicates, the data clearly shows that dyskerin protein levels were substantially 
reduced in the siRNA treated samples compared to the experimental controls. 
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3.3.2.2. TERC Levels 
TERC levels were drastically reduced from 48hr onward in response to the 
knockdown of either dyskerin, NOP10 or NHP2 but not GAR1 (figure 3.8). In the 
dyskerin experiment this effect was slightly staggered over the time course, TERC 
levels falling to between 35-45% by 48hr before reaching a low of 18-25% at 72hr 
(figure 3.8d). A similar effect was also evident in the NHP2 experiment but not with 
both siRNAs. TERC levels fell to 37.8% by 48hr and then 15.2% at 72hr with siRNA 
3, but for siRNA 1 TERC levels were between 15-20% at both time points (figure 
3.8b). Knocking down NOP10 reduced TERC levels to between 20-25% at both time 
points (figure 3.8a). Despite these subtle variations, by 72hr TERC levels are similarly 
reduced to between 15-25% in each of these three knockdown experiments. In 
contrast, TERC levels under the suppression of GAR1 reveal only inconsistent 
fluctuations, similar to those seen in the controls, and remain consistently higher at 
60-100% (figure 3.8c). Unfortunately, due to the limited number of experimental 
replicates, meaningful statistical analysis of these results was not feasible.  
 
 
  
Figure 3.7. Western blot data showing dyskerin knockdown. Dyskerin levels 
were analysed in samples from both duplicates of the dyskerin knockdown 
experiment as indicated. β-actin levels were measured as a loading control. 
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3.3.2.3. Telomerase Activity Levels 
TRAP assay analysis at 48hr indicates that telomerase activity was severely impaired 
by the knockdown of dyskerin or NOP10 but not NHP2 or GAR1 (figure 3.9a-d). The 
most dramatic impact was seen in the NOP10 experiment where activity dropped to 
below 28% compared to controls with both siRNAs (figure 3.9a). Less strikingly, in 
the dyskerin experiment activity was reduced to below 47% for one siRNA and 29% 
for the second (figure 3.9d). Conversely, telomerase activity appeared largely 
unaffected in both the GAR1 and the NHP2 experiments where in each case activity 
was sustained above 80% compared to controls (figures 3.9b & c). Once again, 
meaningful statistical analysis of these results was precluded by the small number of 
experimental replicates.  
 
Unfortunately, in each knockdown experiment the negative siRNA also reduced 
telomerase activity to between 23-70%, suggesting a non-specific off target influence 
that potentially undermines these results. Off target affects in RNAi experiments are 
discussed in chapter 3.1. Sustained activity in the GAR1 and NHP2 experiments 
excludes the simple presence of siRNA as the negative influence, which is what this 
control would indicate. Instead, this signifies something specific to the negative 
siRNA used and suggests a sequence dependent off target effect. To investigate this 
further the negative siRNA was compared against three other commercial alternatives 
for impacts on this assay. HeLa cells were transfected with the four different negative 
siRNAs (details in appendix A), a GAPDH siRNA and NOP10 siRNA 2 (each at 
50nM) alongside mock and untransfected controls. TRAP assay analysis was then 
performed on samples taken after 48hr (figure 3.10). As a positive control for an 
effect on telomerase activity the NOP10 siRNA dramatically reduced TRAP activity, 
reproducing the results of the NOP10 experiment. Acting as a ‘mock’ negative control 
for an effect on telomerase activity (positive siRNA silencing of a target having no 
association with telomerase) the GAPDH siRNA did not affect TRAP activity as 
expected. In contrast, all four negative siRNAs variably impacted on telomerase 
activity. Indicating that this effect is not specific to one negative siRNA, this would 
suggest a sequence independent off target effect. Once again though, this is 
contradicted by the other controls which demonstrate that the transfection procedure 
itself or the use of siRNAs generally does not have a negative impact.    
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3.3.2.4. H/ACA RNA Levels 
Striking fluctuations were observed when quantifying the H/ACA RNAs: TERC, E3, 
U64, U68, U70, U108, and the C/D box RNA U3, in these knockdown experiments 
(figure 3.11). Inconsistency between controls and experimental duplicates was evident 
across the different experiments, compounded by further variability from 48 to 72hr. 
This was a particular problem in the GAR1 experiment which has subsequently been 
excluded here on this basis. Results for the siRNA treated samples were generally 
more consistent, though in some cases disagreement between the two siRNAs was 
observed. It is difficult to discern if this variability is the result of biological 
fluctuations, experimental influences or a combination of the two. Therefore, it is 
difficult draw any firm conclusions from this data. However, it does provide some 
indication of how the H/ACA RNAs may have been affected in these experiments.  
 
One of the more consistent results, TERC levels agree with those of the previous 
analysis and reiterate a dramatic reduction in response to the knockdown of dyskerin, 
NOP10 or NHP2. Also, again there is suggestion of a gradual effect in which TERC 
Figure 3.10. TRAP activity in HeLa cells transfected with negative siRNA 
controls. Measured at 48 hours post transfection and calculated relative to the 
untransfected control, values are the average of duplicate experiments with 
error bars marking the SD. (Neg1 corresponds to that used in the transient 
experiments) 
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levels fell considerably by 48hr (figure 3.11a, c, & d) but did not reach their lowest 
until 72hr (figure 3.11b & e). Expanding the analysis to the other H/ACA RNAs 
measured shows indications of a variable affect that differed depending on the 
knockdown target.  
 
Reducing NHP2 appeared to have the broadest potential impact with both siRNAs 
exhibiting substantial and comparable decreases in all of the H/ACA RNA tested at 
both 48 and 72hr (figure 3.11d & e).  
 
In the NOP10 knockdown there were indications of a decrease in U68, U70 and U64 
at both 48 and 72hr with a possible, more subtle decline in U108 as well (figures 
3.11a & b).  
 
Surprisingly, knocking down dyskerin appeared to have less impact, possibly 
reflecting the reduced efficiency of the siRNAs in this experiment. After 48hr only 
U68 was found to be substantially reduced, though E3, U64 and U70 were also 
suggested to suffer small decreases (figure 3.11c). The 72hr data has been excluded 
here because of the issues discussed earlier but it is worth noting that the results 
would indicate more substantial decreases by that time. 
 
Finally, in all of the knockdown experiments the U3 C/D box RNA control proved to 
be erratic, correlating poorly between experimental duplicates and time points. 
However, best indications from the averaged data are that this RNA was not 
negatively affected by the suppression of either dyskerin, NOP10 or NHP2 (figure 
3.11a-f) 
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3.3.3. Discussion 
Aiming to effect independent transient knockdown experiments against dyskerin, 
NOP10, NHP2 and GAR1, siRNAs were successfully used to reduce their gene 
expression over a 72hr period. Reflecting results from the initial efficiency tests, 
NOP10 and NHP2 suppression was highly effective (90%+ reductions) along with 
GAR1 (70%+). DKC1 suppression (60%+) did not meet expectations following the 
initial tests, possibly indicating reduced transfection efficiency, however, there was 
still a considerable reduction in expression with supporting data to confirm a 
substantial decrease in dyskerin protein levels by 48hr. 
 
Studies in yeast and mice have demonstrated that the orthologues of dyskerin, NOP10 
and NHP2 but not GAR1 are important for the stable accumulation of H/ACA RNAs 
including TERC. Seeking to investigate this for the first time in human cells (with the 
exception of dyskerin), the results here confirm that TERC levels were dramatically 
reduced as a direct consequence of knocking down either dyskerin, NOP10 or NHP2 
but not GAR1 (published Walne et al. 2007; Vulliamy et al. 2008). Expanding this 
analysis to a panel of other H/ACA RNAs posed some issues but suggests there were 
some decreases and indicating a broader negative impact on these RNAs in response 
to knocking down dyskerin, NOP10 or NHP2. This impact is variable and does not 
affect all the RNAs equally, also differing depending on the protein targeted. In the 
yeast studies subtle variations were similarly observed with some RNAs affected 
more severely than others (Dez et al. 2001). One possible explanation could be that it 
reflects variation in their individual expression levels and stability. With regards to 
this analysis in the GAR1 knockdown experiment, poor consistency between 
experimental duplicates led to the data being excluded, however, best indications 
would suggest there was little or no affect on H/ACA RNA levels (data not shown).    
 
Within these data sets there are suggestions that the impact on RNA levels was 
slightly staggered over the 72hr period, particularly in the dyskerin experiment. It is 
probable that this reflects a staggered decrease of the target protein. In knockdown 
experiments such as these it is important to consider the issue of protein stability and 
half life. This determines how quickly transcript suppression translates through to the 
protein level and directly influences how long the effects of the knockdown take to 
manifest. Therefore, while target expression levels indicate a high level of transcript 
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suppression from 24hr onward a delayed or gradual effect at the protein level is 
possible. Unfortunately, protein levels could only be verified in the dyskerin 
experiment. With protein levels only analysed at 48hr, a time staggered effect was not 
investigated but instead served to confirm that dyskerin protein levels were 
substantially suppressed in the siRNA treated samples by this time. The potential for a 
delayed effect should be considered in the GAR1 experiment where protein levels 
could not be verified. However, the studies in yeast demonstrated depletion of the 
Gar1p protein within 12hr of its suppression as well as the absence of any impact on 
H/ACA RNA levels within 48-72hr (Girard et al. 1992; Dez et al. 2001). 
 
Together, these results agree with those of the yeast and mice studies and indicate that 
dyskerin, NOP10 and NHP2 but not GAR1 are important for the stability and 
accumulation of H/ACA RNAs in human cells. Studies in mice have indicated that 
GAR1 is not involved in H/ACA RNA recruitment by demonstrating that dyskerin, 
NOP10 and NHP2 form a core trimer which binds the H/ACA RNA before 
associating with GAR1 (Wang and Meier 2004; Darzacq et al. 2006). This is 
supported by the crystal structure of a complete archaeal H/ACA RNP complex which 
has been published during the course of this study (figure 3.12) (Li and Ye 2006). In a 
triangularly shaped complex, NOP10 (Nop10) is tightly sandwiched between dyskerin 
(Cbf5) and NHP2 (L7Ae), which form two of the corners. As if stretched between 
these corners the H/ACA RNA component reaches across and interacts with all three 
of these proteins. Situated away from this RNA binding, GAR1 makes up the third 
corner of the complex and interacts only with dyskerin. In this structure the core 
trimer and its importance for H/ACA RNA binding and recruitment is clearly visible 
while it is apparent that GAR1 is not directly involved in this interaction. Instead 
GAR1 has been implicated in modulating the conformation of a loop structure 
identified in dyskerin, the thumb loop, which regulates substrate turnover by 
controlling the loading and release of the target substrate RNAs  (Li and Ye 2006; Li 
et al. 2011).  
 
Investigating telomerase activity, TRAP assay analysis at 48hr suggests that this was 
impaired as a result of reducing NOP10 and dyskerin but not NHP2 or GAR1. Studies 
have shown that depleting dyskerin levels has a detrimental impact on both TERC 
levels and telomerase activity (Montanaro et al. 2006) and it has been demonstrated 
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that TERC levels are a limiting factor for telomerase activity (Fu and Collins 2003; 
Marrone et al. 2004; Wong and Collins 2006). Consequently, based on TERC levels 
in these experiments, the knockdown of dyskerin, NOP10 or NHP2 was expected to 
adversely affect telomerase activity. Therefore, the lack of a discernible impact in the 
NHP2 knockdown was somewhat surprising and contradicts the established 
correlation between TERC levels and telomerase activity. Certainly, similar impacts 
on TERC levels in the NOP10 and dyskerin experiments had a negative effect. It is 
difficult to rationalise this result, which is reproducible between siRNAs and 
experimental duplicates. Yeast studies have shown that H/ACA RNPs readily form in 
a cell free context, more importantly that incomplete but functional complexes can 
form in the absence of Nhp2p and retain more than 50% activity (Henras et al. 2004b; 
Li et al. 2011). However, This does not reflect the impact on H/ACA RNA levels and 
pseudouridylation when Nhp2p is depleted in yeast which suggests that these 
L7ae 
Cbf5 
Gar1 Nop10 
PUA domain 
H/ACA RNA 
Figure 3.12. The crystal structure of a Pyrococcus Furiosus (Pf) H/ACA RNP. 
Each component is coloured differently, the PUA and catalytic domains of 
Cbf5 also shaded differently and a red star marking the active site. (Figure 
adapted from Li and Ye 2006). 
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complexes are not stable in vivo (Henras et al. 1998; Dez et al. 2001). It is interesting 
to speculate the possibility of similar complexes forming in the cell lysate used for the 
TRAP assay, perhaps providing levels of activity that are not a true reflection of that 
in vivo. Further experiments are needed to investigate this possibility.      
 
GAR1 suppression had no influence on TERC levels at 48hr and here the TRAP assay 
results suggest that it does not play a more direct role in telomerase activity either. 
Studies have shown that GAR1 associates with the H/ACA RNP post RNA 
recruitment and speculate that its role is not central to the stability of the complex 
(Darzacq et al. 2006). The results here would support this, indicating that GAR1 is not 
implicated in either the stability or catalytic activity of telomerase. A distinction 
between telomerase activity and function should be made at this point, the catalytic 
process of transcription being its activity and the extension of telomeres its function. 
It is therefore important to note that successful telomerase function is as dependant on 
its correct localisation as it is its catalytic activity and a failure in either would be 
detrimental to telomere maintenance. The TRAP assay measures telomerase activity 
in homogenised cell lysates, free of cellular compartmentalisation and any restrictions 
or regulatory influences this may impose. Consequently factors such as localisation 
that may affect telomerase function rather than direct activity may be neutralised and 
undetected in this assay. In consideration of this, while these results indicate that 
GAR1 is not required for the formation of a stable, catalytically active telomerase 
complex they do not exclude the possibility that GAR1 may still have some other 
critical role in telomerase function and telomere maintenance. 
 
Unfortunately the negative siRNA control also had a negative impact that implies off 
target influences were affecting telomerase activity in these experiments, potentially 
undermining the validity of these results. The lack of a similar impact using the GAR1 
and NHP2 siRNAs suggest this effect to be specific to the negative siRNA. To 
investigate, the negative siRNA was compared against three other commercial 
alternatives for effects on this assay and surprisingly all four caused a variable 
reduction in TRAP activity. This result adds complexity rather than clarity to the 
situation. Four different negative siRNAs causing the same detrimental effect would 
point toward a sequence independent off target influence but this is countered by 
normal activity in the mock transfection and GAPDH siRNA samples. It is unlikely 
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that these independent siRNAs generate the same profile of sequence specific off 
targets, though some overlap could be expected. However, with the potential to affect 
numerous cellular pathways it is quite feasible that the broader cellular consequences 
of off targeting could overlap. Indeed, studies have shown that some siRNAs, 
including non-targeting controls, can induce adverse affects on cell cycle, 
proliferation and viability. Having confirmed that neither an interferon response or 
target specific effects were the cause this was attributed to sequence dependent off 
targeting bringing about changes in gene expression that culminate in a common 
overall effect (Fedorov et al. 2006; Tschaharganeh et al. 2007). Telomerase activity is 
a tightly regulated process and is influenced by cell cycle and proliferation (Greider 
1998). Conceivably, the effects observed here could be the result of direct changes in 
telomerase associated pathways or indirectly through consequential changes in 
cellular processes that influence its activity. Unfortunately, either way this serves to 
diminish the value of the TRAP assay in these experiments. Importantly, however, 
this is not a concern when analysing target expression and TERC levels where the 
results for the negative siRNA generally agree with those of the untransfected and 
mock transfection controls.  
 
The important question is: are the results of the TRAP assay reliable and informative? 
Indications are that this effect is not generic to all siRNAs so it is possible that in 
these experiments the effect is isolated to the negative siRNA control. In the GAR1 
and NHP2 experiments there is no cause to doubt this as the knockdown of either 
failed to elicit an effect on telomerase activity, targeted or other. Instead the difficulty 
arises when considering the NOP10 and dyskerin knockdown experiments, but there 
is support for a genuine target mediated effect. In both cases there is consistency 
between the two siRNAs which reinforces the result in favor of a targeted effect. 
Also, both knockdowns have an impact on TERC levels that would be expected to 
impair telomerase activity as observed. Finally, with regards to dyskerin there is 
already evidence of its importance for telomerase activity in other studies and mouse 
models presented in the literature (Mitchell et al. 1999b; Mochizuki et al. 2004; Wong 
et al. 2004; Montanaro et al. 2006; Wong and Collins 2006; Montanaro et al. 2008). 
Therefore, while acknowledging the limitations imposed by the negative siRNA, in 
view of supporting evidence elsewhere, the inclination is to accept these results as a 
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good indication that knocking down either NOP10 or dyskerin has a direct negative 
impact on telomerase activity. 
 
In conclusion, these experiments show that dyskerin, NOP10 and NHP2 are important 
for the stable accumulation of TERC and other H/ACA RNAs, demonstrating this for 
the first time in a human context (except for dyskerin). This would support these 
proteins having a central role in H/ACA RNP stability including telomerase, but only 
dyskerin and NOP10 were shown to be important for telomerase activity. Based on its 
significance for TERC levels, however, NHP2 was expected to be similarly 
implicated in this activity and further investigation of this is warranted. In contrast 
GAR1 does not appear to be significant for either TERC levels or telomerase activity 
in these experiments, though an indirect effect cannot be ruled out.  
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Chapter 4. Stable Knockdown Experiments 
4.1. Introduction 
Transient siRNA experiments offer an easy method for determining the immediate 
effects of suppressing a gene of interest and as such provided a beneficial approach 
for the functional characterisations described in chapter 3. However, some 
downstream consequences take longer to manifest than the experiment allows, 
changes in telomere length being a relevant example. Inversely, some consequences 
may only be transient and not sustained over time. In view of this it was sought to 
confirm and clarify the findings of the transient experiments in knockdown studies 
that could be sustained and monitored over a longer period.   
 
In order to achieve long term knockdown experiments a stable system of gene 
suppression is required. This could be achieved by adapting the method of RNAi from 
siRNAs to the more sustainable short hairpin RNA (shRNA) mediated approach. In 
summary, shRNA is expressed in the cell from a DNA construct encoding the sense 
and antisense strands of the siRNA separated by a short loop sequence. The RNA 
transcript folds at the loop and self anneals to form a dsRNA stem loop structure: a 
short hairpin RNA.  The shRNA is structurally related to endogenous miRNAs and is 
processed accordingly by the RNAi machinery to mediate target silencing (figure 4.1). 
Conventionally the RNA polymerase III promoters U6 and H1 are used for shRNA 
expression, generating transcripts lacking a long poly (A) tail that may hinder 
subsequent RNAi processing machinery. However, RNA polymerase II promoters 
such as the CMV promoter have been used. (Brummelkamp et al. 2002; Gou et al. 
2003; Amarzguioui et al. 2005) 
 
Attempts were made to create shRNA expression vectors for generating stable cell 
lines that express shRNA against DKC1, NOP10, NHP2 and GAR1, where the 
silencing effect could be sustained indefinitely.  
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RNA 
processing 
Dicer 
siRNA 
RNAi Pathway 
RNA transcript 
shRNA 
DNA shRNA construct 
Sense Antisense Loop 
Figure 4.1. shRNA mediated RNAi. A DNA construct encodes the sense and 
antisense sequences separated by a short loop sequence. The expressed RNA 
transcript folds at the loop allowing complementary sense and antisense 
sequences to anneal forming the short hairpin RNA (shRNA) structure. This 
double stranded RNA molecule is then recognised by the Dicer protein and is 
processed into siRNA as it enters the RNAi pathway as depicted in figure 3.1. 
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4.2. PCR Strategy 
Initial attempts to create the shRNA expression constructs followed a PCR based 
strategy described in the literature (Castanotto et al. 2002; Gou et al. 2003). In a two 
step, overlapping PCR process depicted in figure 4.2, shRNA and U6 promoter 
sequences are linked to create an shRNA expression cassette. The expression cassettes 
can be used independently for transient effects or subsequently cloned into selectable 
plasmid expression vectors for stable transfection experiments. 
 
4.2.1. Experimental Procedure 
Sequence data for the human U6 promoter (AY623053) and the siRNAs used in 
chapter 3 were used to design an shRNA expression cassette against NOP10 and 
appropriate oligonucleotides for its contsruction (detailed in appendix B). Using 
genomic DNA as a template, the human U6 promoter was PCR amplified using the 
hU6 Forward and hU6 Reverse primers (details in appendix B) in a standard PCR 
reaction (described in chapter 2.2.8). The hU6 Forward primer is complementary to 
22nt in the 5’ end of the U6 promoter with a MluI linker appended to the 5’ end, used 
in all subsequent PCRs. The hU6 Reverse primer is complementary to 19nt at the 3’ 
end of the U6 promoter and has a NotI linker appended to the 5’ end. The purified U6 
promoter was subsequently used to create the NOP10 shRNA expression cassette in 
the two step PCR process summarised in figure 4.2, using the universal hU6 forward 
primer and the reverse primers NOP10 shRNA 1 and 2.  Standard reaction conditions 
were used in both steps (described in chapter 2.2.8) and products were purified by gel 
extraction between steps. To increase product yield, step 2 reactions were scaled up 
from 25 to 50µl. 
 
PCR 1: Purified U6 promoter acts as template in a PCR with the hU6 Forward and 
NOP10 shRNA 1 primers. 5’ to 3’ the NOP10 shRNA 1 primer has 7nt of loop 
sequence, 19nt of sense strand sequence and 9nt of complementary sequence with the 
amplified U6 promoter 3’ end.  The result is attachment, and amplification, of the 
shRNA sense strand and loop sequence to the 3’ end of the U6 promoter (figure 4.2)  
 
PCR 2: Purified product from step 1 acts as template in a PCR with the hU6 Forward 
and NOP10 shRNA 2 primers. 5’ to 3’ the NOP10 shRNA 1 primer is composed of an 
EcoRI linker, transcription termination sequence (poly(T)6), 19nt of antisense strand 
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and 14nt of complementary sequence with the 5’ end of NOP10 shRNA 1. The result 
is attachment of the shRNA antisense strand and the transcriptional terminator 
sequence completing the shRNA expression cassette (figure 4.2). 
 
The purified expression cassette was tested for functional NOP10 silencing by 
transient transfection into HeLa cells alongside untransfected and mock transfected 
controls with samples harvested after 24 and 48hr. RNA was extracted, first strand 
cDNA synthesized and tested for quality and DNA contamination by PCR of the 
endogenous ABL gene (data no shown). NOP10 silencing was assessed by qPCR 
using TaqMan
®
 probes (details in appendix B), expression calculated relative to the 
untransfected control for comparison (described in chapter 2.2.9).  
 
 
 
 
Figure 4.2. PCR synthesis of shRNA expression cassettes. (A) Step 1: PCR 
links the template U6 promoter and an overlapping reverse primer 
containing the sense and loop sequence. (B) Step 2: PCR links products 
from the 1
st
 PCR and a reverse primer containing the loop (for overlap), 
antisense and terminator (Ter) sequence. (C) The final PCR product consists 
of the U6 promoter, sense, loop, antisense and termination sequences – the 
shRNA expression cassette. 
 
 
2nd PCR 
1st PCR 
shRNA expression 
cassette 
Sense Antisense Loop   U6 promoter 
A 
B 
C 
Ter 
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4.2.2. Results and Discussion 
Following the outlined procedure preparation of the shRNA expression cassette by 
PCR was successful, products at each stage of the process demonstrated the 
progressive increase in size from the U6 promoter (346bp) to the finished expression 
cassette (419bp) (figure 4.3).  
 
Functional testing of the NOP10 shRNA cassette, however, failed to elicit a decrease 
in NOP10 expression. The literature suggests that as little as 100ng of the shRNA 
cassette is sufficient to generate a silencing effect (Castanotto et al. 2002). Therefore, 
HeLa cells were transfected with 100, 200, 300 and 400ng of the purified NOP10 
shRNA expression cassette, but after 48hr corresponding NOP10 expression levels 
had not been decreased (figure 4.4). In order to verify this result 350ng of the NOP10 
shRNA cassette was transfected a second time and again NOP10 expression after 24 
and 48hr revealed no decreases (data not shown). To investigate this lack of function 
the expression cassette was sequenced using the hU6 Forward primer and revealed an 
insertion event in the antisense sequence of the construct (figure 4.5). Repeating 15nt 
of the upstream sequence this would certainly interfere with stem loop formation of 
the shRNA and explain the lack of function. The cause of this insertion can only be 
speculated but its location at the point of overlap between the NOP10 shRNA 2 
primer and the template in step 2 of the process suggests promiscuous annealing or 
rearrangement.  
 
While this problem could probably be overcome with repeated PCR and optimisation, 
this finding highlighted PCR errors as a potential problem for this strategy. A single 
PCR generates a limited amount of the shRNA cassette, often requiring several 
reactions to be pooled to achieve required amounts. Every new PCR would have to be 
sequenced for quality control which would be impractical and costly. In light of these 
problems an alternative strategy was sought.  
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Figure 4.4. NOP10 expression in HeLa cells transfected with NOP10 
shRNA. Measured 48 hours after transfection with different amounts of the 
NOP10 shRNA expression cassette and calculated relative to the 
untransfected control. Values are the average of triplicate measurements 
made from a single experiment with error bars marking the SD. 
 
300bp 
400bp 
a b c 
Figure 4.3. PCR formation of the NOP10 shRNA expression cassette.  
(a) U6 promoter, (b) Step 1: U6 promoter-sense-loop, (c) Step 2: The 
finished cassette; U6 promoter-sense-loop-antisense. 
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          1                                               50 
Expected: ACGCGT-GTGGAAAGACGCGCAGGCAAAACGCACCACGTGACGGAGCGTG 
  Actual: ACGCGTAGTGGAAAGACGCGCAGGCAAAACGCACCACGTGACGGAGCGTG 
 
          51                                             100 
Expected: ACCGCGCGCCGAGCGCGCGCCAAGGTCGGGCAGGAAGAGGGCCTATTTCC 
  Actual: ACCGCGCGCCGAGCGCGCGCCAAGGTCGGGCAGGAAGAGGGCCTATTTCC 
 
          101                                            150 
Expected: CATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAA 
  Actual: CATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAA 
 
          151                                            200 
Expected: TTAGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGA 
  Actual: TTAGAATTAATTTGACTGCAAACACAAAGATATTAGTACAAAATACGTGA 
 
          201                                            250 
Expected: CGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTT 
  Actual: CGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTT 
 
          251                                            300 
Expected: TAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCT 
  Actual: TAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCT 
 
          301                                            350 
Expected: TGGCTTTATATATCTTGTGGAAAGGACGAAACAGCGGCCGCCTCGAGCCC 
  Actual: TGGCTTTATATATCTTGTGGAAAGGACGAAACAGCGGCCCCC---AGCCC 
 
          351                                            400 
Expected: ATAAAGGGAACACATTCCACACCAATGTGTTCC---------------CT 
  Actual: ATAAAGGGAACACATTCCACACCAATGTGTTCCACACCAATGTGTTCCCT 
 
          401                             435 
Expected: TTATGGGGTCGACTCTAGAAAAAAGGCGCGAATTC 
  Actual: TTATGGGGTCGACTCTAGAAAAAAGGCGCGAATTC 
 
 
Figure 4.5. Sequence data for the NOP10 shRNA expression cassette. The 
actual sequence is aligned against the expected sequence. The sense strand is 
marked in red, the antisense in orange and the loop in green. Mismatches are 
highlighted in yellow with dashed lines marking missing/inserted sequence. 
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4.3. Cloning Strategy 
The previous approach attempted to create shRNA expression cassettes that could be 
cloned into a suitable plasmid. Therefore it was decided to employ a direct cloning 
strategy. Here the sense - loop - antisense sequence is encoded in a pair of 
complementary oligonucleotides which are annealed to create a double stranded 
synthetic DNA molecule. Incorporating restriction sites at each end enables 
subsequent cloning into the plasmid of choice (figure 4.6). This straight forward 
cloning method eliminates the potential of introducing sequence errors like those seen 
in the PCR approach.  
 
4.3.1. Experimental Procedure 
Specifically designed for shRNA expression, pSilencer™ 2.1-U6 neo (Ambion) 
(appendix C) was the plasmid chosen for this procedure and came with a pre-prepared 
negative control pSilencer plasmid. Ambion’s matching online design tool 
(http://www.ambion.com/techlib/misc/psilencer_converter.html) was used to generate 
suitable oligonucleotide sequences for the NOP10 shRNA insert: NOP10 shRNA (+) 
and NOP10 shRNA (-) (details in appendix B). Corresponding PAGE purified 
oligonucleotides were purchased (Sigma-Genosys) and annealed to create a synthetic 
DNA molecule with BamHI (5’) and HindIII (3’) ‘sticky ends’. This was subsequently 
ligated into the pre-linearised pSilencer™ 2.1-U6 neo plasmid (figure 4.7). Aliquots 
of the ligation were used to transform DH5α ™ competent cells (Invitrogen) and 6 
colonies selected for small scale plasmid preparation and sequencing with the M13 
primer pair (details in appendix B). 
 
Functional tests were carried out via a transient transfection experiment in which 
HeLa cells were co-transfected with the NOP10 pSilencer and pIRES2-EGFP 
plasmids (1µg each), also co-transfecting with the negative control pSilencer 
accordingly. GFP expression was visualised under fluorescence microscopy after 24hr 
as an indicator of transfection efficiency. At 48hr post transfection RNA was 
extracted, first strand cDNA synthesized and tested for quality and DNA 
contamination by PCR of ABL as previous (primers ABL1 and ABL2; data not 
shown). NOP10 silencing was assessed by qPCR using TaqMan
®
 probes (details in 
appendix B), calculated relative to the untransfected control for comparison 
(described in chapter 2.2.9). 
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To establish stable cell lines expressing the pSilencer constructs, HeLa cells were 
independently transfected with 1µg of the NOP10 pSilencer and negative control 
pSilencer plasmids under neomycin selection (described in chapter 2.2.2.2). At the 
first passage (~3 weeks post transfection) samples were used to extract RNA and first 
strand cDNA synthesized to evaluate NOP10 silencing by qPCR as described earlier. 
Genomic DNA was also extracted and PCR used to confirm integration of the 
pSilencer construct (pSilencer FWD and REV primers, details in appendix B). 
Simultaneously, limiting dilutions were used to create clonal cell lines for both and 
NOP10 silencing was verified once established (as previous). 
Figure 4.6. A schematic representation of the shRNA cloning process. 
(A) A pair of complementary oligonucleotides comprising of the sense – 
loop – antisense – termination (Ter) sequence are annealed. (B) A 
synthetic DNA molecule encoding the shRNA is created, designed to 
have ‘sticky ends’ for directional subcloning. (C) Ligation into 
pSilencer™ 2.1-U6 neo creates the finished shRNA expression plasmid. 
 
 Sense Antisense  Loop Ter A 
B 
Neomycin resistance 
expression cassette Ampicillin resistance 
expression cassette 
pSilencer™ 2.1-U6 neo 
plasmid 
U6 promoter 
C 
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4.3.2. Results 
Oligonucleotide annealing and cloning into the pSilencer™ 2.1-U6 neo plasmid was 
straight forward and highly successful with all of the 6 clones sequenced found to 
contain the correct shRNA insert (figure 4.7).  
 
 
 
Functional tests in HeLa cells transfected with the NOP10 pSilencer plasmid 
demonstrated effective NOP10 silencing.  Visual GFP analysis estimated transfection 
efficiency to be between 50-60% after 24hr (figure 4.8). Corresponding to this level of 
transfection, NOP10 levels measured at 48hr had decreased to 49.2% under the 
NOP10 pSilencer while remaining at a higher 143.9% under the negative control 
pSilencer (figure 4.9). 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
Transfection and neomycin selection was subsequently used to generate stable 
polyclonal cell lines expressing these constructs. At 3 weeks post transfection 
genomic integration of the pSilencer constructs was verified by PCR (figure 4.10) and 
analysis of NOP10 expression confirmed suppression in the NOP10 pSilencer cell 
line, levels decreased to 19.6% compared to an untreated control (figure 4.11). 
However, NOP10 expression was also reduced to 48.3% in the negative control 
pSilencer cell line (figure 4.11), an effect that had not been seen in the earlier transient 
test of this construct. To exclude the possibility of a mistake the integrated pSilencer 
constructs were PCR amplified a second time and sequenced using the same primers, 
(pSilencer FWD and REV). Results confirmed that each line contained the correct 
construct (data not shown). 
Figure 4.7. Sequence data for NOP10 pSilencer. The shRNA insert of clones 1-6 
(C1-6) are aligned against the expected sequence (Exp), sense strand sequence is 
marked in red, antisense in orange and the loop in green.  
 
1 70
Exp: GGATCCGCCCATAAAGGGAACACATTCCACACCAATGTGTTCCCTTTATGGGCTTTTTTTGGAAAAGCTT
C1: GGATCCGCCCATAAAGGGAACACATTCCACACCAATGTGTTCCCTTTATGGGCTTTTTTTGGAAAAGCTT
C2: GGATCCGCCCATAAAGGGAACACATTCCACACCAATGTGTTCCCTTTATGGGCTTTTTTTGGAAAAGCTT
C3: GGATCCGCCCATAAAGGGAACACATTCCACACCAATGTGTTCCCTTTATGGGCTTTTTTTGGAAAAGCTT
C4: GGATCCGCCCATAAAGGGAACACATTCCACACCAATGTGTTCCCTTTATGGGCTTTTTTTGGAAAAGCTT
C5: GGATCCGCCCATAAAGGGAACACATTCCACACCAATGTGTTCCCTTTATGGGCTTTTTTTGGAAAAGCTT
C6: GGATCCGCCCATAAAGGGAACACATTCCACACCAATGTGTTCCCTTTATGGGCTTTTTTTGGAAAAGCTT 
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A 
B 
Figure 4.8. GFP expression in HeLa cells 24 hours post transfection. 
Corresponding bright field (left), fluorescence (middle) and overlaid (right) 
images of (A) NOP10 pSilencer transfected cells. (B) Negative control 
pSilencer transfected cells. 
Figure 4.9. NOP10 expression in HeLa cells transfected with pSilencer 
plasmids. Measured 48 hours post transfection with 1µg of the NOP10 
pSilencer and negative control pSilencer plasmids, expression was 
calculated relative to the untransfected control. Values are from a single 
experiment, error bars marking the SD between assay triplicates. 
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a b c 
300bp 
400bp 
Figure 4.10. PCR confirming genomic integration of the pSilencer 
constructs. (a) NOP10 pSilencer plasmid (positive control; 330bp). (b) 
negative control pSilencer cell line. (c) NOP10 pSilencer cell line. 
 
Figure 4.11. NOP10 expression in the pSilencer cell lines. Measured in the 
negative control pSilencer and NOP10 pSilencer cell lines 3 weeks post 
transfection and calculated relative to an untreated HeLa control cell line. 
Values are from single cell lines, error bars marking the SD between assay 
triplicates. 
lines with error bars marking the SD. 
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After  a couple of attempts to generate clonal cell lines by limiting dilution, five 
NOP10 pSilencer and three negative control pSilencer cell lines were eventually 
produced. To begin functional analysis NOP10 expression and TERC levels were 
evaluated in each (9-10 weeks post transfection at this stage) (figure 4.12).  Compared 
to an untreated HeLa control, NOP10 transcript levels were substantially suppressed 
in all five of the NOP10 pSilencer clones (average expression below 30%). However, 
corresponding with the polyclonal parent line, NOP10 levels were also reduced in the 
negative control pSilencer clones. Corresponding TERC levels were reduced in all 
cases, though subtle differences were observed between the NOP10 pSilencer clones 
(16% or less) and the negative pSilencer clones (20-30%).   
 
 
 
 
 
Figure 4.12. NOP10 and TERC levels in clonal pSilencer cell lines. 
Measured in negative control pSilencer (Neg pSi) and NOP10 pSilencer 
(NOP pSi) cell lines and calculated relative to the untreated HeLa control. 
Values are from single cell lines, error bars marking the SD between assay 
triplicates. 
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4.3.3. Discussion  
After changing the strategy to a direct cloning approach, the NOP10 pSilencer 
plasmid was created and confirmed to be functional. Given that the sense and 
antisense sequence of the shRNA matches that of NOP10 siRNA 3, used in the 
transient experiments (chapter 3), it is reasonable to assume that both would be 
equally effective. Yet, initial transient tests of the plasmid elicited only a 50% 
decrease in NOP10 expression after 48hr, unimpressive in contrast to the 90%+ 
decrease after only 24hr using the siRNA. There are important factors to be 
considered in this comparison though. Firstly, siRNA takes effect much faster than 
shRNA. RNAi using shRNA requires DNA expression and subsequent downstream 
processing to produce a functional siRNA (outlined in figure 4.1). These steps are not 
involved when using siRNA directly and allow it to take effect more swiftly. 
Secondly, differences in transfection efficiency. Only cells containing the siRNA or 
shRNA can be subjected to their suppressive effects; therefore, silencing efficiency 
can never exceed the transfection efficiency. Vastly different in size, the smaller 
siRNA (19bp) will transfect with far greater efficiency than the larger pSilencer 
plasmid (4585bp). Indeed, the observed 90%+ decrease in NOP10 expression when 
using the siRNA would indicate that at least 90% of the cell population was 
transfected. In comparison, visual GFP analysis (estimated by eye) suggests NOP10 
pSilencer transfection efficiency to be no more than 50-60% which correlates with the 
level of NOP10 silencing observed. Moreover, this correlation suggests that NOP10 
pSilencer is highly effective with delivery into the cell being the limiting factor. On 
this basis it was expected that as the number of cells positive for the NOP10 pSilencer 
increased, NOP10 expression levels would decrease further.  
 
This was confirmed in the stable cell line generated under neomycin selection where 
NOP10 expression fell to less than 20% in the NOP10 pSilencer cell line. 
Unfortunately this was marred by NOP10 levels being reduced to less than 50% in the 
negative control pSilencer cell line as well, though this had not been observed in the 
initial transient test of this construct. In view of this contradiction, both cell lines were 
confirmed to have the correct pSilencer construct integrated in their genome by PCR 
and sequencing. Exacerbating the issue, clonal cell lines derived from the negative 
control pSilencer cell line exhibited further reductions in NOP10 expression, 
comparing closely to those derived from the NOP10 pSilencer cell line (between 20-
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30%). Corresponding to this, TERC levels were also reduced in all the lines. At this 
stage it was clear that the effects observed in the NOP10 pSilencer lines could not be 
attributed to NOP10 pSilencer specifically and consequently the experiment was 
terminated. 
 
On reflection this strategy had not proved to be straight forward and required more 
than one attempt, particularly the limiting dilutions. The time taken to conduct these 
experiments and the degree of uncertainty involved was a concern, especially with 
regards to the selection process and clonal expansion. This is effectively an 
indeterminable ‘black box’ period before the experiment can truly begin and is of 
variable duration depending on the recovery and proliferation of the cells, on this 
attempt 9-10 weeks. Having already spent significant time on this strategy careful 
evaluation was warranted before deciding how to proceed.  
 
Indications were that the negative control pSilencer exerted a detrimental effect on 
NOP10 and TERC levels that was not observed transiently but manifested gradually 
over time. This was quite different to the targeted effect of the NOP10 pSilencer that 
was evident from 48hr suggesting a subtle and cumulative indirect effect. Off 
targeting in RNAi experiments has been discussed in chapter 3.1 and could potentially 
be the issue here. Another possibility is that this is the result of something more 
fundamental to the experimental process, perhaps the neomycin selection. 
Unfortunately the experiment lacks a suitable neomycin resistance only (or mock) 
control to distinguish the two possibilities. However, this method of generating stable 
cell lines is not uncommon and the use of antibiotic selection unavoidable. Instead, 
investigating a different negative control pSilencer presented a more feasible option 
but, with no substitute available, this would have to be designed and produced. 
Alternatives were available in other commercial shRNA expression systems, the 
expanding market of RNAi resources also offering pre-designed and prepared shRNA 
expression vectors against an increasing number of targets. Switching to an alternative 
system presented a quick and simple solution to replacing the negative control without 
the complication of further cloning. Importantly, the NOP10 pSilencer could also be 
substituted with the same ease, as would be necessary for maintaining consistency in 
the experiment. Therefore, this strategy was reconsidered with a view to changing 
direction and implementing a different shRNA expression system. 
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4.4. Lentiviral Strategy 
Lentiviral infection provides a highly efficient method for delivery and stable 
integration of expression constructs into cells that avoids the need for transfection, a 
potentially harsh process not suitable for all cell types. On this basis lentiviral vectors 
are favoured commercially for pre-designed and prepared shRNA expression 
constructs and were consequently chosen to replace the pSilencer plasmids and the 
negative control used previously.  
 
The initial aim had been to carry out long term knockdown experiments for dyskerin, 
NOP10, NHP2 and GAR1. However, efforts so far had been problematic and time 
consuming and so at this point it was decided to focus on the long term knockdown of 
just a one of these targets. Of the four, dyskerin is the most commonly mutated in DC 
and posed the more significant target. Therefore, efforts were refocused on the stable 
suppression of DKC1 instead. 
 
4.4.1. Experimental Procedure 
The pre-designed and validated lentiviral expression vectors MISSION
®
 DKC1 
shRNA and MISSION
®
 Non-Target shRNA (Sigma) (appendix C) were chosen for 
this experiment. The pre-prepared plasmids were transformed into DH5™ 
competent cells (Invitrogen) and used for large scale plasmid preparations followed 
by transfection into HEK293T cells for lentiviral packaging (described in chapter 
2.2.3). The lentivirus was then concentrated from the culture medium to produce 
aliquots of each virus (described in chapter 2.2.4) which were independently used to 
transduce HeLa cells and generate stable cell lines under puromycin selection 
(described in chapter 2.2.5). Cultured for 18 weeks, cell counts were used to monitor 
population doublings and samples were taken at regular intervals for the analysis of 
DKC1 expression, TERC accumulation, TRAP activity and H/ACA RNA 
accumulation, as described for the transient experiments in chapter 3. To investigate 
for impacts on telomere maintenance, genomic DNA samples were used to assess 
telomere lengths in each cell line by southern blot (described in chapter 2.2.19). 
Measured against two pre-determined reference samples that were used as size 
standards, the values obtained were subsequently adjusted to account for subtelomeric 
DNA (~7.8kb) also encompassed within the fragment. 
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4.4.2. Results 
Preparation of the lentivirus proved to be straight forward and was successfully used 
to create polyclonal DKC1 shRNA and non-target control (NTC) shRNA stable cell 
lines. Comparatively, the DKC1 shRNA cell line took longer to recover from the 
selection process and reach first passage, initially suffering a high level of cell death 
in a crisis period that may indicate poor viral transduction efficiency. As a result 
DKC1 expression levels could not be verified until 5 weeks post transduction, at 
which point analysis revealed a substantial decrease to 17.3% in the DKC1 shRNA 
cell line compared to the untreated control (figure 4.13). Importantly, although 
decreased, DKC1 expression in the NTC shRNA cell line remained much higher at 
66.1% (figure 4.13).  Having confirmed effective DKC1 suppression the cultures were 
maintained for a further 13 weeks (18 weeks in total) during which time population 
doublings were monitored and samples taken for analysis at regular intervals. Over 
this 13 week period the growth of the DKC1 shRNA cell line was comparatively slow 
and impaired, undergoing fewer population doublings than both the NTC shRNA and 
untreated HeLa cell lines which grew similarly to each other (figure 4.14).  
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Figure 4.13. DKC1 expression levels. Measured 5 weeks post 
transduction, expression in the NTC shRNA and DKC1 shRNA cell lines 
was calculated relative to an untreated HeLa control. Values are from 
single cell lines, error bars marking the SD between assay duplicates. 
Figure 4.14. Growth curves for the shRNA cell lines. Proliferation over the 
13 week period from weeks 5 to 18 post transduction is compared for the 
untreated HeLa, NTC shRNA and DKC1 shRNA cell lines.   
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4.4.2.1. DKC1 Suppression 
Measured at 10, 13 and 16 weeks post transduction, DKC1 expression was 
consistently reduced to below 30% in the DKC1 shRNA cell line compared to the 
untreated control (figure 4.15). Corroborating with the analysis at 5 weeks, this 
confirmed a sustained shRNA effect suppressing DKC1 expression, and by 
implication dyskerin, in this cell line. It is noteworthy that in this line there was 
suggestion of a slow, steady increase in DKC1 expression from 18% at 10 weeks to 
28% at 16 weeks. This could be simple fluctuation but considering the polyclonal 
nature of this cell line it may also be evidence of selective pressure against shRNA 
expression, the course of the culture favouring the cells least affected i.e. less potent 
suppression. Certainly, the slow growth of this cell line strongly suggests that the long 
term suppression of DKC1 conveys a disadvantage that would explain any selective 
disadvantage.  
 
Conversely the NTC shRNA cell line exhibits a gradual decline in DKC1 expression 
from 72% to 45% over the term of the culture (figure 4.15). Though this echoes prior 
issues with the negative pSilencer experiments the impact here is somewhat less 
dramatic. The striking decrease observed in the untreated control at 13 weeks is 
inconsistent and most likely an erroneous result. 
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4.4.2.2. TERC Levels 
Supporting the findings of the transient knockdown experiment and consistent with a 
decrease in dyskerin, TERC levels were substantially reduced in the DKC1 shRNA 
cell line at each time point (figure 4.16a). Strikingly, TERC levels were much higher 
at 10 weeks (49.6%) than at 13 and 16 weeks (12 and 20.5% respectively) despite 
comparably low DKC1 expression at all three time points. To investigate this further 
TERC levels were also measured at the earlier 5 week time point, the results showing 
a decrease to less than 25% (figure 4.16b) that is more consistent with the analysis at 
13 and 16 weeks. Therefore, it appears that the TERC level at 10 weeks is somewhat 
irregular may be erroneous.   
 
In contrast, TERC levels in the NTC shRNA cell line were consistently higher 
showing a slow steady increase from 71% at10 weeks to 87% at 16 weeks (figure 
4.16a). Measured at 5 weeks TERC levels in this cell line were 81% (figure 4.16b) 
suggesting no significance to the observed increase other than random fluctuation.    
Figure 4.15. DKC1 expression in the shRNA cell lines. Measured 10, 13 
and 16 weeks post transduction, expression in the NTC shRNA and DKC1 
shRNA cell lines was calculated relative to the untreated HeLa control at 10 
weeks. Values are from single cell lines, error bars marking the SD between 
assay duplicates. 
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Figure 4.16. TERC levels in the shRNA cell lines. (a) Measured 10, 13 and 
16 weeks post transduction, levels in the NTC shRNA and DKC1 shRNA 
cell lines were calculated relative to the untreated HeLa control at 10 weeks. 
(b) Similarly measured at 5 weeks post transduction. Values are from single 
cell lines, error bars marking the SD between assay duplicates. 
(a) 
(b) 
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4.4.2.3. TRAP Activity 
Consistent with the reduced TERC levels, TRAP analysis at each time point 
demonstrates that activity was severely and persistently diminished to below 30% in 
the DKC1 shRNA cell line compared to the untreated control (figure 4.17). In 
comparison TRAP activity in the NTC shRNA cell line was remarkably higher at 103-
179% and although displaying a downward trend over the time course, remained 
within a comparable range to that of the untreated HeLa control (figure 4.17). 
 
 
 
 
 
 
 
 
 
Figure 4.17. TRAP activity in the shRNA cell lines. Measured 10, 13 and 
16 weeks post transduction, activity in the NTC shRNA and DKC1 shRNA 
cell lines was calculated relative to the untreated HeLa control at 10 weeks. 
Values are from single cell lines, error bars marking the SD between assay 
triplicates. 
Functional characterisation of the genes mutated in dyskeratosis congenita 
  102  
4.4.2.4. Telomere Length 
Southern blot analysis of telomere length at 7, 11 and 18 weeks post transduction 
failed to yield a result for week 7 (attributed to sample quality and loading issues) but 
identified measurable bands for weeks 11 and 18 (figure 4.18). It should be noted that, 
seeded from the same stock culture, all cell lines had equivalent telomere lengths 
when the experiment began. 
 
Comparing telomere length across the three lines after 18 weeks shows that over the 
course of the experiment telomeres shortened comparably in both the NTC shRNA 
and DKC1 shRNA cell lines relative to the untreated HeLa control (4, 3.5, 5.7kb, 
respectively). However, making this comparison at 11 weeks only indicates short 
telomeres in the DKC1 shRNA cell line, telomeres in the NTC shRNA cell line 
maintained at a similar length to the untreated HeLa control at this time point (3.8, 
4.8, 5.2kb, respectively). Therefore it is evident that the onset and dynamics of 
telomere shortening were different in each of the lines, commencing sooner in the 
DKC1 shRNA cell line. What’s more, this cell line exhibited comparable telomere 
lengths at both 11 and 18 weeks indicating that they were maintained, albeit shorter, 
over this period and suggesting an early transient period of telomere shortening that 
eventually stabilised.  
 
In contrast, the untreated HeLa cell line showed no sign of telomere shortening during 
the course of the experiment.  
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Figure 4.18. Telomere length in the shRNA cell lines. (a) Southern blot 
analysis of the untreated HeLa control, NTC shRNA and DKC1 shRNA cell 
lines at 7, 11 and 18 weeks post transduction. Diamonds mark the reference 
points used for measurement against the size standards. (b) Adjusted 
telomere lengths at 11 and 18 weeks post transduction.  
 
(a) 
(b) 
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4.4.2.5. H/ACA RNA Levels 
Issues pertaining to sample quality resulted in analysis of the H/ACA RNAs: TERC, 
U19, U64, U68, U70, and the C/D box RNAs U97 and U3, at 10 and 16 weeks only 
(figure 4.19).  
 
Proving to be a more reliable data set than that obtained for the transient experiments 
(chapter 3), the results here reaffirm that, at both time points, TERC levels were 
substantially reduced in the DKC1 shRNA cell line compared to the untreated HeLa 
and NTC shRNA cell lines. Similarly, at 10 weeks the DKC1 shRNA cell line also 
exhibited substantial decreases in levels of the other H/ACA RNAs that were not seen 
in the NTC shRNA cell line, most strikingly U68 and U70.  Behaving differently to 
TERC, however, these decreases did not persist at 16 weeks, by which time only U68 
was still reduced but less substantially. Subtle decreases were still evident in U19 and 
U70 as well, but similar reductions present in the NTC shRNA cell line render this 
less convincing. In contrast, levels of the C/D box RNA U97 were maintained at both 
time points and appear to be unaffected. 
 
It is important to note that in the NTC shRNA cell line the H/ACA RNAs were 
largely unaffected. However, as previous, levels of the U3 C/D box RNA proved to be 
erratic and were discounted. 
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Figure 4.19. H/ACA RNA levels in the shRNA cell lines. Measured at 10 
and 16 weeks post transduction, levels in the NTC shRNA and DKC1 
shRNA cell lines were calculated relative to those in the untreated HeLa 
control. Values are from single cell lines, error bars marking the SD 
between assay duplicates. 
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4.4.3. Discussion 
After encountering serious issues attempting a stable knockdown experiment using 
the pSilencer system, the changes implemented here proved effective and a system for 
investigating the stable knockdown of dyskerin was successfully achieved. Lentiviral 
MISSION shRNAs were used to create the DKC1 shRNA and NTC shRNA stable 
cell lines and their DKC1 expression levels were assessed. The pre-validated shRNA 
in the DKC1 shRNA cell line proved to be highly effective and suppressed DKC1 
expression to below 30% for the duration of the experiment, implicating a 
corresponding reduction in dyskerin levels. Importantly, although the NTC shRNA 
did display a gradual decline to 45% at week 16, for most of the experiment (13+ 
weeks) levels were maintained sufficiently higher at over 60%.  
 
Consistent with the findings of the transient knockdown in chapter 3 and similar 
transient studies elsewhere (Montanaro et al. 2006; Montanaro et al. 2008), 
subsequent analysis confirmed a sustained and substantial negative impact on TERC 
levels and TRAP activity corresponding to the knockdown of dyskerin in the DKC1 
shRNA cell line. Reaffirming the critical role of dyskerin, it is evident that telomerase 
stability and function were compromised in this cell line. As core machinery for 
telomere maintenance, over time this would be expected to have severe ramifications 
on telomere length. Investigating this, telomeres were found to be comparably short in 
both the DKC1 shRNA and NTC shRNA cell lines at the end of the experiment (18 
weeks). Nonetheless, it appears that telomeres shortened much earlier in the DKC1 
shRNA cell line (prior to 11 weeks) than in the NTC shRNA cell line (post 11 weeks). 
Therefore, telomeres were affected differently in the DKC1 shRNA cell line 
compared to the controls which supports the hypothesis of a comparative defect in 
their maintenance. However, with telomeres maintained (albeit shorter) between 11 
and 18 weeks it would appear that this manifested only transiently and then stabilised. 
Reconciling this with the sustained telomerase impairment in this cell line is difficult: 
why would this elicit only a transient rather than equally sustained downstream 
impact? One explanation would be that an alternative mechanism of telomere 
maintenance was activated in response to their shortening. 
 
Cells that proliferate indefinitely, such as immortalised cell lines, will predominantly 
maintain their telomeres using telomerase. Nevertheless, there are telomerase negative 
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cell lines that achieve this via the alternative lengthening of telomeres (ALT) 
pathway, a process of DNA recombination that is not fully understood (Henson et al. 
2002). The yeast model in which this was first characterised is not dissimilar to the 
DKC1 shRNA cell line. Mutated to disrupt telomerase activity, telomere shortening 
and replicative senescence ensued causing the yeast culture to go into crisis. From this 
emerged two types of rare survivors that could be differentiated by growth and 
telomere length. Type I survivors grew slowly and stably maintained a short 
homogeneous population of telomeres. Type II survivors grew normally and exhibited 
a dynamically maintained heterogeneous telomere population that ranged from 
exceptionally long to very short and were prone to abrupt changes as well as the 
gradual shortening that marked the underlying telomerase defect. Subsequent work 
demonstrated that each survivor type was dependent on a different recombination 
pathway, type I mediated through RAD51 and type II through RAD50. These 
pathways are not fully defined and what decides a type I or II survivor outcome is 
unknown (reviewed in Henson et al. 2002; Lundblad 2002; Nabetani and Ishikawa 
2011).  
 
Similarly afflicted with impaired telomerase activity, parallels to this yeast model can 
be identified in the DKC1 shRNA cell line. Compounded and masked by the 
antibiotic selection process, the excessive level of cell death encountered soon after 
viral transduction marks a crisis period in this cell line with the prolonged recovery 
highlighting how few cells survived. Emerging from this, the DKC1 shRNA cell line 
grew comparatively slower than the control cell lines and maintained stably short 
telomeres for the remainder of the experiment. It is therefore plausible that the effects 
of the dyskerin knockdown did cause telomere shortening as suggested, reasoning that 
telomere length rapidly became critical and stimulated levels of replicative senescence 
and cell death that sent the culture into crisis very early on. It is interesting to futher 
speculate that perhaps the small number of cells that survived did so by activating 
ALT pathways to circumvent the telomerase deficiency and restore telomere 
maintenance, slowly reconstituting the culture and the DKC1 shRNA cell line to 
resemble a type I survivor from the yeast model. 
 
Human cell lines that utilise the ALT pathway (commonly referred to as ALT cells) 
typically resemble type II survivors and it was speculated that unlike yeast they 
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possessed only this pathway (Henson et al. 2002; Lundblad 2002; Nabetani and 
Ishikawa 2011). However, ALT cells resembling the type I survivor type have been 
observed. (Fasching et al. 2005; Marciniak et al. 2005). In the yeast model, the slow 
growth of type I survivors gave type II survivors a selective advantage so that type I 
survivors were eventually lost from the culture (Lundblad 2002). Perhaps, both 
pathways exist in human ALT cells with this selection explaining the predominance 
of the type II survivor phenotype. In this scenario, for a type I survivor phenotype to 
dominate the type II pathway must somehow be repressed or blocked. If the ALT 
pathway is active in the DKC1 shRNA cell line then its resemblance to a type I 
survivor may suggest some importance for dyskerin in the type II survivor pathway. 
Interestingly, studies have suggested that dyskerin is involved in the DNA damage 
response pathway with some mutations increasing localisation of DNA damage foci to 
the telomeres (Gu et al. 2008; Kirwan et al. 2011), perhaps there is a link here. 
 
ALT cells are naturally telomerase negative, unlike the DKC1 shRNA cell line in 
which telomerase is simply depleted. There is uncertainty regarding what influence 
telomerase activity has on ALT pathways, some studies suggest a possible inhibitory 
affect that is discounted in other studies (reviewed Lundblad 2002). What’s more, 
these studies all involve the ectopic expression of telomerase in ALT cells, different 
again from the DKC1 shRNA cell line. However, one study has investigated the ALT 
pathway in telomerase deficient mice (through deletion of the telomerase RNA gene) 
and report evidence of only the type I survivor phenotype. Interestingly, this study 
also reported evidence of increased recombination at the telomeres of a DC patient 
with a TERT mutation and very short telomeres. Although inconclusive, this suggests 
that the ALT pathway may be activated in DC, showing resemblance to the type I 
survivor phenotype (Morrish and Greider 2009). The common element in the mouse 
study and the DKC1 shRNA cell line is that telomerase is expressed, albeit 
functionally disrupted, in these cell types. If ALT pathways are active here, perhaps 
this suggests that the expression of telomerase inhibits the type II survivor pathway in 
mammalian cells. More research is needed before these questions can be answered but 
it is interesting to consider a role for the ALT pathway in DC.  
 
The sustained suppression of dyskerin was also shown to have a variable negative 
impact on other H/ACA RNA levels, further supporting the results of the transient 
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knockdown experiment and studies elsewhere (Lafontaine et al. 1998; Dez et al. 2001; 
Mochizuki et al. 2004) Surprisingly, while the impact on TERC persisted this was not 
the case for the other H/ACA RNAs measured, evident at 10 but not 16 weeks (with 
the exception of U68). The reason for this is unclear and may reflect compensatory 
mechanisms such as increased expression levels. The literature offers very little for 
comparison on this, most dyskerin knockdown studies have been transient and not all 
of them investigated H/ACA RNA levels. Therefore, while other studies can 
corroborate the variable impact initially seen in this study, multiple analyses over a 
prolonged period were not carried out (Lafontaine et al. 1998; Dez et al. 2001; 
Mochizuki et al. 2004; Alawi et al. 2011). Functionally, H/ACA RNAs act as guides 
for pseudouridylation which is catalysed by dyskerin. Unfortunately it was not 
possible to assay this process in these experiments but transient studies elsewhere 
have shown that depleting dyskerin impairs global pseudouridylation and rRNA 
processing (Lafontaine et al. 1998; Montanaro et al. 2006). Therefore, it would be 
expected that the sustained suppression of dyskerin in these experiments would have a 
similar impact. The affect on protein biosynthesis and cell survival/proliferation is 
uncertain. In yeast the depletion of dyskerin has no bearing on telomere maintenance 
but is associated with a decrease in cell proliferation and growth arrest (Lafontaine et 
al. 1998). Similarly, the conditional knock out of DKC1 in adult mice has been shown 
to severely disrupt ribosome biogenesis and cell proliferation before telomere 
shortening occurs (Ge et al. 2010). However, studies on human cell lines are 
inconsistent in their findings. Not dissimilar to the DKC1 shRNA cell line, one study 
using telomerase positive prostate cancer cells reports a rapid cessation in 
proliferation and growth from which only a few cells survived after 10 days but 
neither H/ACA RNA levels, rRNA processing or telomerase function were 
investigated (Sieron et al. 2009). Another study using telomerase negative 
ostesarcoma cells reported only a mild decrease in proliferation and cell numbers after 
6 days, also showing a sustained decrease in H/ACA RNA levels but only a transient 
and subtle disruption to rRNA processing (Alawi et al. 2011). In contrast, a study 
using a breast cancer cell line reported protein biosynthesis to be unaffected after 4 
days of dyskerin knockdown but did not comment on changes in cell number or 
proliferation (Montanaro et al. 2010). Therefore, although it is expected that 
pseudouridylation activity would have been affected in the DKC1 shRNA cell line, it 
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is difficult to ascertain the extent of the impact and its contribution to the growth 
impairment observed in this cell line.  
 
In conclusion, these experiments have reiterated dyskerin’s importance for the 
integrity and function of telomerase and demonstrated that in this capacity it is 
essential for maintaining telomere length over time. Nevertheless, it is also evident 
that some cells are able to circumvent the telomerase defect and maintain short 
telomeres, possibly by initiating ALT pathways. The proliferation of these cells is 
impaired, however, and their long term viability remains to be determined. It is 
inevitable that pseudouridylation activity will have also been impaired in these cells, 
but unfortunately it was not possible to determine the extent of the impact and any 
bearing on cell growth and proliferation remains to be verified. 
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Chapter 5. In vitro analysis of DC mutations.  
5.1. NOP10 and NHP2 Mutations 
5.1.1. Introduction 
Discussed in chapter 1, DC patients have been found to harbour mutations affecting 
core components of the telomerase complex, predominantly dyskerin, TERC and to a 
lesser extent TERT. Unpublished prior to commencing this study, genetic analysis 
conducted by Dr Amanda Walne had also identified mutations affecting two other 
telomerase components, NOP10 and NHP2, in previously uncharacterised DC 
patients. 
 
A homozygous NOP10 missesnse mutation, c.100C>T (p.R34W), was identified in a 
large consanguineous family (DCR148) comprising three affected siblings who 
presented with reticular skin pigmentation, nail dystrophy, and hypocellular bone 
marrow. Both parents and three other siblings were heterozygous for this base change 
and remained asymptomatic, demonstrating that the homozygous mutation segregated 
with the disease (figure 5.1a) (Published Walne et al. 2007). Three different NHP2 
missense mutations were identified in two unrelated patients. A homozygous 
c.415T>C (p.Y139H) mutation was identified in a young male who presented with 
nail dystrophy, thrombocytopenia, testicular atrophy, growth and mental retardation, 
liver cirrhosis and also suffered opportunistic infections (family DCR096). Both 
parents were heterozygous for this mutation and asymptomatic (figure 5.1b). 
Compound heterozygous mutations, c.376G>A (p.V126M) and c.460T>A 
(p.X154RextX*52) were identified in another young male who presented with nail 
dystrophy, leucoplakia, reticular skin pigmentation and pancytopenia (family 
DCR177). Both parents were heterozygous for one of the mutations (mother 
c.376G>A, father c.460T>A) and remained asymptomatic, as was a sibling with a 
normal genotype (figure 5.1c) (Published Vulliamy et al. 2008).   
 
Proving evidence of a disruption in telomerase function and telomere maintenance, 
short telomeres are a common feature of DC and investigating this in these patients 
revealed very short telomeres compared to unaffected relatives and healthy controls 
(Work carried out by Dr Tom Vulliamy. Published Walne et al. 2007; Vulliamy et al. 
2008). 
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(a) 
100C/T 
100C/T 
100T/T 100T/T 100T/T 100C/T 
100C/T 
100C/T 
   
 = Nail dystrophy, reticular skin pigmentation, hypocellular bone marrow. 
DCR148 
(b) 
 
Nail dystrophy, 
thrombocytopenia, 
testicular atrophy, 
growth and mental retardation, 
liver cirrhosis, opportunistic 
infections 
415T/C 415T/C 
415C/C 
DCR096 (c) 
 
Nail dystrophy,  
reticular skin pigmentation, 
leukoplakia,  
pancytopenia 
376G/A 460T/A 
460T/A 
376G/A 
460T/T 
376G/G 
DCR177 
Figure 5.1. Family pedigrees. DC families with (a) NOP10 or (b & c) 
NHP2 mutations demonstrate recessive inheritance of the disease. Half 
filled symbols represent unaffected heterozygous and open symbols wild 
type family members respectively, filled symbols the affected homozygous 
or compound heterozygous patients with their abnormalities listed. 
Genotypes for the mutation are marked below each family member. 
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The crystal structure of an archaeal H/ACA RNP shows that dyskerin, NOP10 and 
NHP2 directly interact with the RNA component, stretching it across the surface of 
the complex (Li and Ye 2006; Hamma and Ferre-D'Amare 2010), and the RNAi 
experiments described in chapter 3 have demonstrated that all three of these proteins 
are crucial for the integrity and accumulation of TERC in human cells. Similarly, 
patients with DKC1 mutations have been found to have reduced levels of TERC and 
experiments in mice have demonstrated that mutations affecting dyskerin directly 
impair TERC accumulation (Mitchell et al. 1999b; Mochizuki et al. 2004; Wang and 
Meier 2004). Similarly, TERC levels were found to be significantly reduced in 
patients with NHP2 or NOP10 mutations, implying that these mutations also directly 
impair the ability to accumulate TERC (Work carried out by Yuka Masunari and Dr 
Amanda Walne. Published Walne et al. 2007; Vulliamy et al. 2008).  
 
To investigate this, experiments were conducted to suppress the endogenous levels of 
either NHP2 or NOP10 and exogenously reconstitute expression with the 
corresponding mutant so that their impact on TERC accumulation could be evaluated.   
 
Note: - Only the homozygous NHP2 c.415T>C mutation was investigated in this 
study.  
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5.1.2. Experimental Procedure 
HeLa cell lines stably transfected to individually express wild-type or mutant NHP2, 
wild-type or mutant NOP10 or an empty vector control, were already available in the 
laboratory. PCR amplified form cDNA, the NHP2 and NOP10 coding sequences had 
been separately cloned into the expression vector pEF1/V5-His (Invitrogen) before 
introducing the NHP2 c.415T>C and NOP10 c.100C>T mutations by site directed 
mutagenesis to create both wild-type and mutant NOP10 and NHP2 expression 
constructs. HeLa cells had subsequently been transfected with these constructs or the 
empty vector under neomycin selection to create polyclonal stable cell lines for each 
(Work carried out by Dr Michael Kirwan). 
 
In independent experiments, cells from these lines were transiently transfected with 
siRNA (NHP2 siRNA 1 or NOP10 siRNA 2) to reduce endogenous NHP2 or NOP10 
levels alongside untransfected and mock transfected controls. After 48hr RNA was 
extracted, first strand cDNA synthesised and tested for quality and DNA 
contamination by PCR of the endogenous ABL gene (primers ABL1 and ABL2; data 
not shown). NOP10 or NHP2 expression was assessed alongside TERC levels by 
qPCR using TaqMan
®
 probes (details in appendix B), calculated relative to the 
untransfected control for comparison (described in chapter 2.2.9). Importantly the 
siRNAs chosen are specific to 3’ UTR regions that were not present in the 
corresponding expression constructs. By virtue of this, expression from these 
constructs was immune to the silencing effect of these siRNAs. Similarly, for NHP2 it 
was possible to distinguish endogenous from total (endogenous and exogenous) 
expression levels by using an additional TaqMan
®
 probe set specific to the 3’UTR 
(NHP2.2 – appendix B) and, therefore, only capable of detecting the endogenous 
transcript. 
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5.1.3. Results 
5.1.3.1. Mutant NHP2  
After 48hr the NHP2 siRNA substantially reduced endogenous NHP2 expression to 
less than 15% relative to untransfected controls in all three cell lines (figure 5.2a.). 
Total NHP2 expression in the empty vector cell line was consistent with endogenous 
levels under siRNA treatment as expected. In contrast, total NHP2 levels in the wild-
type and mutant NHP2 cell lines were higher, between 30-40% (figure5.2b), 
indicating expression from the NHP2 constructs reconstituting that of the suppressed 
endogenous NHP2 gene. Despite this rescue effect, compared to controls NHP2 
expression was limited under treatment with the siRNA and consequently 
corresponding TERC levels were reduced in all three cell lines (figure 5.2c). 
However, while TERC was reduced comparably in the empty vector and mutant 
NHP2 cell lines, levels were higher in the wild-type NHP2 cell line (46%, 49%, 61%, 
respectively). This suggests that the mutant NHP2 protein cannot effectively support 
TERC accumulation compared to the wild-type NHP2 protein.  
 
5.1.3.2. Mutant NOP10 
It was not possible to distinguish endogenous from total NOP10 expression in these 
experiments but the analysis shows that after 48hr NOP10 levels were substantially 
reduced compared to untransfected controls in all three lines when treated with the 
NOP10 siRNA (figure 5.3a). NOP10 levels in the wild-type and mutant cell lines 
signify only a very low level of expression from the NOP10 constructs, though a less 
pronounced knockdown effect in these lines compared to the empty vector cell line 
would indicate a small level of reconstituted expression. With overall NOP10 
expression diminished under treatment with the siRNA, corresponding TERC levels 
were reduced in all three cell lines (figure 5.3b) but remained slightly higher in the 
wild-type NOP10 cell line than in both the empty vector and mutant NOP10 cell lines 
(27%, 46%, 39%, respectively). This small effect may suggest that the mutant NOP10 
protein is less capable of supporting TERC accumulation than the wild-type NOP10 
protein. 
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Figure 5.3. NOP10 and TERC levels in the mutant NOP10 experiment. 
(a) Total NOP10 expression and (b) TERC levels in the empty vector 
control, wild type NOP10 and mutant NOP10 cell lines 48 hours post 
transfection with NOP10 siRNA; calculated relative to the untransfected 
control. Values are from single experiments, error bars marking the SD 
between assay triplicates. 
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5.1.4. Discussion 
The aim here was to investigate the implication that homozygous NHP2 and NOP10 
mutations impair the accumulation of TERC. Attempting mutant reconstitution 
experiments, the endogenous expression of either NHP2 or NOP10 was successfully 
reduced over a 48hr period in cell lines stably expressing a corresponding wild-type or 
mutant construct. However the exogenous expression was limited and did not fully 
reconstitute that of the suppressed endogenous gene. In the NHP2 experiment, total 
NHP2 expression levels were reconstituted to between 30-40% in both the wild-type 
and mutant NHP2 cell lines. While in the NOP10 experiment, total NOP10 levels 
indicated only a very low level of reconstituted expression (10-15%) in both the wild-
type and mutant NOP10 cell lines. Consequently, in both experiments corresponding 
TERC levels were reduced regardless of mutation status. Despite this, differences 
could still be seen to suggest that TERC accumulation was further impaired in both 
the mutant NHP2 and NOP10 cell lines compared to their wild-type counterparts. 
These results would support the implication that both the homozygous NHP2 
c.415T>C and NOP10 c.100C>T mutations cause the reduced TERC levels in the 
affected patients and their disease (published Walne et al. 2007; Vulliamy et al. 2008). 
 
Experiments described earlier in this study have demonstrated that both NOP10 and 
NHP2 are important to the integrity of the telomerase complex and its ability to 
recruit TERC. The impaired capacity to accumulate TERC demonstrated both here 
and in the affected patients would suggest that this integrity and recruitment is 
compromised by these mutations. Mapping these mutations on to the crystal structure 
of an archaeal H/ACA RNP offers further insight and support for this (figure 5.4). In 
this structure the mutated NOP10 residue R34 directly binds to the H/ACA RNA as 
part of a highly conserved segment of the protein (residues 34-38) that interacts with 
both dyskerin and the H/ACA RNA simultaneously. A substitution at this residue 
would be predicted to disrupt this binding as it relies on the long side chain of 
arginine to be inserted into the major groove of the RNA (Li and Ye 2006). The 
mutated NHP2 residue Y139 is located towards the C-terminal end of the protein and 
does not appear to be involved in the interactions with either NOP10 or the H/ACA 
RNA. Therefore, disruptions arising from the substitution of this residue are more 
difficult to predict but as a highly conserved residue it is suggested to play an 
important role in the protein.  
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The disruption caused by these mutations has been more clearly demonstrated since 
their publication. Trahan et al used a cell free in vitro system to investigate the impact 
of DC mutations on H/ACA RNP formation, specifically protein-protein interactions 
and H/ACA RNA recruitment (Trahan et al. 2010). They report that the NOP10 
mutation p.R34W (c.100C>T) did not disrupt formation of the protein core but its 
ability to bind and recruit H/ACA RNAs, including TERC, was severely impaired. 
The NHP2 mutation p.Y139H (c.415T>C) was found to have a more severe impact 
and impaired the interaction of NHP2 with NOP10, disrupting formation of the 
protein core and H/ACA RNA recruitment. Trahan et al also investigated the 
Figure 5.4. DC mutations mapped onto the crystal structure of a (Pf) 
H/ACA RNP. Mutated residues and side chains in NOP10 (Nop10), NHP2 
(L7Ae) and dyskerin (Cbf5) are highlighted in orange with the C-terminal 
extension created in NHP2 also represented. The NOP10 and NHP2 
mutations are labelled. (Figure adapted from Vulliamy et al. 2008, initially 
prepared by Kepiong Ye for Dr Vulliamy) 
 
R34W 
X154RextX*52 
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compound heterozygous NHP2 mutations that have not been examined here. They 
report that p.V126M (c.376G>A) similarly disrupts formation of the protein core and 
H/ACA RNA recruitment but less severely than the p.Y139H mutation. Surprisingly, 
p.X154RextX*52 (c.460T>A) was found to have no impact on the formation of the 
protein core or H/ACA RNA recruitment. As recessive inheritance still implicates this 
mutation in the disease the authors logically suggest that its impact must be further 
down the biogenesis pathway. Indeed, it is important to consider the limitations of the 
cell free in vitro system used. Complex formation is contrived and simplified in this 
system but in vivo the stoichiometry of this process is likely to be more complex. It is 
plausible that this mutation may still have an impact through in vivo factors that are 
neutralised in this cell free context, such as chaperone interactions or protein 
localisation. Alternatively, the complex formed with this mutant may simply be 
aberrant or unstable and degraded more rapidly in vivo. Trahan et al have, therefore, 
demonstrated that H/ACA RNP integrity and H/ACA RNA recruitment are directly 
compromised by these mutations, providing a mechanism for the impaired 
accumulation of TERC seen in the affected patients and suggested in the 
reconstitution experiments described here.  
 
In conclusion, these experiments sought to investigate the impact of homozygous 
NOP10 and NHP2 missense mutations observed in patients with DC. As indicated by 
patient TERC levels, these reconstitution experiments provide evidence to suggest 
that TERC accumulation is impaired as a direct consequence of these mutations. 
Subsequent studies by Trahan et al confirm that these mutations have a direct negative 
impact on H/ACA RNP integrity and H/ACA RNA recruitment, including TERC 
(Trahan et al. 2010). Together, these findings provide substantive evidence and a 
mechanism to directly incriminate these mutations in the disease of these patients; 
through a telomerase defect that serves to further implicate defective telomere 
maintenance in DC. 
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5.2. Dyskerin Mutations 
5.2.1. Introduction 
Short telomeres are a common feature of DC and the mutations identified in various 
telomerase components strongly implicate this complex and defective telomere 
maintenance in DC disease. However, sharing a common protein core with all other 
all H/ACA RNPs there is functional overlap that potentially implicates 
pseudouridylation defects in DC as well, specifically from mutations affecting 
dyskerin, NOP10 and NHP2.  
 
Dyskerin mutations account for the largest proportion of characterised DC cases, most 
are unique with a small number seen in multiple cases and one that is particularly 
common (p.A353V) (Vulliamy et al. 2006). Mapping dyskerin mutations onto the 
archaeal crystal structure of the H/ACA RNP (refer to figure 5.4) or the proposed 
structural model of dyskerin (Rashid et al. 2006) (figure 5.5) demonstrates the large 
number (including p.A353V) that are located in or around the RNA binding PUA 
domain. 
 
Figure 5.5. Dyskerin mutations mapped onto a model of the human protein 
structure. Created based on homology between dyskerin and (Pf) Cbf5. The 
mutated residues are highlighted in orange, white labels indicating those that 
occur in multiple families. (Figure taken from Rashid et al. 2006). 
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It is plausible to assume that these mutations may weaken or disrupt dyskerin-H/ACA 
RNA interactions and would therefore suggest that their role in DC is mediated 
through influences on H/ACA RNAs rather than a direct impact on dyskerin's 
catalytic ability. This is consistent with the strong implications for defects in 
telomerase and telomere maintenance in DC which are not directly dependant on the 
catalytic activity of dyskerin.  
 
One study has investigated the impact of two dyskerin mutations, p.A353V and 
p.G402E, when introduced into mouse ES cells and reported marked decreases in 
some H/ACA RNAs and pseudouridylation for both, but only p.A353V was 
associated with reduced TERC levels, telomerase activity and telomere length 
(Mochizuki et al. 2004). On the other hand, studies of dyskerin mutations in patient 
material have not reached similar conclusions and found no evidence to suggest that 
H/ACA RNA levels or pseudouridylation are affected only TERC levels, telomerase 
activity and telomere length (Mitchell et al. 1999b; Wong et al. 2004). However, it is 
noteworthy that the mutations investigated in patient studies differ from those in the 
mouse study. Different again, a cell free in vitro study that specifically investigated 
the dyskerin-TERC interaction has shown that this to be severely disrupted by both 
the p.A353V and p.G402E mutations (Ashbridge et al. 2009). Yet, several dyskerin 
mutations had no impact on protein interactions or H/ACA RNA recruitment in the 
cell free study on H/ACA RNA assembly by Trahan et al, except for a mild decrease 
in TERC with the p.A353V mutation (Trahan et al. 2010). Despite this, reduced 
TERC levels have been reported in a large number of patients with various dyskerin 
mutations but other H/ACA RNAs were not investigated for comparison (Walne et al. 
2007; Vulliamy et al. 2008). 
 
Therefore, the impact of dyskerin mutations on H/ACA RNAs in DC patients remains 
somewhat ambiguous. To investigate this, a panel of H/ACA RNAs were quantified 
in primary material from DC patients with dyskerin mutations and compared to those 
of healthy controls. 
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5.2.2. Experimental Procedure 
All the individuals included in this study were recruited to the DCR in London with 
written consent and ethical approval as defined in chapter 2.1.6. Where cDNA 
samples were available, 13 patients with confirmed dyskerin mutations were selected 
(6 x p.A353V, 3 x p.G402E, p.P40R, p.M350T, p.H68T, and p.L314Del) along with 
12 healthy controls. For both sample sets, absolute levels for the H/ACA RNAs: U19, 
U64, U68, U70, and the C/D box RNA U97, were determined by qPCR using SYBR 
green, normalised to that of the ABL endogenous control and expressed as a 
target/ABL ratio for comparison (described in chapter 2.2.9, primers in appendix B). 
Where appropriate P values were calculated using the Mann-Whitney U test 
(described in chapter 2.2.27). 
 
 
5.2.3. Results 
The results of this analysis suggest that not all H/ACA RNAs are affected by dyskerin 
mutations (figure 5.6). Compared to healthy controls the ratios for TERC, and less 
strikingly, U19 and U68 are significantly lower in the DC patient group (p=0.0002, 
p=0.0226, p=0.0133, respectively). The other two, U64 and U70, as well as the 
control C/D box RNA U97, show no significant differences (p=0.4303, p=0.5316, 
p=0.2648, respectively).  
 
Analysing the patient cohort by mutation shows that this discriminatory impact varies 
for each (figure 5.7). Further, this analysis highlights a striking consistency to the 
impact on TERC that is not seen with any of the other H/ACA RNAs investigated. 
Due to insufficient numbers statistical significance could only be determined for the 
p.A353V and p.G402E mutations which highlights that only TERC is significantly 
reduced with the p.A353V mutation (p=0.01), but both TERC and U19 reductions are 
significant with the p.G402E mutation (p=0.0115, p=0.0115, respectively).  
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Figure 5.6. H/ACA RNA levels in patients with dyskerin mutations. Box 
whisker plots comparing H/ACA RNA levels in 12 healthy controls and 13 
DC patients. Calculated as a target/ABL ratio the data is plotted on a log 
scale to correct for a skewed distribution with median values and outliers 
(>1.5 box lengths) marked. U97 is a C/D Box RNA control. 
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(d) (e) (f) 
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Figure 5.7. Differences in the impact on H/ACA RNA levels. Box whisker 
plots showing the variable impact of different dyskerin mutations on 
H/ACA RNA levels. Calculated as a target/ABL ratio the data is plotted on 
a log scale to correct for a skewed distribution with median values and 
outliers (>1.5 box lengths) marked.  
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5.2.4. Discussion 
Levels of the H/ACA RNAs: TERC, U19, U64, U68, U70, and the control C/D box 
RNA U97, were measured in control and patient cohorts and show that while TERC is 
significantly reduced in the patient group some but not all of the other H/ACA RNAs 
are similarly affected, namely U19 and U68. Corroborating with previous patient 
studies to indicate that dyskerin mutations adversely affect TERC recruitment and 
accumulation, this observation goes further to suggests that they have a variable 
impact on H/ACA RNAs generally and discriminate against certain species only. 
Analysing each individual mutation demonstrates further variability while 
highlighting TERC as the only one to be affected consistently. 
 
With the exception of TERC, there is a lack of data in the literature regarding H/ACA 
RNA levels in DC patients for comparison. One study investigated TERC, U17, U64 
and U85 levels in primary material from a single patient with the dyskerin mutation 
p.Q31E and found no observable differences except decreased TERC (Wong et al. 
2004). A separate study similarly found TERC to be reduced but U64, E1 and E2 
unaffected in EBV transformed lymphoblast cell lines and primary fibroblasts from 
two different patients with dyskerin mutations, one harbouring a p.T66A mutation the 
other a p.L37Del (Mitchell et al. 1999b). These specific mutations are not represented 
in this study for direct comparison, but further demonstrate that not all H/ACA RNAs 
are affected by dyskerin mutations and were initially considered to suggest a selective 
impact on TERC alone. Taken in retrospect with the findings from the patient analysis 
here, it could be suggested that these studies provide further support for a consistent 
impact on TERC while highlighting that the restricted H/ACA RNA analysis 
performed was a limitation that allowed other discriminatory affects to be overlooked. 
A mouse ES cell study investigating the p.A353V and p.G402E mutations analysed a 
broader selection of H/ACA RNAs and also observed a selective impact (Mochizuki 
et al. 2004). They report decreases in the levels of TERC, U68, U64 and U70 for the 
common p.A353V mutation but only in U64 levels for the p.G402E mutation. In the 
patient cohort analysed here only TERC was significantly decreased with the 
p.A353V mutation while the p.G402E mutation significantly reduced both TERC and 
U19. This disparity may reflect species variation between mice and humans or 
variation between cases of the same mutation, as is seen in the patient cohort. 
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However, both studies agree in suggesting that dyskerin mutations affect multiple 
H/ACA RNAs in a discriminatory impact. 
 
It has been specifically shown that the p.A353V and p.G402E mutations severely 
disrupt the dyskerin-TERC interaction (Ashbridge et al. 2009). However, a cell free in 
vitro study into H/ACA RNP assembly found  that several dyskerin mutations had no 
impact on the recruitment of U17, U64, U92 and, surprisingly, TERC which was only 
mildly impaired with the p.A353V mutation (Trahan et al. 2010). This would imply 
that dyskerin mutations alone do not cause sufficient disruption to prevent H/ACA 
RNA recruitment to the complex as a whole, stressing the involvement of NOP10 and 
NHP2 in this interaction. However, this is inconsistent with the impacts observed in 
patients and indicates compounding influences in vivo. It is conceivable that the 
stability of the H/ACA RNA interaction is diminished in these complexes; their 
simplified stoichiometry and exaggerated ‘turn over’ in vitro may compensate for this 
and overstate the stability of the RNA recruitment compared to that in vivo. This 
potentially suggests that the impact of these mutations can be influenced by the 
stoichiometry of the complex and so perhaps the discrimination regarding which 
H/ACA RNAs are affected relates to differences in their individual expression and 
stability. Comparing the relative abundances of the H/ACA RNAs analysed in this 
study shows that the unaffected U64 and U70 are much more abundant than the 
affected U19 and U68, but any correlation is undermined by TERC which is highly 
abundant but severely affected (figure 5.8).  
 
However, the consistency of the impact on TERC suggests that it is particularly 
susceptible to these mutations compared to other H/ACA RNAs. Accommodating its 
unique pseudoknot domain, TERC is larger (451nt against an average 100-150nt) than 
other H/ACA RNAs and more complex in structure, its interactions with the RNP are 
likely to be more complex and therefore more susceptible to disruption. Certainly, it is 
conceivable that its larger size alone may render this interaction more vulnerable to 
disruption and it is noteworthy that the study by Trahan et al, which observed normal 
TERC recruitment in the presence of dyskerin mutations, did not use the full length 
TERC molecule. Studies in yeast have suggested that the stability of the H/ACA 
RNA-RNP interaction differs for each H/ACA RNA (Henras et al. 2004b). Therefore, 
the discriminatory impact on H/ACA RNAs probably reflects combined differences in 
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their individual structures and specific interactions with the RNP as a whole, as well 
as their relative abundances.  
 
 
In conclusion, analysing different H/ACA RNAs in a cohort of DC patients has 
revealed that only some are significantly affected, varying for each mutation. 
Strikingly, the only RNA found to be consistently affected was TERC, indicating that 
it is highly susceptible to mutational disruptions. In fact, TERC decreases are 
consistently observed across various knockdown, mutation and patient studies 
investigating dyskerin, NOP10 or NHP2, which demonstrates that it is vulnerable to 
disruptions affecting the RNP complex as a whole. Combining the observations of 
this study with those elsewhere suggests that dyskerin mutations have a 
discriminatory impact on H/ACA RNAs that may relate to differences in their 
expression and the stability of their individual interactions with the RNP complex. 
Though more research is needed to elucidate the functional repercussions on 
pseudouridylation activity, any impact is likely to be limited and variable in 
comparison to the consistent impact that is observed on TERC and telomerase 
function - highlighting its predominant role in DC pathology.  
 
Figure 5.8. Relative abundance of the different H/ACA RNAs. Compared in 
both the healthy control (n=12) and DC patient (n=13) groups, averaged from 
target/ABL ratios measured in each cohort. 
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Chapter 6. Telomere Length in Dyskeratosis Congenita.  
6.1. The Prevalence of Short Telomeres in DC 
6.2. Introduction 
When this study began DC had been associated with mutations affecting five different 
genes, all of which could be linked to telomere maintenance through the telomerase 
complex. Since then mutations have been reported that implicate three other genes in 
this disease: TINF2, TCAB1, and C16orf57 (Savage et al. 2008; Walne et al. 2010; 
Zhong et al. 2011). TINF2 encodes the core shelterin component TIN2; shelterin is 
important for telomere stability and telomerase recruitment (de Lange 2005; Abreu et 
al. 2010). The specific impact of these mutations has not been confirmed but the 
affected patients were found to have very short telomeres (Savage et al. 2008; Walne 
et al. 2008). TCAB1 encodes the newly identified telomerase component TCAB1 
which is important for telomerase localisation and trafficking through cajal bodies to 
the telomeres (Venteicher et al. 2009). TCAB1 mutations directly impair the correct 
localisation of telomerase and short telomeres are observed in the affected patients 
(Zhong et al. 2011). Initially uncharacterised, C16orf57 has recently been shown to 
encode the protein USB1, important for modifying the 3’ end of the spliceosomal U6 
snRNA, part of the pre-mRNA splicing machinery (Hilcenko et al. 2012; Mroczek et 
al. 2012). This is the first DC gene not to implicate defective telomere maintenance as 
the underlying cause of disease and affects only a small subset of patients, all of 
whom had normal length telomeres (Walne et al. 2010). 
 
Overall, mutations affecting eight different genes have now been identified in DC: 
DKC1, TERC, TERT, NOP10, NHP2, TCAB1, TINF2, and C16orf57, accounting for 
approximately 50-60% of DCR cases. As seven of these genes are linked to telomere 
maintenance complexes, the predominant underlying cause of DC continues to be 
defective telomere maintenance and telomere shortening. Indeed, short telomeres are 
now considered a hallmark of this disease and have even been proposed as a 
diagnostic marker for DC (Alter et al. 2007). However, DC has a heterogeneous 
clinical presentation and disease severity is seen to differ between genetic subtypes 
despite the common underlying defect. Though telomere length has been investigated 
in each of these subtypes to indicate impacts on telomere maintenance very little 
comparison has been made between them. Also, approximately 40-50% of DCR 
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patients still have no known genetic basis and telomere length has not been widely 
investigated in this group. Therefore, it could be argued that the true extent of the 
telomere length defect in DC remains to be seen and C16orf57 mutations have 
demonstrated the potential for alternative defects in this disease.  
 
In this part of the study telomere lengths were analysed and compared in an 
unprecedentedly large cohort of DC patients representing the most common genetic 
subtypes: DKC1, TINF2, TERC and TERT, as well as those with no known genetic 
basis.   
 
 
6.3. Experimental Procedure 
All the individuals included in this study were recruited to the DCR in London with 
written consent and ethical approval as defined in chapter 2.1.6. Telomere lengths 
were analysed in 102 healthy controls and 145 DC patients: 39 with DKC1 mutations, 
19 with TERC mutations, 11 with TERT mutations, 24 with TINF2 mutations, and 52 
that were genetically uncharacterised (no mutations in known DC genes). 20 AA 
patients were also analysed for comparison. Measurements were taken from DNA 
samples using MMqPCR (described in chapter 2.2.21) and expressed as a T/S ratio 
normalised to that of an independent reference sample included in every sample set. 
The Mann-Whitney U test was used to calculate P values for the different 
comparisons (described in chapter 2.2.27). 
 
Note: - All DNA samples were assessed for quality by agarose gel electrophoresis and 
only those that displayed a clean DNA band (no smearing) were accepted for analysis 
(data not shown).   
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6.4. Results  
The analysis performed here shows that on average telomeres were significantly 
shorter in DC patients compared to healthy controls (P<0.0001) (figure 6.1a). In 
contrast, telomere length in the AA patient group did not differ significantly from the 
healthy controls and demonstrates that BMF is not the cause of telomere shortening in 
DC (P=0.6283) (figure 6.1a).  
 
Corroborating with studies elsewhere, telomeres were significantly shorter in the 
DKC1, TERC, TERT and TINF2 patient groups compared to the healthy control group 
(P<0.0001, P<0.0001, P=0.0011, and P<0.0001, respectively) (figure 6.1b). Plotting 
telomere length against age enables this comparison to be made in context to normal 
age related telomere shortening and emphasises that the patients had excessively short 
telomeres for their age (figure 6.2a). All four subgroups shared a closely overlapping 
range of telomere length and there were no significant differences between the TERC, 
TERT and TINF2 groups. However, the DKC1 group had a comparatively broader 
range of telomere length that was on average significantly longer than the TERC and 
TINF2 groups (P=0.0038, P=0.0168, respectively).  
 
The range of telomere length was much broader in the uncharacterised patient group 
and did not differ significantly from the healthy control group (figures 6.1b). 
Nonetheless, there was considerable overlap with the other patient groups and a 
subgroup with very short telomeres was evident. Plotting telomere length against age 
further demonstrates a number of patients that had excessively short telomeres for 
their age but also patients in which telomere length was normal (figure 6.2b).   
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Figure 6.1. Telomere length in DC patients. (a) Box whisker plots 
comparing telomere length in healthy controls, DC and AA patients. (b) 
Comparison of telomere length in different genetic subtype of DC.  
 
(b) 
(a) 
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Figure 6.2. Telomere length plotted against age at report. (a) Characterised 
DC and (b) uncharacterised DC patients are plotted alongside the healthy 
controls for comparison. The trend line highlights normal age related 
telomere shortening in the healthy control group.  
 
(a) 
(b) 
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6.5. Discussion 
Telomere lengths were investigated in a large cohort of 145 DC patients, differing 
from previous studies by encompassing a broader spectrum of DC subtypes rather 
than focusing on one specifically. This comprehensive analysis has reiterated that 
telomeres are significantly short in the four major subtypes of DC: DKC1, TERC, 
TERT, and TINF2, also demonstrating that telomere shortening in these patients is 
excessive for their age. Emphasising the prevalence of the telomere length defect in 
this disease, these findings are consistent with the predominant cause of DC being a 
defect in telomere maintenance.    
 
DC displays a variable spectrum of clinical presentation and severity, the later 
generally gauged by the age of onset (particularly BMF) along with the number of 
somatic abnormalities: BMF before the age of 10yrs along with several other disease 
features classed as severe; haematological abnormalities after the age of 20yrs classed 
as mild (Dokal 2000). Interestingly, disease appears to manifest differently depending 
on the genetic subtype. DKC1 and TINF2 mutations are generally associated with 
severe disease that manifests at a very young age, DKC1 patients mostly presenting 
with classical DC while TINF2 patients often develop severe AA ahead of other DC 
features. In contrast, TERC and TERT mutations are typically associated with a mild 
disease that displays anticipation and does not manifest in all the affected generations 
of a family. The age of onset is more varied but typically later in life and with fewer 
abnormalities, predominantly presenting haematological defects.   
 
Comparing telomere length between these subtypes reveals no correlation to their 
differences in disease, on average telomeres are comparatively longer in the DKC1 
group but all four subtypes share a close overlapping range of telomere length. 
Disease anticipation demonstrates that disease only manifests when telomere length 
becomes critical and so it is perhaps understandable that patients presenting disease 
exhibit similarly short telomeres: critically short (Vulliamy et al. 2004; Marrone et al. 
2005). However, it is interesting to consider this in conjunction with differences in the 
typical age of disease onset for each of these groups (highlighted in figure 6.3). This 
indicates differences in the time taken for telomeres to become critically short and, 
therefore, differences in the rate of telomere shortening associated with each genetic 
subtype.  
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TERC and TERT mutations have already been associated with a slow rate of telomere 
shortening that is demonstrated by the disease anticipation seen in affected families. 
Telomeres shorten progressively and silently through the affected generations, each 
inheriting shorter telomeres than the previous until after several generations critical 
length is reached and disease finally manifests. The age of onset and the severity of 
disease in these patients vary depending on the number of generations involved 
(Vulliamy et al. 2004; Marrone et al. 2005). This is a stark contrast to the rapid 
telomere shortening that is evident in the DKC1 and TINF2 patient groups where 
disease manifests in the first generation and without inheriting short telomeres. In 
these subtypes disease typically presents during infancy and early childhood, 
indicating that telomere length becomes critical within the first few years of life. 
Therefore, it is the rate of telomere shortening that appears to correlate with disease 
severity, rapid telomere shortening being associated with a severe DC phenotype. 
 
Telomere shortening only has a pathological impact when telomeres become critically 
short. Directly influencing the speed with which this happens, the rate of telomere 
shortening governs the latency with which the telomere maintenance defect delivers a 
pathological impact (reflected by the age of onset). However, driven by cell division, 
Figure 6.3. Relative age at report for patients in the different subtypes of DC.   
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only cell types and tissues that are actively proliferating are susceptible to telomere 
shortening. Therefore, the body is more widely susceptible when in a state of rapid 
growth and development during early life than when it is fully developed in 
adulthood. Potentially, rapid telomere shortening that delivers a pathological impact 
during early life will have broader consequences giving rise to a more severe disease, 
as is evident in the DKC1 and TINF2 patients. Conversely, the scope of the disease 
arising from a latent impact that occurs in later life will be more limited and milder by 
comparison, as observed in the TERC and TERT patients. Therefore, by governing the 
latency with which the telomere length defect delivers a pathological impact, the rate 
of telomere shortening conceivably influences the extent and severity of the disease. 
This is difficult to verify empirically but supporting evidence can be found in disease 
anticipation where inheriting shorter telomeres brings the age of disease onset forward 
in successively afflicted generations and is associated with an increase in disease 
severity (Vulliamy et al. 2004; Marrone et al. 2005).  
 
The range of telomere length in the DKC1 subtype was broader and significantly 
longer than the other subtypes. It appears that not all of these patients have critically 
short telomeres, but still have disease, indicating a second defect in these patients. 
Other aspects of this study have provided evidence to suggest that DKC1 mutations 
impact on pseudouridylation activity, though the extent of this defect has yet to be 
determined. However, the most severe DC phenotypes are seen in DKC1 patients and 
it is intriguing that mucocutaneous features are more prominent in this group of 
patients compared to the TINF2, TERC and TERT patients. It is interesting to consider 
that these differences may be evidence of a contributing pseudouridylation defect in 
the DKC1 patients.  
 
Telomere length analysis in the uncharacterised group has identified a subset of 
patients that do not have short telomeres, indicating some other defect causing their 
disease. The possibility of an alternative pathology in DC has already been raised by 
patients with C16orf57 mutations, which do not implicate telomere maintenance 
defects (Walne et al. 2010). However, perhaps it is also prudent to consider the 
possibility of misdiagnosis too. DC is defined and diagnosed based on clinical criteria 
alone but the complex spectrum of presentation and its overlap with other diseases can 
cause confusion. As these patients differ from the majority of DC patients at a 
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molecular level this raises the question: do these patients have overlapping diseases 
that have been confused for DC? There is argument for this with the C16orf57 
patients. Mutations in this gene were first identified in patients with poikiloderma 
neutropenia (PN) and have also been seen in cases of Rothmund–Thomson syndrome 
(RTS), two diseases that are often confused due to considerable clinical overlap that is 
also shared with DC (Volpi et al. 2010; Walne et al. 2010; Colombo et al. 2012). As 
the defect in patients with C16orf57 mutations differs from all other characterised DC 
patients and in view of the clinical and genetic overlap with other diseases, some 
would argue that the diagnosis of DC should be reconsidered for these patients. 
Indeed, there is already evidence of C16orf57 mutations being used to distinguish PN 
from RTS and DC (Colombo et al. 2012). As the genetic and molecular defects in 
uncharacterised patients with normal length telomeres are elucidated it will be 
interesting to see if there is further overlap with other diseases to implicate a potential 
misdiagnosis.  
 
In conclusion, analysing telomere length in a large cohort of DC patients has 
reiterated the prevalence of short telomeres in this disease but has also demonstrated 
that differences in severity do not correlate with telomere length. Instead, this analysis 
indicates that it is differences in the rate of telomere shortening that influence the 
severity of this disease. However, comparatively longer telomeres in the DKC1 
patient group provides further evidence for a defect in pseudouridylation contributing 
to their disease that perhaps correlates with differences in the disease phenotype 
associated with these patients. Lastly, identifying a subset of patients that do not have 
short telomeres, this analysis provides further evidence of alternative defects causing 
DC. However, the potential for misdiagnosis also raises the question as to whether 
defective telomere maintenance should now be used to further define DC rather than 
clinical presentation alone and, therefore, whether these patients actually have DC. 
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6.6. Telomere Length as an Indicator of DC  
6.6.1. Introduction 
Touched upon in the previous section, DC has a clinical presentation that can be 
confused with other diseases and initial diagnosis can often be confused for AA, other 
DC features developing later. Similarly, a subset of AA patients that do not respond to 
conventional therapy have been found to have TERC mutations and short telomeres, 
their phenotype not sufficient to warrant a DC diagnosis but considered to be ‘DC 
like’ (Vulliamy et al. 2002; Yamaguchi et al. 2003). Correctly identifying patients 
with DC related disease has important implications for managing their condition 
though. Alter et al have reported that analysing telomere length in specific leukocyte 
subsets by flow FISH can be used to distinguish DC from non DC patients and 
propose this as a diagnostic marker in cases where there is ambiguity (Alter et al. 
2007).  
 
The DCR in receives many samples from AA patients suspected of having DC related 
disease, using the telomere length to further evaluate the DC potential in these 
patients may help to prioritize or eliminate them for DC screening. To investigate this, 
flow FISH was used to analyse telomere length in patients submitted to the DCR 
according to the criteria defined by Alter et al (Alter et al. 2007).   
 
 
6.6.2. Experimental Procedure 
Flow FISH (described in chapter 2.2.20) was used to determine relative telomere 
lengths (RTL) for lymphocyte and granulocyte subsets in blood samples obtained 
from 42 healthy controls and 58 patients; 16 with DC* and 42 with idiopathic AA. 
Measured in kilobases (kb), RTLs were calculated using a calibrator sample of 
predetermined length. All samples were collected with written consent and ethical 
approval.  
 
* DC patients had mutations in the following genes: 3 x TERC, 2 x TERT, 2 x DKC1, 
1 x TINF2 and 8 were genetically uncharacterised. 
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6.6.3. Results and Discussion 
Following the flow FISH protocol outlined by Baerlocher et al telomere lengths were 
successfully analysed in lymphocyte and granulocyte subsets of the healthy control 
and patient blood samples (Baerlocher et al. 2006). In the diagnostic criteria outlined 
by Alter et al, DC patients are identified as having telomeres shorter than the first 
percentile of healthy controls, further reporting that the lymphocyte subset provides 
greater sensitivity and specificity for this discrimination (Alter et al. 2007). In the 
analysis here 13 of the 16 DC patients had lymphocyte telomeres shorter than the first 
percentile (81% sensitivity) but only 10 had granulocyte telomeres below the same 
mark (62% sensitivity) (figure 6.4). It should be pointed out that the granulocyte 
subset proved variable and often few in number, making them less reliable and more 
difficult to analyse. Alter et al also reported difficulties analysing granulocytes in 
some patients (Alter et al. 2007). As the more reliable and discriminative subset, 
analysis of the AA patients was centred on the lymphocyte telomeres. It is also 
noteworthy that the 3 DC patients who did not have short lymphocyte telomeres have 
no known genetic basis and so it is interesting to consider that this may indicate 
misdiagnosis. 
 
Of the 42 AA patients analysed 15 were found to have lymphocyte telomeres below 
the first percentile (figure 6.4), suggesting DC related disease and highlighting them 
for genetic screening. Another 5 had telomeres below the tenth percentile. Though the 
indicator for DC is telomeres shorter than the first percentile, this is still considered 
short and therefore worthy of further investigation. Subsequent genetic analysis of 
these 20 patients (carried out by Dr T Vulliamy) identified 3 with TERC mutations 
that confirm they have DC related AA. The rest were not found to have either TERC 
or TINF2 mutations, the common genetic overlap between AA and DC. However, the 
potential for DC related disease in these patients may merit screening other DC 
related genes, a consideration for future projects perhaps.  
 
Applying the criteria defined by Alter et al, using telomere length analysis by flow 
FISH to evaluate cases of unresponsive idiopathic AA submitted to the DCR was 
beneficial in identifying patients for DC screening. It has also identified 3 
uncharacterised DC patients that do not have a telomere length defect, an important 
consideration for the future analysis and treatment of these patients. Setting up the 
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Figure 6.4. Telomere length in lymphocyte and granulocyte subsets. 
Plotted against age at report for DC (n=15) and AA (n=42) patients. 
Dashed lines plot the 1
st
, 10
th
 and 50
th
 percentiles for age groups 0-10, 
10-20, 30-40, 40-50 and 50+ of the healthy controls (n=42). 
 
Note: - The age at report was unknown for one DC patient, however, 
their lymphocyte and granulocyte telomeres were below the 1
st
 percentile 
at all ages (4.3kb and 2.1kb respectively). 
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flow FISH procedure was relatively straight forward, however, establishing the ability 
to use this as a discriminatory tool proved more problematic. This requires a large 
number of healthy controls of evenly distributed ages to achieve well defined 
percentiles across the entire age range. The study by Alter et al used 400 healthy 
controls to accomplish this (Alter et al. 2007). Though obtaining such numbers 
presents a challenge in itself the bigger problem is achieving the age distribution 
required, especially for the very young. This study managed to obtain a cohort of only 
42 healthy controls that was bias towards the 20-50 year age range. Sufficient for the 
purposes of this study perhaps, but in truth the normal range of telomere length is not 
well represented for all ages and the percentiles are badly defined. Certainly, they are 
a poor comparison to those used by Alter et al to define the discriminating criteria. 
Therefore, establishing a truly representative control cohort is highlighted as a 
potential difficulty for any laboratory wishing to employ this procedure and a 
limitation for its use diagnostically.  
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Chapter 7. Concluding Remarks  
Prior to this study commencing, mutations affecting dyskerin, TERC and TERT had 
been reported in DC patients while unpublished research from our group had also 
identified patients harbouring mutations affecting NOP10 and NHP2. These are linked 
as components of the telomerase complex which is important for telomere 
maintenance and patients are commonly found to have short telomeres. To further 
examine the implications for a telomere maintenance defect in this disease and to 
support the publication of NOP10 and NHP2 as causative DC genes, this study has 
looked at the roles of dyskerin, NOP10 and NHP2 in the telomerase complex. 
Specifically, their importance, along with GAR1, for the integrity and function of 
telomerase has been investigated in human cells followed by in vitro analysis of the 
potential impact homozygous NOP10 and NHP2 missense mutations have on this 
complex. To consider the implications for a pseudouridylation defect, the integrity of 
other H/ACA RNPs has also been investigated in these experiments and in patients 
with DKC1 mutations. Finally, the extent of the telomere length defect in this disease 
has been further investigated; telomere lengths were analysed in a patient cohort of 
unprecedented size and comparisons made between the different genetic subtypes of 
DC.  
As part of telomerase; dyskerin, NOP10, NHP2 and GAR1 associate with TERC to 
produce an H/ACA RNP that forms the structural basis of the larger telomerase 
complex (reviewed Collins and Mitchell 2002). H/ACA RNP studies in yeast and 
mice infer that dyskerin, NOP10 and NHP2, but not GAR1, are crucial for H/ACA 
RNA recruitment and stability, including TERC in the context of telomerase 
(reviewed Meier 2005). While dyskerin has been confirmed to be important for TERC 
levels and telomerase activity in human cells, NOP10, NHP2 and GAR1 had not been 
similarly investigated (Mitchell et al. 1999b; Montanaro et al. 2006). The RNAi 
experiments conducted in this study confirm that in human cells TERC levels are 
dependent not only on dyskerin, but also NOP10 and NHP2, supporting the inference 
that these proteins are central to the structure of telomerase and stable TERC 
recruitment (Walne et al. 2007; Vulliamy and Dokal 2008). However, only dyskerin 
and NOP10 were found to be important for telomerase activity in these experiments. 
TERC is an essential component of telomerase and a limiting factor for its activity 
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(Marrone et al. 2004; Wong and Collins 2006). In light of its importance for stable 
TERC recruitment it seems unlikely that NHP2 has no bearing on telomerase activity 
as suggested here and it would be prudent to verify this through further investigation. 
Certainly, differences between the in vitro TRAP assay and the in vivo process should 
be taken into account. In a cell free context, incomplete but functional yeast H/ACA 
RNP complexes have been shown to form in the absence of Nhp2p, though the impact 
on H/ACA levels and pseudouridylation in Nhp2p depletion studies does not suggest 
their stable existence in vivo (Henras et al. 1998; Li et al. 2011). The possibility of 
similar complexes forming in the homogenised TRAP lysate (used to assay 
telomerase activity) should be considered. GAR1 was not found to be important for 
TERC accumulation or telomerase activity and is therefore not likely to be relevant 
for the integrity of telomerase or its activity, though again, further verification would 
be prudent. Also, these experiments cannot rule out the possibility of a less direct role 
in the function of telomerase and telomere maintenance, just as the more recently 
discovered TCAB1 is important for telomerase function through its role in correctly 
localising telomerase within the cell (Venteicher et al. 2009). As an H/ACA RNP 
component essential for pseudouridylation in yeast, GAR1 has now been indicated to 
modulate interactions with the target RNAs (Li and Ye 2006; Li et al. 2011). As this 
role is unnecessary in telomerase it is possible that GAR1 is simply redundant in this 
complex and it is noteworthy that this is the only known telomerase component not to 
be implicated in DC.  
Though previous studies have shown that dyskerin is important for TERC levels and 
telomerase activity the implications on telomere length have only been investigated in 
mice and inferred in humans. Telomere shortening was not evident until the fourth 
generation in hypomorphic DKC1 mutant mice; whereas, an in vitro mouse ES cell 
study demonstrated an immediate and steady decrease in telomere length as a result of 
introducing the common p.A353V mutation (Ruggero et al. 2003; Mochizuki et al. 
2004). Conducting long term RNAi experiments in this study has reiterated the 
importance of dyskerin for sustaining TERC levels and telomerase activity over time 
and demonstrated that in this capacity dyskerin is imperative for maintaining telomere 
length in human cells. Moreover, telomeres were found to shorten rapidly when 
dyskerin expression was suppressed. Intriguingly, this rapid shortening stabilised and 
telomeres were eventually maintained at a much shorter length in the cells that 
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survived, also growing more slowly. It is interesting to speculate the involvement of 
ALT pathways here and some parallels with yeast models could be observed to 
suggest this, but more research is needed to verify this possibility (Henson et al. 2002; 
Lundblad 2002). Unfortunately, after encountering difficulties, long term experiments 
were limited to dyskerin only, however, similarly important for TERC levels and 
telomerase activity, it could be inferred that NOP10, and possibly NHP2, is likely to 
be necessary for maintaining telomere length as well. Together, these RNAi 
knockdown studies (summarised in table 2) provide support for the implications that 
in DC, mutations affecting either dyskerin, NOP10 or NHP2 have the potential to 
impact upon TERC levels, telomerase function and telomere maintenance.  
 
Table 2. The effects of knocking down DKC1, NOP10, NHP2 or GAR1 expression. 
Functional impact Knockdown experiment 
 Dyskerin 
(DKC1) 
NOP10 
(NOP10) 
NHP2    
(NHP2) 
GAR1   
(GAR1) 
H/ACA RNA levels Variable 
reductions 
Variable 
reductions 
Variable 
reductions 
 
TERC levels 
>55% 
decrease 
>70% 
decrease 
>60% 
decrease 
<40% 
decrease 
TRAP activity >60% 
decrease 
>70% 
decrease 
<20% 
decrease 
<15% 
decrease 
Telomere length* Shortened 
rapidly 
   
Cell growth & 
proliferation* 
Impaired    
NOP10, NHP2 and GAR1 experiments were transient, dyskerin transient and stable. *Data from stable 
experiments. Blank sections indicate no data available. 
 
In the context of DC, dyskerin mutations have already been shown to impact on 
TERC levels and telomerase activity (Mitchell et al. 1999b; Vulliamy et al. 2001a). 
Having verified that NOP10 and NHP2 are also important for the integrity of 
telomerase and stable TERC recruitment, reconstitution experiments were carried out 
to investigate the impact of homozygous missense mutations identified in these 
proteins. Though only low level mutant reconstitution was achieved, there was 
sufficient evidence to suggest that both the homozygous p.R34W NOP10 and 
p.Y139H NHP2 mutations directly impair TERC recruitment and accumulation. 
These observations offer direct support that the mutations were responsible for 
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reduced TERC levels in the affected patients and are disease-causing (Walne et al. 
2007; Vulliamy et al. 2008). Based on the crystal structure of an archaeal H/ACA 
RNP, NOP10 residue R34 is directly involved in the proteins interaction with both 
dyskerin and the H/ACA RNA simultaneously, however, NHP2 residue Y139 is not 
shown to be directly involved in any of the proteins interactions within this complex 
(Walne et al. 2007; Vulliamy et al. 2008). Trahan et al have since reported that in a 
cell free system the p.Y139H NHP2 mutation prevented the protein’s association with 
the H/ACA RNP entirely while the p.R34W NOP10 mutation severely impaired 
H/ACA RNA recruitment (including TERC) but did not affect formation of the 
protein core (Trahan et al. 2010). Together, these studies provide substantive evidence 
that these mutations disrupt the integrity of telomerase and TERC recruitment in the 
affected patients. The subsequent impact on telomerase activity has not been directly 
investigated in this study or elsewhere, but is inferred based on TERC levels being a 
limiting factor for this activity and the telomere length defects that are evident in these 
patients. The ambiguity surrounding NHP2’s significance for telomerase activity 
observed in this study may detract from this argument, but the short telomeres in 
patients with NHP2 mutations offers convincing support.  
In the broader context, H/ACA RNPs are important for pseudouridylation, yeast and 
mice studies inferring that dyskerin, NOP10, NHP2 and GAR1 are all essential for 
this process (reviewed Meier 2005). It has since been confirmed that dyskerin (the 
catalytic component) is important for pseudouridylation in human cells but H/ACA 
RNA levels were not analysed (Montanaro et al. 2006). Investigating a selection of 
H/ACA RNAs, this study has observed that knocking down either dyskerin, NOP10 
or NHP2 had a variable impact in which not all the RNAs were affected equally; 
possibly reflecting differences in their individual expression and stability. Certainly, 
the more stable and abundant RNAs would be favoured for recruitment into the 
diminished pool of H/ACA RNPs that are able to form in these experiments. 
Unfortunately it has not been possible to assay pseudouridylation activity directly. 
However, it would be reasonable to assume that the overall impact on H/ACA RNA 
accumulation would manifest in a corresponding degree of overall decrease in total 
pseudouridylation activity. These findings would support the implications for a broad 
impact on H/ACA RNPs in DC patients with dyskerin, NOP10 or NHP2 mutations, 
potentially affecting not just telomerase function but also pseudouridylation. Specific 
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to telomerase, TERC and TERT mutations in other patients had already indicated 
defective telomere maintenance to be the primary underlying cause of DC. However, 
of all characterised DC cases, dyskerin mutations are the most common cause and are 
associated with a more severe phenotype than TERC or TERT mutations; it is 
interesting to speculate that their disease may be exacerbated by an additional defect 
in pseudouridylation. 
The majority of dyskerin mutations are located in the RNA binding PUA domain 
indicating their influence to be mediated through effects on H/ACA RNA recruitment 
rather than on catalytic ability directly (Rashid et al. 2006). However, the actual 
impact of dyskerin mutations on H/ACA RNA levels and pseudouridylation has been 
ambiguous. Mouse studies have demonstrated impacts that were not evident in patient 
studies, though it is fair to say that the later have not been extensive (Mitchell et al. 
1999b; Mochizuki et al. 2004; Wong et al. 2004). In this study a broader selection of 
H/ACA RNAs have been analysed in a larger number of patients with more different 
mutations than previously reported, and it was found that dyskerin mutations have a 
selective impact in which only some H/ACA RNAs are significantly affected. This 
highlights that the analysis of only a few H/ACA RNAs is a limitation that may have 
prevented previous patient studies from observing any affect. Which H/ACA RNAs 
are impacted probably reflects differences in their specific structures and interactions 
with dyskerin or the RNP as a whole, as well as their relative stability and expression. 
Strikingly, TERC was the only RNA to be consistently affected in this analysis 
suggesting that it is particularly susceptible to disruptions in the RNP, possibly due to 
its larger size and more complex structure. Certainly, TERC decreases have been 
consistently observed in knockdown or mutation studies investigating dyskerin, 
NOP10 or NHP2, even when impacts on other H/ACA RNAs were not. It is evident 
from this analysis that dyskerin mutations do not have a universal impact on all 
pseudouridylation targets and emphasises the need to consider the repercussions here 
more specifically. Though the overall importance of pseudouridylation is understood, 
little is known about the particular significance of specific targets. Further research is 
needed to profile which H/ACA RNPs are affected and to investigate the downstream 
significance of their specific targets. Over 100 different H/ACA RNAs have been 
identified to date, with an expression profile that is likely to change for each cell type 
and with each mutation impacting differently; to investigate all of these is not a small 
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task. Therefore, the full extent and severity of the pseudouridylation defect remains to 
be elucidated, but is suggested to be limited and variable. In contrast, the impact on 
TERC, telomerase and telomere maintenance is consistently demonstrated, both in 
this study and elsewhere, supporting a more predominant role in the pathology of 
these patients (Mitchell et al. 1999b; Vulliamy et al. 2001a; Wong et al. 2004; Wong 
and Collins 2006). 
Together, the RNAi experiments in this study have demonstrated the significance of 
dyskerin, NOP10 and NHP2 for H/ACA RNA recruitment and stability in human 
cells, which is in turn important for both telomerase activity and pseudouridylation. 
Moreover, this study has provided evidence to suggest that this function is diminished 
by mutations affecting these proteins in DC patients. 
When this study began three genes (DKC1, TERC and TERT) had been associated 
with DC and mutations in two others (NOP10 and NHP2) were being investigated. 
However, mutations in these genes only account for about a third of DC cases and 
during the course of this study mutations in other genes have been reported. The most 
significant of these is TINF2 which implicated a second telomere maintenance 
complex and was found to be commonly mutated in DC (Savage et al. 2008; Walne et 
al. 2008; Vulliamy et al. 2011a). This gene encodes the TIN2 component of shelterin; 
a complex of proteins comprising: TIN2, TRF1, TRF2, POT1, RAP1 and TPP1, that 
interact to structure the telomere, important for protecting it from DNA repair 
mechanisms and regulating telomere elongation (de Lange 2005) Telomerase 
recruitment has also been linked to this complex (Abreu et al. 2010). TIN2 is the 
central component tethering the three DNA binding elements of the complex: TRF1, 
TRF2 and POT1 (de Lange 2005). The specific impact of TIN2 mutations is unknown 
but the affected patients have very short telomeres (Savage et al. 2008; Walne et al. 
2008; Vulliamy et al. 2011a). Mutations have also been identified in TCAB1 which 
encodes a newly discovered telomerase component TCAB1 (Zhong et al. 2011). 
Directly interacting with dyskerin and TERC, TCAB1 is important for the correct 
localisation and trafficking of active telomerase through cajal bodies to the telomere 
(Venteicher et al. 2009). TCAB1 mutations are rare and directly impair the correct 
localisation of telomerase; the affected patients had short telomeres (Zhong et al. 
2011). Mutations have also been observed in a gene that is not linked to telomere 
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maintenance: C16orf57 (Walne et al. 2010). Uncharacterised at the time, this gene has 
been found to encode USB1 which is indirectly implicated in pre-mRNA splicing 
through its role in modifying the 3’ end of the spliceosomal U6 snRNA (Hilcenko et 
al. 2012; Mroczek et al. 2012). Telomere length was established to be normal in the 
small subset of patients with C16orf57 mutation, but any impact on pre-mRNA 
splicing remains to be investigated (Walne et al. 2010). However, somewhat 
surprisingly the knockdown of USB1 in HeLa cells was not found to affect pre-
mRNA splicing significantly (Mroczek et al. 2012).   
Overall, approximately 50-60% of DCR patients are now characterised by mutations 
in one of eight genes, most commonly: DKC1, TINF2, TERC, and TERT, then more 
rarely: NOP10, NHP2, TCAB1, and C16orf57. Defective telomere maintenance and 
telomere shortening are indicated to be the cause of disease in seven of these genetic 
subtypes and short telomeres are now considered a typical feature of DC. Despite the 
common defect the severity of the disease phenotype differs between subtypes. 
Generally, DKC1 and TINF2 mutations are associated with a severe disease that 
presents in early life; TERC and TERT mutations with a milder disease that displays 
anticipation and only manifests in the later generation of affected families, typically 
later in life. Investigating telomere length in a large cohort of DC patients, this study 
has reiterated the point that telomeres are significantly short in these subtypes but 
found no correlation between telomere length and their differences in disease severity 
(Vulliamy et al. 2011b). Instead, this data indicates that it is a difference in the rate of 
telomere shortening that is most important in determining severity, with rapid 
telomere shortening associating with a more severe DC phenotype. The body is more 
widely susceptible to telomere shortening during early life, when in a state of rapid 
growth and development, than in maturity when it is fully developed. Governing the 
latency with which the telomere maintenance defect delivers a pathological impact 
(reflected by the age of onset), it is conceivable that the rate of telomere shortening 
determines the extent to which the body is affected and the severity of the disease. It 
is difficult to verify this empirically but the disease anticipation associated with TERC 
or TERT mutations provides convincing support. Demonstrating the latency of the 
impact here, disease only manifests in later generations when telomere length finally 
becomes critical. But more significantly, each successive generation develops disease 
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at an earlier age, associated with an increase in disease severity (Marrone et al. 2004; 
Vulliamy et al. 2004).  
Comparing disease phenotypes more closely, it is intriguing that the mucocutaneous 
abnormalities are particularly prominent in the DKC1 patient group but much less so 
in the TINF2, TERC and TERT patients where haematological abnormalities are 
foremost and the initial diagnosis may often be confused with AA. It is interesting to 
associate this with the potential for additional pseudouridylation defects in the DKC1 
subtype, evidence for which has been provided by other aspects of this study, though 
the extent and severity has yet to be verified. What’s more, while all four subtypes 
shared a closely overlapping range of telomere length, the range was broader in the 
DKC1 subtype and the average length significantly longer by comparison. It appears 
that not all of these patients have critically short telomeres, but still have features of 
disease, providing further evidence for a contributing pseudouridylation defect in 
these patients. Mucocutaneous abnormalities are also prominent in the patients with 
C16orf57 mutations where telomere length is normal (Walne et al. 2010). The defect 
here is indicated to be mediated through impacts on the 3’ modification of the 
spliceosomal U6 snRNA; it is perhaps interesting that this and other spliceosomal 
snRNAs are targets for pseudouridylation (Meier 2005; Hilcenko et al. 2012; Mroczek 
et al. 2012). Targeted by scaRNAs, it would be appealing to investigate the potential 
for a correlation here by profiling the impact of dyskerin mutations on these RNAs 
specifically.  
This study has also observed a subset of genetically uncharacterised patients that do 
not have short telomeres, indicating an alternative pathology to their disease. Clearly 
the telomere length defect, though highly prevalent, is not universal to all cases of 
DC. This has already been highlighted by patients with mutations in C16orf57, so far 
the only gene associated with DC that does not implicate a defect in telomere 
maintenance (Walne et al. 2010). However, mutations in the this gene were first 
implicated in poikiloderma with neutropenia (PN) and have also been reported in 
cases of Rothmund-Thomson syndrome (RTS), the two diseases often confused due to 
considerable clinical overlap that is shared to a lesser extent with DC (Volpi et al. 
2010; Walne et al. 2010; Colombo et al. 2012). In view of the clinical and genetic 
overlap here it seems prudent to consider the possibility of a confused diagnosis for 
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these patients. Like many disorders DC was characterised before any knowledge of its 
molecular basis and is defined and diagnosed on clinical criteria alone, but its 
complex spectrum of presentation and overlap with other diseases can cause 
confusion.  
With research continuing to elucidate the genetic and molecular defects in this disease 
and related disorders it offers the opportunity to further define and differentiate them. 
This is already seen in DC where TERC mutations are used as a molecular diagnosis 
to distinguish the mild DC phenotype from AA. Short telomeres (measured in 
lymphocytes by flow FISH) have also been proposed as a marker for distinguishing 
DC from overlapping disorders (Alter et al. 2007). However, as this study has 
highlighted, the size of the control set needed to achieve accurate discrimination is a 
limitation for the widespread use of this approach. As the molecular basis to the 
disease caused by C16orf57 mutations is distinct from that implicated in all other 
characterised cases of DC there is argument that the diagnosis in these patients should 
be reconsidered. Indeed, the use of C16orf57 mutations as a molecular diagnosis to 
distinguish PN from RTS and DC has already been reported (Colombo et al. 2012). 
The question is whether DC should now be further defined by defective telomere 
maintenance rather than clinical criteria alone and, therefore, should patients with 
normal length telomeres now be considered to have an overlapping disease which has 
been confused for DC? It seems prudent to at least consider the possibility of 
misdiagnosis in these patients and to examine their disease more closely; perhaps 
there are discernible differences in their general phenotype, as seen between other DC 
subtypes. This issue aside, as the molecular pathways involved clearly differ, it may 
benefit future genetic research to analyse telomere lengths in all of the 
uncharacterised patients (approximately 40-50% of the DCR) and differentiate those 
that exhibit telomere maintenance defects from those that do not. It will be interesting 
to see if there is further overlap with other diseases as the molecular defects in these 
patients continue to be elucidated.  
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 Appendix A – siRNA Details 
siRNA  5’ to 3’ Sequence (Sense then antisense) 
NOP10 siRNA I   GGGUCCCUUAAACUGAUGUtt   
  ACAUCAGUUUAAGGGACCCtc   
NOP10 siRNA II   GGGAACACAUUUGACUUUUtt   
  AAAAGUCAAAUGUGUUCCCtt   
NOP10 siRNA III   CCCAUAAAGGGAACACAUUtt   
  AAUGUGUUCCCUUUAUGGGtg   
NHP2 siRNA I   GGUAAUGCUAGUCUUCUGUtt   
  ACAGAAGACUAGCAUUACCtt   
NHP2 siRNA II   GGCACAGAGAUCUGUAAUUtt   
  AAUUACAGAUCUCUGUGCCtt   
NHP2 siRNA III   GGCUGUUCCAAGAAUGUGGtt   
  CCACAUUCUUGGAACAGCCtt   
GAR1 siRNA I   GGACCUCCAGAACHUGUAGtt   
  CUACACGUUCUGGAGGUCCtt   
GAR1 siRNA II   CGUGUAGUCUUAUUAGGAGtt   
  CUCCUAAUAAGACUACACGtt   
GAR1 siRNA III   CGGAAUAGUGAAUUUUGCUtt   
  AGCAAAAUUCACUAUUCCGtt   
DKC1 siRNA I   GCUUUCUAGGGCCCUAGAAtt   
  UUCUAGGGCCCUAGAAAGCtg   
DKC1 siRNA II   GGACGGCAUUGAGGUCAAUtt   
  AUUGACCUCAAUGCCGUCCtc   
DKC1 siRNA III   CCUUUAUGUCCUAUUUGGAtt   
  UCCAAAUAGGACAUAAAGGtc   
DKC1 siRNA IV   GGACAACACACUAUACACCtt   
  GGUGUAUAGUGUGUUGUCCtt   
DKC1 siRNA V   GGACAGGUUUCAUUAAUCUtt   
  AGAUUAAUGAAACCUGUCCtg   
DKC1 siRNA VI   GGUUUCAUUAAUCUUGACAtt   
  UGUCAAGAUUAAUGAAACCtg   
Neg 1 - Ambion 
Negative control * 
Unknown 
Neg 2 - Invitrogen 
Negative control  
Unknown 
Neg 3 - Qiagen 
Negative control 
Unknown 
Neg 4 - GenePharma 
Negative control 
UUC UCC GAA CGU GUC ACG UTT  
ACG UGA CAC GUU CGG AGA ATT  
*Used in the transient knockdown experiments. 
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Appendix B – Primer Sequences 
B.1. Miscellaneous primers 
Name 5’ to 3’ Sequence 
ABL 1 GGAGTGTTTCTCCAGACTGTTG 
ABL 2 TTCAGCGGCCAGTAGCATCTGACTT 
hU6 Forward  ACGCGTAGTGGAAAGACGCGCAGGCAAA 
hU6 Reverse GCGGCCGCTGTTTCGTCCTTTCCACAA 
M13 Forward TGTAAAACGACGGCCAGT  
M13 Reverse CAGGAAACAGCTATGAC 
 
B.3. H/ACA RNA quantification primers (SYBR green) 
Name 5’ to 3’ Sequence 
U19 FWD CGGTTGTCAGCTATCCAGG 
U19 REV CTCAGCTACAACACCAAAACAG 
U64 FWD CTCTCTCGGCTCTGCATAG 
U64 REV AAGAGAGGCCACAGTAAGG 
U68 FWD CCTAAACCCAAGAATCACTG 
U68 REV AAATTCACTTTGAGGGGCACG 
U70 FWD CAATTAAGCCGACTGAGTTCC 
U70 REV TCCCTTAGAGCAACCCATAC 
U108 FWD TTCAAATGGGCCTAACTCTGC 
U108 REV TGATGCAGGAAAGGCTTAAGAG 
U3 FWD CACGAGGAAGAGAGGTAGC 
U3 REV CCAATACGGAGAGAAGAACG 
U97 FWD TGCCCGATGATTATAAAAAGAC 
U97 REV AATCTTCGCTCACAGGACGCTG 
ABL FWD GATACGAAGGGAGGGTGTACCA 
ABL REV CTCGGCCAGGGTGTTGAA 
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B.3. TaqMan
®
 primer/probe sequences and reaction concentrations 
Primer/Probe 5’ to 3’ Sequence Conc (nM) 
ABL Forward GATACGAAGGGAGGGTGTACCA 100 
ABL Reverse CTCGGCCAGGGTGTTGAA 100 
ABL Probe FAM-TGCTTCTGATGGCAAGCTCTACGTCTCCT-MGB 300 
TERC Forward GGTGGTGGCCATTTTTTGTC 300 
TERC Reverse CTAGAATGAACGGTGGAAGGC 300 
TERC Probe FAM-CGCGCTGTTTTTCTCGCTGACTTTC-MGB 200 
NOP10 
(Hs00430282_m1) 
TaqMan
®
 Gene Expression Assays (Applied Biosystems). 
Pre-mixed primer and probe set at 20x concentration. 
Individual sequence and concentration details undisclosed. 
1x 
 
NHP2 
(Hs00750357_s1) 
NHP2.2 
(Hs00950765_g1)* 
Dyskerin 
(Hs00154737_m1) 
GAR1 
(Hs00255867_m1) 
*3’ UTR specific - used to distinguish endogenous and exogenous NHP2 expression. 
 
B.4. NOP10 shRNA oligonucleotide sequences 
Name 5’ to 3’ Sequence 
NOP10 shRNA 1 GGAACACATTGGTGTGGAATGTGTTCCCTTTATGGGCTCGAGGCG
GCCGC 
NOP10 shRNA 2 GAATTCGCGCCTTTTTTCTAGAGTCGACCCCATAAAGGGAACACA
TTGGT 
NOP10 shRNA (+) GATCCGCCCATAAAGGGAACACATTCCACACCAATGTGTTCCCTT
TATGGGCTTTTTTTGGAAA 
NOP10 shRNA (-) AGCTTTTCCAAAAAAAGCCCATAAAGGGAACACATTGGTGTGGAA
TGTGTTCCCTTTATGGGCG 
 
B.5. MMqPCR primers  
Name 5’ to 3’ Sequence 
telg ACACTAAGGTTTGGGTTTGGGTTTGGGTTTGGGTTAGTGT 
telc TGTTAGGTATCCCTATCCCTATCCCTATCCCTATCCCTAACA 
hbgu CGGCGGCGGGCGGCGCGGGCTGGGCGGCTTCATCCACGTTCACCTTG 
hbgd GCCCGGCCCGCCGCGCCCGTCCCGCCGGAGGAGAAGTCTGCCGTT 
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Appendix C – shRNA Expression Vectors 
C.1. pSilencer™ 2.1-U6 neo 
 
 
 
The pSilencer™ 2.1-U6 neo shRNA expression vector from Ambion, now part of Life 
Technologies Ltd, Paisley, UK. This map was taken from their website 
(http://www.lifetechnologies.com) 
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C.2. TRC1.5 MISSION
®
 shRNA vector  
 
 
 
The TRC1.5 MISSION shRNA lentiviral expression vector (based on pLKO.1-puro) 
from the Sigma-Aldrich Company Ltd, Dorset, UK. This vector map was taken from 
their website (http://www.sigmaaldrich.com).  
 
cppt Central polypurine tract 
hPGK Human phosphoglycerate kinase eukaryotic promoter 
puroR Puromycin resistance gene for mammalian selection 
SIN/LTR 3' self inactivating long terminal repeat 
f1 ori f1 origin of replication 
ampR Ampicillin resistance gene for bacterial selection 
pUC ori pUC origin of replication 
5' LTR 5' long terminal repeat 
Psi RNA packaging signal 
RRE Rev response element 
 
 
